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HOST DERIVED MARKERS OF LYME DISEASE AND OTHER SPIROCHAETAL INFECTIONS: 
THEIR DISCOVERY AND DIAGNOSTIC POTENTIAL 
 
UK laboratory diagnosis of Lyme disease involves the Standard Two-Tier serological 
approach. The negative predictive value of the test has been challenged, particularly in 
the early stages of disease. In order to better understand the host response to Lyme 
disease and to identify any potential host biomarkers that may correlate with early 
infection, proteomic and transcriptomic analyses were undertaken on Lyme disease 
patient samples.  
 
Label free quantitative spectrometry was used to measure and compare the serum 
proteome of seropositive patients against that of individuals that had tested 
seronegative for Lyme disease and a control group consisting of samples from normal 
healthy donors and patients with related infectious disease including leptospirosis and 
syphilis. Seropositive and seronegative individuals were found to be remarkably 
similar at the serum proteome level. Of the 12 proteins found to be at significantly 
different abundance between groups, the protein Lipocalin-2 was of particular interest 
due to role its role modulation of immune responses. Further analysis by ELISA in 
additional samples showed that Lipocalin-2 was significantly increased in Lyme 
disease positive patients when compared to normal healthy donors.  
 
Whole blood samples from patients with Lyme disease were then RNA sequenced and 
differential gene analysis was performed using sequencing data for healthy controls.  
Several pathways associated with bacterial immune response in the host were 
	
	 iii	
identified, together with actin rearrangement and oxidative stress pathways. eIF2 
signalling was found to be significantly reduced in patients with early Lyme disease. 
The pathway has previously been identified as being down regulated during Lyme 
disease. In later samples from patients, following antibiotic therapy, eIF2 signalling 
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CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 
 
The main aim of this thesis was to use proteomic and transcriptomic approaches to 
investigate the blood of Lyme disease patients and to identify host protein and/or gene 
biomarkers that may have future diagnostic or prognostic potential. The majority of 
Lyme disease diagnosis currently relies on the detection of host antibodies to Borrelia 
burgdorferi sensu lato (s.l.) antigens in patient serum. Particularly in early disease, 
when the patient is mounting an immune response to infection, the negative 
predicative value of these tests has been questioned and there is therefore great 
interest in the development of improved diagnostic methods. Here, a background on 
Lyme disease including an in-depth discussion of the current diagnostic methods is 
given together with a review of the use of ‘omics-based technologies in biomarker 
discovery studies.  
 
During mass spectrometry analyses in chapter 3, serum samples from leptospirosis 
and syphilis positive patients were included as a related-disease control group. A 
range of differentially abundant proteins were observed in these groups and some 
protein markers were taken forward for further analyses in chapter 4, both as a proof-
of-concept of the proteomic approach and because they represented interesting and 
novel findings; Therefore, background information regarding these spirochaetal 







1.1.  CLASSIFICATION, DISCOVERY AND EPIDEMIOLOGY 
 
1.1.1. The Spirochaete phylum 
A spirochaete is a member of the phylum Spirochaetes. Spirochaetes are long, 
helically coiled, highly motile bacteria and can be described as gram-negative as they 
possess inner and outer membranes separated by a peptidoglycan layer within a 
periplasmic space. The bacteria are generally from 3 to 250 µm in length and 0.1-75 
µm in diameter (1). The spirochaetes have a unique cellular structure, with flagellae 
located internally within the periplasmic space. The specialised flagella, termed axial 
filaments, rotate within the periplasm causing propulsion of the bacterial cell. The 
phenotypic characteristics shared between species of the phyla reflect the 
phylogenetic relationships between genera (2). 16S rRNA gene sequence comparisons 
show a distinct evolutionary progression within the phyla. Figure 1.1 shows the 
phylogenetic tree of the spirochaetes. Species within several genera are free-living in 
the environment and anaerobic, but the group is diverse and there are several 
exceptions. Beyond the presence of the distinctive endoflagella, genera within the 
species share few other characteristics and are widespread in the environment. Despite 
being a relatively small phylum of bacteria, several species cause prevalent disease in 
humans. Clinically important genera include the Borrelia, Treponema, Leptospira and 
Brachyspira. Figure 1.2 shows a phylogenetic tree based on protein homology 
between genospecies of the Borrelia genus. The tree includes data from 30 Borrelia 
strains including 17 associated with Lyme disease/borreliosis and 11 associated with 






Figure 1.1: Phylogenetic tree based on 16S rRNA sequencing of species of the 
phylum Spirochaetes.  Data obtained from the Living Tree Project (4). Genera 




























Figure 1.2.: Phylogenetic tree of 30 Borrelia species based on protein homolog data – 
Percentage of conserved proteins (POCP). Data used to create tree obtained from 
Margos et. al 2018 [3]. Borrelia strains associated with Lyme borreliosis/disease are 
highlighted in orange. Those associated with relapsing fever are highlighted in green. 
B. turica and ‘Candidatus B. tachyglossi’ are from intermittent clades and are 
associated with reptile and echidna hosts.  
N.B. All node support values are 100 except where indicated (in purple) 
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1.1.2. Borrelia  
Borrelia is a genus of bacteria of the spirochaete phylum. Several species within the 
genus are responsible for the zoonotic diseases Lyme disease and relapsing fever. The 
major species causing Lyme disease are Borrelia burgdorferi sensu stricto (s.s.), 
Borrelia afzelii and Borrelia garinii, referred to collectively as B. burgdorferi sensu 
lato (s.l.). Causative species associated with Lyme disease are generally 
geographically distributed with B. garinii and B. afzelli responsible for the majority of 
cases in Europe, and B. burgdorferi s.s. responsible for the majority of cases in the 
United States. Other pathogenic species include B. bavariensis, B. spielmanii and B. 
mayonii. The s.l. group is continually expanding, with at least 20 recognised or 
proposed species (5).  B. burgdorferi s.l. bacteria are spread to humans by tick vectors 
from a natural reservoir among small to medium mammals, reptiles and birds. Hard-
bodied ticks of the genus Ixodes are the main vectors of Lyme disease. In Europe, 
mainly Ixodes ricinus and I. persulcatus hard ticks are implicated in the spread of 
Lyme disease. In the US, I. scapularis (deer tick) are the most common vector for 
Lyme disease (6).  
 
Lyme disease was first formally clinically identified in 1975 following an outbreak of 
arthritis and juvenile arthritis in Old Lyme, Connecticut and surrounding areas. Initial 
studies by a group at the Yale School of Medicine, together with the Connecticut State 
Department of Health, found incidence of the now well-documented erythema 
migrans (EM) rash, clustering of symptoms coinciding with tick-feeding season and in 
some cases, known history of tick bite (7). While EM rash had previously been 
identified in Europe, it was suspected to be caused by localised-skin infection and had 
not yet been associated with incidence of arthritis. In the early 1980s, Willy 
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Burgdorferi identified spirochaetes in deer ticks and demonstrated this new bacterium, 
Borrelia burgdorferi  is the causative agent of Lyme disease (8). In 1991, the disease 
was designated as a notifiable condition in the United States. 
 
Generally, the spread and incidence of Lyme disease correlates to environments that 
facilitate the survival of Ixodes tick vectors. These includes temperate regions of the 
Northern Hemisphere. In Europe, distribution and density of I. ricinus and I. 
persulcatus generally correspond to the levels of Lyme disease seen in a particular 
region. The percentage of ticks that carry pathogenic species of Borrelia has been 
shown to vary in different geographical locations and this may be influenced by the 
species of tick that is dominant in that region, together with the small mammal 
population (9). Variation in percentage of ticks carrying Borrelia has also been shown 
to vary by season, with higher incidence seen during spring and summer months, 
coinciding with tick life cycle (10). Tick vectors have increased in density over time 
and have spread into higher latitudes and altitudes as the climate of these areas has 
changed (11, 12).  
 
Lyme disease is the most commonly reported tick-borne disease in the United States 
and Europe. A total of 262,481 confirmed cases of Lyme disease were reported in the 
United States between 2007 and 2016 (13). In Europe, incidence varies widely by 
country, with 464 cases per 100,000 population seen per year in Sweden and 0.001 
cases per 100,000 population seen per year in Italy (14). Lyme disease is not a 
statutorily notifiable disease in the United Kingdom. Since October 2010 under the 
Health Protection Regulations Act, every microbiology laboratory in England is 
required to notify all laboratory diagnoses of Lyme disease to Public Health England 
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(PHE) (15). In 2017, 1579 laboratory reports of Lyme disease were recorded in 
England and Wales (16). This figure is based on laboratory confirmed cases only and 
therefore the true incidence of Lyme disease, including unreported and misdiagnosed 
cases is likely to be significantly higher. In England and Wales, the incidence of 
laboratory-confirmed Lyme disease rose from 1.62 per 100,000 in 2013 to 1.95 cases 
per 100,000 in 2016 (17). 
Due to the nature of infection via tick vectors, participation in outdoor activities is a 
risk factor in contracting the disease, particularly in high-risk areas including grassy 
and wooded areas in southern England and the Scottish Highlands; however, ticks in 
urban environments have also been shown to carry B. burgdorferi s.l. (8).  
 
The Borrelia genus has at least two genospecies B. turica and B. tachyglossi that are 
not thought to be pathogenic to humans but are typically found in reptiles (18). A third 
group of the Borrelia genus contains over 29 species associated with relapsing fever. 
Tick-borne relapsing fever (TBRF) is a febrile disease, characterised by recurring 
episodes of fever and nonspecific symptoms, many of which are shared by Lyme 
disease including: myalgia, headache and arthralgia. TBRF is spread by exposure to 
the bite of an infected Ornithodoros tick. The tick species has a wide geographic 
spread and cases of TBRF are found throughout most of the world. It is endemic to 
several areas of North, Central and South America, the Mediterranean, Central Asia 
and much of Africa (19). TBRF has been associated with several small outbreaks (<62 
cases) of infectious disease in the United States from the late 1960s onwards (20-24). 
The incidence of TBRF is difficult to estimate as many cases are unrecognised or 
misdiagnosed. TBRF is not endemic to the UK, and reported cases are assumed to be 
imported. Louse-borne relapsing fever (LBRF) is caused by B. recurrentis and is 
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spread by human lice vectors including Pediculus humanus and P. capitis. LBRF 
tends to occur in outbreaks and can cause severe symptoms with a fatality rate of 10-
40% in untreated cases (25). LBRF is endemic in several East African countries 
including Ethiopia, Eritrea and Somalia. Cases in Europe are thought to be imported 
cases, often in refugees from East Africa (26). 
 
1.1.3. Leptospira  
Leptospira is a genus of the Spirochaetes phylum that contains several pathogenic 
species that together are responsible for causing the infectious human disease 
leptospirosis. 
A total of 22 species of Leptospira have been identified, divided into three clades 
generally based on pathogenicity. At least 8 species of Leptospira are capable of being 
pathogenic in animals (27). Pathogenic species do not multiply in the environment, 
requiring an animal host (28). In 1915, Leptospira were first described as the 
causative agent of leptospirosis (Weil’s disease) in humans (29).  
 
Leptospirosis is found worldwide, but with incidence around 10 times greater in 
tropical and subtropical climates than that of more temporal climates (30). The 
bacteria have been shown to be capable of surviving for longer periods in warm and 
humid environments. Due to socioeconomic reasons, these areas are also less likely to 
have well developed surveillance systems for leptospirosis, together with conditions 
that facilitate greater transmission of Leptospira including inadequate sanitation and 
closer contact with animal species that are capable of carrying the bacteria. More 
cases occur during summer and autumn in temperate regions and during rainy seasons 
in warmer climates (31). Occupations that involve contact with carrier animals, or 
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with potentially contaminated water including farmers, veterinarians, rodent control 
works and sewer workers have a higher risk of contracting leptospirosis (32). 
Similarly, those participating in recreational activities that involve contact with water 
are at higher risk. The WHO has estimated an incidence of 873,000 cases worldwide 
annually, with over 40,000 deaths (33).  Between 2007 and 2012, 301 cases of 
leptospirosis were confirmed in the UK, with around a quarter of these causes 
acquired abroad (34).  
 
1.1.4. Treponema 
Treponema is a genus of spirochaete bacteria that contains the important human 
pathogen species, Treponema pallidum. Subspecies of Treponema pallidum are 
responsible for the diseases syphilis, bejel, pinta and yaws (35). 
 
Syphilis is a chronic sexually transmitted infectious disease caused by the bacteria 
Treponema pallidum subspecies pallidum (T.p. pallidum). While transmission of 
syphilis-causing T.p. pallidum is generally limited to close sexual contact or vertical 
transmission from mother to child in congenital syphilis, other pathogenic treponemes 
including T. pallidum subspecies pertenue, the causative agent of yaws, are 
transmitted by skin contact and development of infective lesions. Pinta, caused by 
Treponema carateum, and bejel, caused by T. pallidum endemicum,  are chronic skin 
and tissue diseases.   
 
T.p. pallidum was first identified in syphilitic sores (chancres) in 1905; however, 
evidence suggests syphilis or related diseases have been present for centuries and that 
an early European epidemic coincided with the return of Columbus from the New 
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World in 1493 (36).  No animal reservoir exists for venereal syphilis, being a human 
only disease. There were an estimated 6 million new cases of syphilis worldwide in 
2016. Incidence varies by country, with developing nations showing the largest 
burden of disease. The incidence of congenital syphilis in 2017 was 23.3 cases in 
100,000 live births in the United States (37). Worldwide, between 700,000 and 1.6 
million pregnancies are thought to be affected by syphilis, with the majority of 
perinatal deaths occurring in low-income countries. Incidence of congenital syphilis is 
very low in the UK, between 2010 and 2015, 17 cases were identified with no 
mortality (38). Incidence of venereal syphilis steadily decreased from the late 1940s 
due to the availability of antibiotic treatment; however, the number of cases has 
increased in recent years, with 7,149 cases diagnosed in 2017, up from the 2,874 cases 
diagnosed in 2008. A 20% rise in syphilis cases was seen between 2016 and 2017 
alone (39) and a further rise of 5% to 7541 (40). 
 
 
1.2  CELL STRUCTURE AND GENOME ORGANISATION 
 
1.2.1.  B. burgdorferi s.l. 
B. burgdorferi s.l. is a helical shaped spirochaete, with a flexible cell wall that 
facilitates cell motility. The bacteria are typically 0.33 µm wide, and up to 25 µm long 
(41). As with all species within the spirochaete phylum, Borrelia have 7-11  internally 
located flagella between the inner and outer cell membranes. The flagella are 
structurally similar to flagella of other bacteria, comprising a basal-motor complex, 
hook and filament. Rotary motion action allows movement of the bacterium and 
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facilitates movement through host tissue (42). The flagellar filaments consist of 
repeating protein units encoded by the genes FlaA and FlaB (43). 
 
Figure 1.3: Schematic diagram of the structure and morphology of Borrelia. The 
helical shape of the bacteria is imparted by the presence of the flagellar ribbon. The 
cell has an inner and outer membrane as seen in the cross-section diagram. The 
periplasmic space between the membranes contains peptidoglycan (gram-negative) 
and the flagellar ribbon. Diagram author’s own. 
 
Borrelia express several outer surface proteins (OSPs) that have key roles in 
transmission between hosts. OspA is expressed on the surface of the bacterium whilst 
located within the tick midgut (44). Upon feeding, blood from the mammalian host 
enters the tick midgut, and expression of OspC is increased by the bacterium. Borrelia 
mutants lacking OspC have been shown to be competent to replicate and migrate to 
the salivary glands of the tick, but are not capable of infecting mice. OspC has been 
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shown to be indispensible for establishing infection in the mammalian host (45).  
Therefore, the reciprocal regulation of OspA and OspC facilitates pathogen transfer 
from the tick to its mammalian host and facilitates productive infection. The 
mechanism of action of OspA, OspC and other outer surface proteins is not fully 
understood in Borrelia, but their expression has repeatedly been shown to be vital for 
transmission between hosts and survival within diverse environments.  
 
The genome of B. burgdorferi s.l. is one of the largest and most complex of any 
bacterium (46), likely a reflection of the wide range of genes that facilitate survival in 
tick and mammalian hosts. Borrelia have a ~950-kb linear chromosome with a 
number of circular and linear plasmids that can vary between species and subspecies. 
B. burgdorferi s.s. contains over 20 linear and circular plasmids (47). The majority of 
genes associated with encoding outer membrane lipoproteins are located on the 
plasmids (48). 
 
Despite their large genome, Borrelia lack the capacity to synthesize amino acids, fatty 
acids, nucleotides and several enzyme cofactors. Therefore, Borrelia are reliant on 
obtaining these from the host, and the bacteria have a wide range of genes encoding 
transporters and binding proteins for carbohydrates, peptides and amino acids (49, 
50). Borrelia remains the only known organism that does not require iron for growth 
(51). During bacterial infection, as part of the innate immune response, host cells 
typically increase production of lactoferrin to limit availability of iron together with 
several other mechanisms, including the production of iron sequesters such as 
lipocalin 2 (52). Lacking requirement for iron, Borrelia have greater immunity to 
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these host defences. Previous studies have shown that for several functional proteins, 
Borrelia have adapted to use magnesium as a cofactor rather than iron (53). 
 
1.2.2.  Leptospira 
As spirochaetes, the Leptospira share several key cell structures with Borrelia 
including a long, helically coiled shape; however, leptospires differ from other 
spirochaetes as they have single flagellum rather than a bundle (54). The outer 
membrane of the Leptospira contains a wide range of lipoproteins and transmembrane 
OSPs that are associated with pathogenicity. OSPs have been shown to be particularly 
important in pathogenic species of Leptospira for attaching to host extracellular 
matrix as well as to immune mediators including the complement protein Factor H 
(55).  
 
The genome of Leptospira consists of two chromosomes that vary in size depending 
on the particular species. The genome of Leptospira interrogans consists of a 4.33 Mb 
circular chromosome and a 350 kb small chromosome (56). The genome of 
pathogenic species has a large proportion dedicated to pathogenic related genes. The 
L. interrogans genome contains a wide range of pathogen-specific genes together with 
a host of housekeeping genes that facilitate survival of the bacteria in diverse 
environments from stagnant water to mammalian host (57).  
 
1.2.3.  T.p. pallidum 
T.p. pallidum share the helical structure and internal flagella that facilitate their 
transmission into human hosts via a corkscrew motion through mucous membranes or 
breaks in the skin. Unlike Borrelia and Leptspira, however, T.p. pallidum has an outer 
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membrane that has very few integral membrane proteins. Due to the fragile, sparse 
nature of membrane proteins in syphilis, few have been elucidated and their influence 
on infection is not fully defined (58).  
In contrast to the large, complex genome of Borrelia, T.p pallidum has one of the 
smallest bacterial genomes at 1.14 Mb and does not synthesise lipids, nucleotides and 
the majority of amino acids and are therefore highly dependent on the host for 
nutrients (59). The very small genome in relation to Borrelia and the Leptospira 
concurs with its inability to survive outside its obligate human host. The bacteria are 
highly adapted to evade recognition by the host’s innate and adaptive immune 
responses to facilitate colonisation and chronic infection. T. pallidum utilises most of 
the essential substrates from the host environment using a large number of specific 
transporters (60).  
 
1.2.4. Genome diversity amongst the spirochaetes 
Whilst showing great diversity in pathogenicity, transmission and niche, the 
spirochaetes share several structural and genomic features. A comparison of L. 
interrogans, B. burgdorferi s.l. and T.p. pallidum showed that 41% of the genes found 
in B. burgdorferi s.l. were also found in L. interrogans, and that 57% of the genes in 
T.p. pallidum are found in the L. interrogans genome. 362 genes were found to be 








1.3  TRANSMISSION AND PREVENTION 
 
1.3.1.  Ixodes tick life cycle and the transmission of B. burgdorferi s.l. 
In Europe, the Ixodes ricinus tick is the most common vector for transmission of 
Borrelia spp.. The bacteria can be transmitted to between small and medium 
mammalian hosts and to humans when the tick vector attaches and takes a blood meal. 
The tick is found across Europe, commonly in areas with abundance of appropriate 
reservoir hosts. In particular, remote forested areas and heathland have high incidence 
of ticks (62); however, they are also present in some urban and suburban habitats and 
have previously been sampled in South London parks (63). While the risk of 
transmission from ticks is greatest amongst those who work or spend significant 
amount of time in rural locations, including farmers and hill walkers, there is still 
measurable risk of tick-bite throughout the UK, wherever Ixodes ticks and reservoir 
species exist. 
 
Ixodes ticks are widely distributed throughout the Northern Hemisphere with their 
range continually expanding due to reforestation and increasing temperatures 
providing habitable conditions for new populations of host mammals (64). In the UK, 
a 2008 study found that Ixodes ricinus distribution had increased by 17% since 2005, 
with increases in tick numbers coinciding with local increases in deer population (65, 
66). Public Health England’s passive Tick Surveillance Scheme found Ixodes ricinus 
to be the most frequently recorded endemic tick species in the UK at 59.2% of all 
recordings (67). Ixodes ricinus has a three-host life cycle with four life stages: egg, 
larva, nymph and adult (figure 1.4). In order to produce eggs and moult, female ticks 
require a sufficient blood meal and can feed on a wide range of hosts including small 
	
	 16	
rodents during earlier stages of their life cycle often progressing to larger mammals 
such as roe deer at adult stages of development. Large mammals are essential for the 
survival of most tick populations, providing sufficient feed for large numbers of adult 
ticks and facilitate distribution of ticks and eggs into new areas; however, they are not 
competent reservoirs are spirochaetes. The main reservoirs for Borrelia in both 
Europe and the United States are small mammals including mice, voles and some 
species of bird (68).  
 
The ecology and biodiversity of an area, particularly the population size of competent 
Borrelia reservoir species influences the positivity rate in ticks and ultimately the risk 
of contracting Lyme disease The percentage of ticks that carry the Borrelia pathogen 
varies widely depending on geographical location and species of tick. A large scale 
study in the United States involved the screening of 16,080 ticks submitted by the 
public for several species of B. burgdorferi s.l. found a prevalence of 19.5% in adult 
ticks, 11.0% in nymphs and 5.1% in larvae (69).  In the UK an assessment to the 
suitability of urban greenspace for ticks such as urban woodlands showed a mean 
prevalence of Borrelia-infected I. ricinus ticks at 18% (70). The majority of humans 
are infected through the bites of nymphs as larger adult ticks are more likely to be 
identified and removed before transmission. A 2018 study found an approximate 10% 
transmission rate by 48 hours of nymph tick attachment, rising to 70% by 72 hours 
(71). In North America, Ixodes scapularis and I. pacificus are the most common 
vector for Borrelia and are also capable of transmitting the causative agents of 
anaplasmosis and babesiosis.  I. persulcatus represent the major vector for Borrelia in 





Figure 1.4: Lifecycle of the Ixodes tick vectors of B. burgdorferi. Small mammals are 
confirmed resorvoirs for pathogenic species of Borrelia and pass on the spirochaete to 
tick vectors during nymphal feeding 
 
Preventative methods such as encouraging the use of insect repellent on exposed skin, 
wearing protective clothing and guidelines on the prompt and safe removal of ticks 
form the basis of public health protection strategies (73).  
 
There is no vaccine currently in use for Lyme disease. LYMErix™, a recombinant 
Lyme vaccine, was approved for use by the FDA in 1998. The vaccine was in 
production for until 2001 when the manufacturer voluntarily withdrew the vaccine 
from market following reports of adverse reactions and widespread media coverage 
(74). 1.4 million Lyme vaccine doses had been administered by this point. Studies 





1.3.2.    Transmission of Leptospira 
In the majority of leptospirosis cases, transmission of the pathogen is through 
abrasions or cuts in the skin or via the conjunctiva of the eye (77). Pathogenic strains 
of Leptospira are capable of surviving in stagnant water for many days to weeks (78) 
and water supplies can be contaminated by the urine of an infected mammalian host. 
Spending prolonged periods of time in contaminated water is the major risk factor for 
contracting leptospirosis (79). Inhalation of aerosols containing the spirochaetes can 
also lead to infection through the respiratory tract mucous membranes (77). Lack of 
sanitation, poor housing and inadequate water treatment facilities contribute to the 
endemic levels of leptospirosis seen in tropical and subtropical regions, together with 
weather conditions that facilitate survival of the spirochaetes. The bacteria is carried 
by several animal species, with rodents representing the most important primary hosts 
in the majority of human infections (80). Prevention of leptospirosis is based on 
spreading awareness of transmission risks; particularly those associated with entering 
potentially contaminated water supplies. Local infrastructure, including water supply, 
rodent prevention and housing standards are important for the prevention of 
leptospirosis (77).  
 
1.3.3. Transmission of T.p pallidum  
Unlike Borrelia and Leptospira the causative agent of syphilis, T.p. pallidum is an 
obligate human pathogen with no known animal reservoir or vector. Syphilis is 
transmitted primarily by direct sexual contact with the infectious lesion of another 
person. Cases of acquisition through blood products and organ donation have been 
reported (81, 82), but these are rare incidences. Congenital syphilis is spread in utero 
or during birth from an infected mother (83). Transmission of congenital syphilis can 
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generally be prevented successfully by treatment of infected mothers using antibiotics 
prior to childbirth (84). For venereal syphilis, prevention strategies rely on safe sex 
practices, including the use of appropriate prophylactics, Sexually Transmitted 
Infection (STI) screening availability and public awareness of STI risks. The 
availability of pre-exposure prophylaxis medication (PrEP) for HIV, has resulted in a 
decrease in condom use particularly in men who have sex with men. This may 




1.4 DISEASE PATHOGENESIS 
 
1.4.1. Lyme disease 
In human hosts, the bite of an infected Ixodes tick is required for the introduction of B. 
burgdorferi s.l. through healthy skin. Colonisation and persistence in the dermal layer 
allows adaptation of the pathogen through altered gene expression facilitated by the 
movement from the environment of the tick midgut to the human host (86, 87). 
Broadly, Lyme disease can be split into three stages; early localised Lyme disease, 
early disseminated Lyme disease and late disseminated Lyme disease. The infecting 
Borrelia genospecies influences the likelihood of development of certain sequelae 
during dissemination due to differing tissue tropism. Figure 1.5. shows the 
progression of Lyme disease through these stages. It should be noted that Lyme 
disease is a complex condition and several of the symptoms described have at least 
some element of host autoimmunity; therefore, a wide range of symptoms have been 
attributed to Lyme disease, several of which are shared with other infectious and non-
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infectious disease. The pathogen does not produce any known toxins or proteases that 
could be directly responsible for tissue damage seen during colonisation (88). Here, 
well-documented conditions associated with Borrelia infection are given along with 
estimations of their incidence in Lyme disease patients. In reality, Lyme disease 
patients are likely to present with a complex set of symptoms, particularly in the later 



























































































































































































































































1.4.1.1. Early localised Lyme disease 
The presence of Borrelia bacteria in the dermal layer stimulates host proinflammatory 
immune responses that cause a radiating rash around the site of tick-bite that 
subsequently clears from inside, causing the characteristic erythema migrans (EM) 
rash. While successful colonisation of the dermal layer is requisite for Lyme disease 
and progression to later stages of disease, EM rash is not seen in all patients. The 
incidence of EM rash in Lyme disease cases is thought to be around 70%, although 
estimates vary widely depending on the study (89). EM rash can vary greatly in shape 
and may include vesicular or necrotic areas towards the centre, further complicating 
its recognition. EM alone is usually asymptomatic, but it may be painful and 
accompanied by other symptoms including fever, generally feeling unwell, headache 
and myalgia. If diagnosed during the early, localised stage, treatment in the UK 
should involve a 3 week course of oral antibiotics such as doxycycline (90). Antibiotic 
treatment has a high success rate when administered during this stage (91). Lyme 
disease may progress to a disseminated form when early, acute cases are missed due 
to asymptomatic presentation, or due to misdiagnosis.  
 
1.4.1.2. Early disseminated Lyme disease 
In the majority of cases, the innate immune system is capable of controlling bacterial 
burden in the dermis but is often unable to clear infection allowing for the 
dissemination of Borrelia and progress of disease. Dissemination to secondary 
colonisation sites requires continual and wide-ranging adaptation to overcome 
environmental changes and to allow successful evasion of the host immune response.   
can spread through non-haematogenous routes including by direct spread though 
tissue and the lymphatic system while dissemination through the circulatory system 
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allows colonisation of more distant sites (92) The most common manifestation of 
early, disseminated Lyme disease seen in the United States is the presence of multiple 
EM rashes, distinct from the original site of tick bite. The presence of multiple EM 
rashes is significantly more common in North America than in Europe (93). These 
secondary lesions appear around 2 weeks after the development of primary EM (94). 
Other symptoms associated with Lyme disease include Bell’s palsy and other cranial 
nerve palsies and meningitis. Neurological symptoms are more common in European 
cases of Lyme disease (95). Rarely, early stages of infectious carditis can also occur 
(96). Systemic symptoms during dissemination are again wide-ranging and non-
specific to Lyme disease including fever, myalgia, headache and fatigue. Treatment of 
Lyme disease that has progressed to the early dissemination stage often depends on 
the symptoms observed. The presence of multiple EM rashes, cranial palsy and early 
carditis are often still treated by oral antibiotics. In more severe cases of palsy or 
carditis, intravenous courses of antibiotics may be administered (97).  UK NICE 
guidance for treatment of early disseminated stages of Lyme not affecting the Central 
Nervous System (CNS) involves oral doxycycline for 21 days (90).  
 
1.4.1.3. Late disseminated Lyme disease 
Several factors influence the progression of disease from this early, localised disease 
to dissemination and the development of sequelae associated with later stages of 
Lyme disease. These include whether antibiotic treatment has been administered, 
together with host immunological factors. Without medical intervention, early, 
disseminated Lyme can progress to late stage disseminated Lyme disease. This stage 
of disease is often characterised by an increase in severity of previous systemic 
symptoms including headaches and fever, but is also associated with the development 
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of chronic conditions including Lyme arthritis, neuroborreliosis and more rarely, 
acrodermatitis chronicum atrophicans (ACA) or carditis. Encephalomyelitis and 
polyneuropathy are rare late stage manifestations (98). In the United States, Lyme 
arthritis is the most commonly recorded symptom of late stage infection, usually 
occurring several months following tick bite. Lyme arthritis can be intermittent or 
persistent depending on severity. Without prior antibiotic treatment, it is estimated 
60% of patients would develop Lyme arthritis (99), although several factors including 
host immunity and infecting genospecies of Borrelia are likely to influence the 
incidence of arthritis. The arthritis is usually monoarticular, affecting the large joints, 
but other manifestations of arthritis are not uncommon. In Europe, the condition 
acrodermatitis chronica atrophicans (ACA), a chronic dermatitis associated with EM 
rash is a common feature of late stage disseminated Lyme disease Prevalence of ACA 
in all European patients with Lyme disease is estimated to be 1-10%, although this 
figure is likely to vary widely depending on geographical location (100, 101).  
Neurological complications associated with Lyme disease, collectively known as 
neuroborreliosis, can occur during late stages of disease. Neuroborreliosis is more 
common in European patients, and often includes painful meningoradiculitis. More 
severe cranial nerve symptoms occur in around half of patients with neuroborreliosis, 
often with unilateral or bilateral facial nerve involvement (102). Symptoms of CNS 
involvement, including encephalitis and myelitis are rare in patients with early stage 
neuroborreliosis, but risk increases in absence of medical intervention (103). 
 
Treatment of the majority of late stage manifestations of Lyme disease including 
Lyme arthritis, early neuroborreliosis and ACA is usually by a 3-4 week of oral 
antibiotics. In more severe cases, or in the case of CNS involvement, intravenous 
	
	 25	
antibiotics may be prescribed. The benefit of long-term antibiotic therapy in the 
treatment of late stage Lyme disease has been widely discussed, but current evidence 
does not support any benefit in long-term treatment outweighing the well-documented 
risks associated with prolonged courses of antibiotics (104). 
 
1.4.1.4. Post-treatment Lyme disease syndrome 
The term post-treatment Lyme disease syndrome (PTLDS) has been used to describe 
continuing or relapsing symptoms in patients with previously treated Lyme disease. 
Some studies have shown up to 10% of patients with previously documented Lyme 
disease continue to report musculoskeletal or cognitive dysfunction after 
recommended antibiotic treatment (105). Most of these issues resolve with time, but 
in some cases, symptoms attributed to PTLDS have been reported several years after 
tick bite (106). PTLDS has not been fully defined, and the term is often used 
interchangeably with Chronic Lyme disease (CLD). The Centres for Disease Control 
and Prevention (CDC) in the United States describe PTLDS as: “Symptoms of pain, 
fatigue, or difficulty thinking that lasts for more than 6 months after a patient finishes 
treatment” (107). Other national guidelines on diagnosis and management of Lyme 
disease, including those of the National Institute for Health and Care Excellence 
(NICE), have avoided using either term and have concentrated on providing advice on 
treatment and diagnosis based on available evidence (83). Regardless of definition, the 
underlying biological mechanisms that result in some patients experiencing persisting 
symptoms following Lyme disease are not known. Many persistent symptoms 
reported in PTLDS share characteristics of autoimmune disease, potentially triggered 
by Borrelial infection. Other groups believe that ongoing symptoms can be attributed 
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to a persistent,  but difficult to detect, infection. Potential mechanisms of persistence 
in the host by Borrelia are discussed in the next section (1.4.1.5.). 
 
It can be argued that documented Lyme disease diagnosis and/or positive serology are 
requisite features of patients with PTLDS; however; misdiagnoses, false negative 
serology, and prescription of antibiotic treatment without serological confirmation of 
causative agent do occur in Lyme disease cases. Significant research challenges need 
to be met to understand how Lyme disease may be attributable to the development of 
any long-term symptoms.   
 
1.4.1.5. Chronic Lyme disease 
Chronic Lyme disease (CLD) can be broadly defined as the presence of persistent 
long-term symptoms that are associated with Lyme disease. There is no agreement on 
the exact criteria that constitutes a CLD patient, or an accepted clinical definition. The 
term has grown to cover a broad range of symptoms, some of which are associated 
with Lyme disease, including peripheral neuropathy and arthralgias (108); however, 
presence of more general symptoms including fatigue, cognitive dysfunction and 
headaches are too broad to rule out numerous other diseases. Without a definition for 
CLD, studies published using populations with putative CLD as a cohort seem to hold 
little value. The broad range of symptoms documented in patients with Lyme disease, 
together with the fact that certain manifestations of the disease including Lyme 
arthritis are chronic in nature, has likely led to cases of putative PTLDS or long-term 
symptoms of disease being missed from research, while patients suffering from other 
maladies are misdiagnosed as having CLD. Most criteria given of CLD, including 
those of the International Lyme and Associated Diseases Society (ILADS) (109), do 
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not include prior positive serology for Lyme disease, history of tick-bite or presence 
of certain distinguishing features including EM rash. The diagnosis of Lyme disease 
by conventional serology and by other more novel testing, including methods often 
associated with CLD diagnosis, are discussed in section 1.6.  
 
The underlying pathophysiological aspects of persistent symptoms attributed to Lyme 
disease are not well understood and remain a controversial subject. In other infectious 
diseases, some prior studies have shown higher risks of developing certain 
autoimmune diseases, including lupus in patients with prior Epstein-Barr virus (EBV) 
infection (110). The role of autoimmunity in Lyme disease is currently not well 
understood. ILADS and other groups attribute PTLDS/CLD to persistent infection 
with Borrelia s.l.. Several theories have been proposed to explain how the bacteria 
could persist whilst avoiding the host immune system, antibiotic treatment and 
detection by diagnostic methods. Some groups propose that Borrelia s.l. are capable 
of becoming an intracellular pathogen, penetrating host cells (111). Borrelia s.l. have 
previously been shown to predominantly occupy the extracellular matrix (112), and 
have been shown to disrupt pathways associated with host cell cytoskeletal 
rearrangement, including of collagen, in murine models (113, 114). While disruption 
of host cell structural mechanisms can be associated with intracellular pathogens 
including Listeria monocytogenes (115), Rickettsia rickettsii (116) and Shigella (117), 
the presence of similar mechanisms in Borrelia s.l. may only promote establishment 
within the extracellular matrix. Borrelia s.l. have been shown to be capable of 
invading human primary fibroblasts and endothelial cells following long co-culture in 
an ex vivo assay (118); however, sound peer-reviewed evidence demonstrating 
internalisation of Borrelia s.l. by non-immune system cells during infection in vivo is 
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lacking. Borrelia s.l. may be capable of forced cell internalisation within the human 
host; however, the influence, if any, of this ability on persistence in the host or  on 
disease progression is not known. Proponents of the intracellular persistence theory 
argue that Borrelia s.l. may evade being killed by antibiotics by hiding within host 
cells. In contradiction, doxycycline and other commonly prescribed antibiotics for 
Lyme disease are also currently recommended for the first-line treatment of Rickettsia 
(119) and other facultative intracellular bacterial pathogen (120) infections. 
 
There are numerous study design issues surrounding current publications promoting 
the use of extended antibiotic therapy for treatment of PTLDS or CLD, including a 
study featuring intravenous antibiotic delivery for up to 52 weeks (121). No 
conclusive evidence has shown that long-term use leads to substantial improvement in 
patient outcomes (91). The potential dangers to the patient surrounding long-term 
antibiotic use for Lyme disease are well-documented (122-125), and such therapy may 
drive development of antibiotic resistance (126). Numerous clinical guidelines from 
agencies and groups representing countries with endemic Lyme disease recommend 




Upon human contact with contaminated soil or water, the spirochaetes can enter the 
body through breaches in the skin, or through mucous membranes, then enter the 
bloodstream. A risk factor for contracting leptospirosis in humans is presence of leg 
wounds that allow transfer of the pathogen from a contaminated water source, often 
when performing tasks such as clothes washing (138). Upon entering the bloodstream, 
	
	 29	
the leptospires attach to endothelial cells of the blood vessel walls and subsequently 
move between cell layers facilitated by the corkscrew motion of the pathogen’s 
internal flagella. L interrogans is capable of attaching to a number of human cell 
types, but importantly has high affinity for kidney epithelial cells (139). Upon 
entering the host, Microbial Pathogen-Associated Molecular Patterns (PAMPs) on the 
bacterial surface can be recognised by Pattern Recognition Receptors (PRRs) of the 
innate immune system, causing activation of inflammatory responses. The upstream 
regulator proteins NF-kappa-B and activator protein 1 (AP-1) have been shown to be 
important in activation of immunological cascades in leptospirosis (140). 
Leptospirosis patients show increased expression of pro-inflammatory cytokines 
including IL-6, IL-12, IFNs, tumour necrosis factors (TNFs) that recruit cells of the 
immune system to the site of bacterial attachment. Severe forms of leptospirosis are 
often marked by dysregulation of immune and inflammatory response, often called a 
cytokine storm, that cause persistent inflammation and production of pro- and anti- 
inflammatory cytokines (141).  
 
Clinical manifestations of infection are highly variable in humans and in 90% of cases 
are mild or asymptomatic and resolve spontaneously (142). In the 10% of cases that 
show persistent infection, symptoms can be very severe and may affect multiple 
organs. Systemic symptoms of infection include febrile illness of sudden onset, 
headache, myalgia and, rarely, a skin rash. In such cases of icteric leptospirosis with 
jaundice, the clinical course is often rapidly progressive. Complications of severe 
leptospirosis are wide ranging, a reflection of the multisystem nature of infection. An 
important manifestation of leptospirosis is kidney damage and acute kidney injury 
(AKI), which occurs in up to 40% of icteric cases (143). AKI is characterised by 
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tubule dysfunction, hypokalemia and cell necrosis. Activation of inflammatory 
processes by recognition of bacteria by toll-like receptors (TLRs) elicits tubular 
inflammation and damage and can also lead to the accumulation of extracellular 
matrix in the kidney (144). Ocular manifestations are seen in a significant number of 
cases, with incidence reaching up to 40% in certain high-risk groups (145). 
Conjunctival suffusion is not commonly found in other febrile illnesses and its 
presence, along with sceleral icterus (eleveated serum bilirubin causing yellowing of 
the eye) is considered pathognomic of severe leptospirosis (145). Jaundice is also 
commonly reported in patients with severe leptospirosis, likely to be caused by the 
host inflammatory response. Necrosis of muscle fibres, particularly in skeletal 
muscles is also observed in many cases and may account for the intense myalgia 
reported by some patients (146). Severe leptospirosis can also affect the brain and 
spinal cord with potential development of meningitis and/or encephalitis (147). 
 
1.4.3. Syphilis 
Venereal syphilis can present in four stages: primary, secondary, latent and tertiary. 
Primary infection, most often acquired by sexual contact with the infectious lesions of 
a sexual partner is marked by the development of chancre at the point of contact after 
10-90 days (60). The helical nature and flagella of T.p. pallidum facilitates access of 
the bacteria into the host through breaches in squamous or columnar epithelium. In 
heterosexual men, chancres most often occur on the penis, but can occur in other sites 
including the rectum and oral cavity. In women, primary lesions usually occur on the 
labia or cervix. A significant proportion of lesions are painless, leading to delayed 
diagnosis in a number of cases (148). Secondary syphilis occurs a number of weeks 
following primary infection and is marked by development of symptoms including a 
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non-itchy rash on the skin, condyloma latum lesions on mucous membranes and 
systemic symptoms such as fever, sore throat and general malaise (149). Latent 
syphilis is described as the period of time when no visible signs or symptoms of 
syphilis occur, but the pathogen is still living in the host in a dormant state. Latent 
syphilis occurs as early as 1 year following primary infection and, depending on the 
definition, can last up to 2 years. Depending on the stage of latency, subjects can still 
be contagious during this time (150). Tertiary syphilis relates to long-term, end organ 
complications associated with syphilis infection, occurring several years after primary 
infection. Around 35% of patients with latent syphilis will go on to develop tertiary 
syphilis. Complications involving the CNS (neurosyphilis), the cardiovascular system 
(cardiovascular syphilis) and non-cancerous growths (gummas) are the main 
observations seen with tertiary syphilis. Penicillin injections remain as the most 






















































In most countries, blood serological testing remains the diagnostic standard for 
syphilis. The standard processes involves a nontreponemal test (NTT) followed by a 
treponemal test (TT) (158). Detection of at least one NTT antigen and one TT antigen 
is sufficient to confirm syphilis.  NTTs, such as the rapid plasma reagin test (RPR) are 
used to monitor the state of infection by measuring levels of IgG and IgM antibodies 
produced in response to material released from damaged host cells, primarily 
cardiolipin. As the test measures IgG and IgM, the test is relatively effective even in 
early infection, with 75% sensitivity seen during primary syphilis (158). NTTs can 
also be used to monitor progression of disease and response to treatment. TT tests are 
specific to T. pallidum infection and detect the presence of pathogen-specific 
antibodies. The commonly used T. pallidum hemagglutination assay (THPA) and T. 
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pallidum particle agglutination assay (TPPA) are indirect agglutination tests in which 
bacterial surface antigens are coated onto red blood cells or gelatin particles 
respectively. Patient serum is mixed with these substrates and, if sufficient specific 
host antibodies to T. pallidum are present, agglutination occurs. The TTPA test is one 
of the first tests to become reactive in primary syphilis and is often used as an initial 
test together with specific IgM (159). Western blot methods can be used for detection 
of specific antibodies for both IgM and IgG with many tests now using immunoblots 
of recombinant antigens derived from T. pallidum (160).  
 
No centralised system for diagnostic testing exists for syphilis in the UK, with testing 
often conducted locally or on site following presentation with suspected syphilis. In 
suspected early primary syphilis, PHE guidelines recommend sampling of syphilitic 
lesions (chancres) for treponemal PCR together with dark ground microscopy where 
available (161). For serological testing, the stage of disease may influence the most 
suitable test. Generally, it is recommended that an initial test for treponemal specific 
antibodies is undertaken (EIA or CLIA detecting IgG and IgM). In the case of 
negative results, retesting may be appropriate particularly if tested within 2-4 weeks of 
infection, as the patient may not have seroconverted. In the case of positive EIA or 
CLIA, a second confirmatory test is recommended and may involve TPPA, TPHA or 
TPLA methods. As with other serology based diagnostic methods, laboratory test 
results must be considered together with the clinical and geographical background of 
the patient.  
 




1.6.   DIAGNOSTICS FOR LYME DISEASE  
 
1.6.1.   PCR and culture for diagnosis of Lyme disease 
Quantitative real-time PCR tests have been extensively developed in recent years for 
the routine diagnosis of bacterial diseases. PCR based tests detect the presence of 
specific bacterial DNA directly and therefore do not require the development of an 
antibody response. In Lyme disease, the blood-borne phase of dissemination is 
relatively brief and the number of spirochetes in infected tissues remains low even in 
late stages of disease. For this reason, the efficacy of PCR-based tests for Lyme 
disease diagnosis is highly dependent on the type of biological sample collected. The 
sensitivity of PCR for detection of spirochete DNA in EM lesion samples, where the 
bacteria are actively replicating, is relatively high. In a study using skin biopsy 
samples from patients with EM, DNA was detected in 71% of samples (162). Several 
other studies in Europe and the United States have shown similar levels of sensitivity 
in skin biopsy based PCR tests (162-164). While the sensitivity of PCR for EM skin 
biopsy samples is comparatively high, particularly in cases of acrodermatitis chronica 
atrophicans, performing such biopsies is invasive, not routine and is unlikely to be 
applicable to clinical diagnosis on a wide scale. As most studies only show high levels 
of sensitivity for PCR in patients with EM, it is unlikely that PCR will have value in 
the diagnosis of patients with atypical symptoms. A positive result by PCR confirms 
detection of pathogen DNA but does not distinguish between viable or dead bacteria. 
 
The direct culture of viable spirochetes from clinical specimens remains the gold 
standard for diagnosis of Lyme disease. In routine diagnosis, however, culture is 
rarely utilised. Culture of B. burgdorferi requires expensive Barbour-Stoenner-Kelly 
	
	 36	
medium and, due to the slow replication rate of the bacteria, is a time-consuming 
process. Recovery of spirochetes from 2-4mm biopsy samples of EM lesions can be 
achieved in at least 40% of untreated patients, with some studies reporting a success 
rate of above 86% (165).  Recovery of bacteria from blood, serum and plasma is 
unusual, with success rates generally below 5%. While recent advances in culture 
techniques have improved the sensitivity of culture, it is still an arduous process and 
studies in which B. burgdorferi were recovered required the use of large volumes of 
blood and would therefore be unlikely to be suitable for routine diagnosis (166, 167).  
A recent study describing a novel method for serum culture claimed 94% sensitivity 
and 100% specificity (168) lacked adequate steps to rule out false positivity due to 
contamination. The results of this study have not been able to be validated in other 
laboratories.  
 
1.6.2.  Standard Two-Tier Testing Protocol for Lyme disease diagnosis 
The PHE Rare & Imported Pathogens laboratory (RIPL) provides specialist Lyme 
disease testing for England and Wales, and follows an STT algorithm. The first test 
uses an ELISA to detect host serum antibodies against the C6 peptide, a conserved 26-
amino acid sequence of the variable major protein like sequence-expressed (VLsE) 
lipoprotein of B. burgdorferi. The test has been shown to be capable of detecting all 
the major infectious European Borrelia species (B. afzelii, B. garinii and 
B.burgdorferi s.s.) (169). The C6 ELISA measures the presence of both IgG and IgM 
antibodies and does not differentiate the abundance of one from the other. In the case 
of a positive or indeterminate result by C6 ELISA, samples are taken forward for 
confirmatory testing. At PHE RIPL, this takes the form of an array-based immunoblot 
with separate tests for IgG and IgM antibodies. The base of each well of a 96-well 
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plate is pre-printed with antigen spots (in triplicate) and uses a number of antigens 
from Borrelia, including native antigens purified from the bacteria together with 
recombinant VlsE antigens at defined positions, each in triplicate. The interpretation 
criteria of the tests are dependent on the type (IgG or IgM) and are based upon 
detection of a requisite number of positive reactions to a defined range of antigens. 
The two-tier method was developed from 1995 onwards by the CDC and other 
agencies (170). The fist-step in the assay is intended to generate an objective value 
that correlates with the degree of the antibody reaction to infection. As the 
confirmatory second-step is ultimately based on visual interpretation, pairing the step 
with the objective C6 ELISA serves to reduce erroneous positive results if weak bands 
are scored as positive (171). Figure 1.6 shows the pathway used by PHE RIPL for 





Figure 1.6: Diagram showing the pathway of testing for routine diagnosis of Lyme 
disease in the England, Wales and Northern Ireland. Serological testing should 
interpreted in the context of the patient’s clinical history 
 
1.6.3. Accuracy of STT testing for Lyme disease. A review of European and 
North American studies 
Previous studies into the efficacy of STT and related serological methods have 
reported a wide range of values for sensitivity and specificity of said tests. A variety 
of factors including disease stage, specific assay format and testing regime can 
influence the result of the test. A broad conclusion based on these studies is that 
serological testing is less efficacious in early disease when host immune response to 
infection is still developing. When used in patients with manifestations of 





sensitivity and specificity are much improved. Here, available studies into serological 
testing for Lyme in both Europe and North America were reviewed and details of the 
reported sensitivity and specificity of the test were recorded. Table 1.1-1.4 show a 
summary of data from available studies into serological testing for Lyme disease, and 
is divided into subcategories for early Lyme disease, Lyme arthritis, acrodermatitis 
chronica atrophicans and neuroborreliosis. Reported sensitivity and specificity for IgG 
and IgM are given where available, together with a quality score based on several 
factors including cohort size, inclusion of appropriate controls and risk of bias or 
potential conflict of interest.  
 
1.6.4.  Shortcomings of STT testing for Lyme disease diagnosis 
Serological testing for Lyme disease requires the detection of antibodies against 
borrelia antigens. Unsurprisingly, during acute stages of infection, when the adaptive 
immune response is still developing, serological testing is less effective showing poor 
sensitivity. A study by Aguero-Rosenfeld (172) used a commercially available ELISA 
and immunoblot to test sera from 100 patients at various stages of Lyme disease and 
found that sera of all patients with a history of EM for more than 14 days duration 
were reactive by both tests. A later study by the same group investigated the 
appearance of IgM and IgG to borrelial antigens in patients with culture-proven EM. 
257 serially collected samples were tested by the 2-tier (STT) method. At baseline, 
33% and 43% had positive ELISA and immunoblot results respectively. At 8 to 14 
days, 91% of patients had a positive 2-tier result (173). A study by Engstrom et al 
found that the sensitivities of the IgM and IgG immunoblot for detecting seropositive 
patients were 58.5% and 54.6% respectively at presentation and 100% during their 
second visit, 8 to 12 days into treatment (174). Patients may therefore test 
	
	 40	
seronegative for Lyme disease by confirmatory Western blots at time of presentation 
despite having clinical symptoms of Lyme disease and assessment of in-house scoring 
criteria for WB analyses is essential (175), together with consideration of clinical 
symptoms during diagnosis. Due to the persistence of antibodies and the development 
of memory B and T cells, patients can continue to test positive for Lyme disease long 
after infection has been cleared by antibiotic treatment.  
 
It has been shown that the genotypes of B. burgdorferi s.l. often cause differing 
manifestations of disease with some having greater proclivities for certain tissues than 
others (176). A study by Wormser et al (177) investigated the effect of genotype on 
the sensitivity of C6 and STT testing in the USA. Testing was performed on acute-
phase serum samples obtained from 158 patients with EM for whom genotype of the 
isolate was defined based on analysis of ribosomal DNA or genetic variation in OspC. 
The group found that the sensitivity of C6 testing alone was significantly greater than 
STT testing. The sensitivity of STT testing varied according to genotype, with one 
genotype group twice as likely as another to be seropositive despite all patients having 
culture-confirmed Lyme disease indicating infecting genotype does influence the 
efficacy of current 2-tier testing protocols. A later study by the same group 
investigated the utility of diagnostics designed for the US for Lyme disease acquired 
in Europe and vice versa (178). In the US, Lyme disease is caused exclusively by 
Borrelia burgdorferi s.s. while in Europe, several pathogenic strains circulate 
including B. afzelli and B. garinii (171, 179).  The study found that the sensitivity of 
C6 two-tier testing with US assays was 22.5% for detection of LB acquired in Europe. 
In European patients with neurological involvement, the sensitivity of the US test was 
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even poorer at 20%.  Sensitivity of the European C6 two-tier testing was significantly 
higher at 70%. 
 
1.6.5.  European and North American Systematic reviews of serological testing 
for Lyme disease 
In 2016, the European Centre for Disease Prevention and Control published a 
systematic literature review on the diagnostic accuracy of serological tests for Lyme 
disease. The summary estimates for sensitivity for any enzyme immunoassay or 
immunoblot were: 0.50 (95% CI 0.40-0.61) for erythema migrans stage, 0.77 (95% CI 
0.67-0.85) for neuroborreliosis, 0.96 (95% CI 0.89-0.98) for Lyme arthritis, 0.97 (95% 
CI 0.94-0.99) for acrodermatitis chronica atrophicans and 0.73 (95% CI 0.54-0.87) for 
unspecified disease stage. Estimates for specificity were around 95% for all disease 
stages (180). A large heterogeneity was observed for all disease stages and the study 
concluded that there was not sufficient evidence to make inferences about the value of 
tests for clinical practice; however it was noted that in early stages of disease, 
sensitivity and specificity of serological tests were demonstrably lower. 
A similar systematic review, also published in 2016, was undertaken by the Public 
Health Agency of Canada and covered North American research into the accuracy of 
diagnostic tests for Lyme disease. The summary estimates for sensitivity for any 
enzyme immunoassay or immunoblot were: 0.46 (95% CI 0.39-0.54) for early acute 
Lyme disease, 0.90 (95% CI 0.78-0.95) for early neurological and cardiac Lyme 
disease and 0.99 (95% CI 0.96-0.99) for late neuroborreliosis and Lyme arthritis 
(181).   The wide range of serological testing protocols in laboratories across North 
America was noted, with validation data available for only a small proportion of 
licensed assays. A large number of “in house” assays are also in use. For the majority 
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of these, composition of the test is not publicly available and they are not validated by 
peer-reviewed literature. Criteria used for the evaluation of serological tests, 
particularly those that require discretion of the person conducting the test such as 
Western blot, was also rarely described; therefore, comparison between testing 
regimes and commercial tests was not particularly informative. Generally, the results 
of the North American review correlated with those of the European review: a positive 
association between duration of infection/stage of disease and sensitivity of 
serological Lyme disease tests. A large heterogeneity between studies was found that 
could only partially be explained by covariates. Some studies may have used selection 
criteria that only included patients that were culture positive for Lyme disease. Both 
systemic reviews concluded that serological testing for Lyme disease needs to be 
conducted with caution, and should be conducted in combination with considerations 























































































1.6.6.1. T-cell directed tests 
The Lymphocyte Transformation Test (LTT) measures the proliferation of antigen 
specific T cells in response to antigen challenge in vitro, from which it is assumed 
that proliferation correlates with previous sensitisation of T-cells to the antigen. 
Peripheral blood mononuclear cells are cultured with different concentrations of the 
antigen of interest for a period of several days. Throughout the 1990s, several groups 
investigated the potential of LTTs for the diagnosis of Lyme disease (182-185) mostly 
using lysates from whole B. burgdorferi that were antigenically heterogeneous and 
included known non-specific mitogens such as bacterial lipopolysaccharides (186, 
187). The LTTs themselves were often non-validated and non-standardised and the 
sensitivity and specificity were found to be generally poor in most studies and results 
were not reproducible. 
 
In 2006, Valentine-Thon et al reported an improved LTT format, the memory 
lymphocyte immunostimulation assay (LTT-MELISA) for use in the diagnosis of 
Lyme disease (186).  The test uses a higher number of lymphocytes (1x106 per well) 
with 4 well-characterised recombinant Borrelia antigens (from B. afzelii and B. 
garinii but not B. burgdorferi s.s.) as stimuli. Similarly, Von Baehr et al also sought 
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to improve the borrelia LTT by using lysate antigens from B. burgdorferi s.s., B. 






diagnosis	of	Lyme	disease.		An alternative type of test that detects stimulated antigen 
specific T cells is the enzyme-linked	immunospot	(ELISpot). After short, typically 
overnight, antigen challenge, cytokine secretion, commonly interferon-gamma (IFN-
g), by activated antigen-specific T cells is detected as a spot around the secreting cell. 
These tests can also be known as IFN-g release assays (IGRAs) and IFN-g can be 
measured in the soluble phase as an alternative to the spot-based ELISpot systems. 
Commercial IGRA and ELISPOT test are licensed for the diagnosis of tuberculosis.	
As with LTT, there is great variability in ELISpot formats, particularly around the 
selection of stimulating antigens and questions surround the clinical validity of 
ELISpot- based tests for Lyme disease. There is again an urgent need for independent 
studies to determine whether ELISpots have a higher sensitivity during early infection 
than STTT or MTTT and whether they are able to discriminate between past and 
active infection. Preliminary evidence suggests that the ELISpot cannot discriminate 
between past and active neuroborreliosis (189) and more comprehensive studies are 





1.6.6.2. Alternative tests for Lyme disease 
Another proposed method for Lyme disease diagnosis is the detection of biological 
material from B. burgdorferi in the host. Many of the tests based on this method are 
likely to suffer the same issues seen in the use of PCR for detection of bacterial DNA: 
that in Lyme disease, bacteraemia is low and any testing methods would need to be 
very sensitive, assuming any bacterial material is present in a test sample at all. An 
antigen capture test for OspA of B. burgdorferi in patient urine has been proposed 
several times since the mid-1990s, but has repeatedly been shown to be unreliable in 
peer-reviewed validation studies (191). A 2015 study into the use of particle based 
high-affinity chemical baits, known as nanotrap, for detection of OspA in urine 
showed sensitivity and specificity values approaching 100% for early Lyme disease 
(192); however, the study was funded by the test manufacturer and no independent 
studies assessing the approach have subsequently been published. Several other 
proposed testing methods for Lyme disease including measurement of antibodies in 
joint fluid, quantitative CD57 lymphocyte assays and immunofluorescence staining 
lack adequate scientific review and are not recommended for diagnosis of Lyme 










1.7.    PROTEOMIC ANALYSIS FOR DIAGNOSTIC BIOMARKER 
DISCOVERY 
 
Proteomics is the large-scale study of a set of proteins produced in an organism, 
system or within a given biological specimen. Advances in study methods and 
instruments has allowed the field to move from being purely qualitative to being 
quantitative, allowing comparison of the quantity of specific proteins between sample 
groups with increasing accuracy. This has led to great interest into the discovery of 
proteins that are biomarkers of disease; proteins that are consistently present at 
abnormal levels that can be measured with specific and sensitive methods. Over the 
last two decades, many studies have utilised proteomics approaches for discovery of 
potential biomarkers for many diseases, including genetic disorders, cancer and 
infection.  
 
1.7.1.  Proteomic based studies of Lyme disease 
Relatively few proteomic based Lyme disease biomarker discovery studies have been 
published. A 2011 study by Schutzer et al (194) used a high-resolution mass 
spectrometry approach to compare pooled cerebrospinal fluid from well-characterised 
Neurologic Post Treatment Lyme disease (nPTLS) patients, Chronic Fatigue 
Syndrome (CFS) patients and healthy controls. They found that groups and 
individuals within groups could be distinguished based on their CSF proteins. While 
these comparisons were made between the entire CSF proteomes of the groups, the 
results showed that each condition has a multitude of candidate diagnostic biomarkers 
for future validation studies. A similar study was conducted in 2012, comparing the 
CSF proteome of patients with acute Lyme disease to a control group (171). Liquid 
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chromatography tandem mass spectrometry (LS-MS/MS) was used to compare 
pooled CSF patients diagnosed with early disseminated Lyme disease and CSF 
inflammation (n=26) against control samples (n=19) and identified 108 proteins that 
differed significantly and consistently between groups. 
 
Both of these studies showed promising results and proof of concept that highly 
sensitive proteomic analysis can be used to distinguish between patient groups. 
However, it should be noted that both studies were based on the analysis of 
cerebrospinal fluid that, while representing the best biological specimen for studying 
the pathogenesis of brain infections, including Lyme neuroborreliosis (LNB), would 
not form the ideal basis for a novel diagnostic test for early Lyme disease The lumbar 
puncture operation involved in obtaining CSF is not a routine procedure and is usually 
avoided unless neurological complications are suspected (195). In a targeted approach 
of 58 immune mediators and 7 acute phase proteins, the T cell chemokines CXCL9, 
CXCL10 and CCL19 and serum amyloid A1 were found to be increased the serum of 
Lyme disease patients (196). A similar targeted study of chemokine response 
proposed the protein CCL19 as a marker of posttreatment Lyme disease syndrome 
(197). 
 
1.7.2. Proteomic biomarker discovery in other infectious diseases 
While there has been relatively little research into proteomics-based biomarker 
discovery in LD, many studies have been conducted on several other infectious 
diseases. The decision to treat active tuberculosis (TB) shares several problems with 
Lyme disease diagnosis. In a similar manner to the 2-tier serology based test currently 
in use for LD, the tuberculin skin test and interferon-gamma release assay are based 
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on the host immune response and cannot distinguish active TB from cleared or latent 
infection (198, 199). As with Borrelia, mycobacteria are slow growing bacteria and 
attempts to culture from patient samples have low sensitivity (200). DNA detection by 
PCR is often complicated due to difficulty in obtaining suitable samples from the site 
of infection. Microscopy remains the first-line diagnostic approach, but its efficacy is 
dependent on bacteremia and ability of the operator. Therefore, many studies have 
investigated the discovery of biomarkers for improved diagnostics of active TB. A 
2013 study by Liu et al (201) comparing serum samples from 180 cases of TB to 211 
control samples established a model based on four biomarker proteins that could 
distinguish TB from controls with sensitivity and specificity of 83.3% and 84.2% 
respectively. 
 
While studies such as this and numerous others have shown promising results, there 
has been relatively little progress in the development of biomarker based diagnostic 
tests. A review by Haas et al (202) of all TB proteomic biomarker studies published 
to date found that biomarker candidates reported varied considerably between studies 
and that there was an inability to verify certain biomarkers in subsequent studies. 
 
1.7.3. Proteomic biomarker discovery in non-infectious diseases 
The field of cancer diagnostics has demonstrated the potential of biomarkers. Over-
expression of HER-2/neu has previously been shown to play a role in the 
development of node-negative breast cancer (203, 204). The protein is now used as 
the basis of several diagnostic tests to determine HER-2 status, with a positive result 
leading to HER-2 targeting therapy such as trastuzumab. Similarly, overexpression of 
epidermal growth factor receptor (EGFR) has previously been used as a selection 
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criterion for the enrolment of patients for clinical studies of the colorectal cancer drug 
cetuximab (205).  In general, cancer biomarkers represent proteins that are involved 
in disease development and are typically expressed at such high levels to allow 
detection. This, in part, explains the relative success of biomarkers in cancer 
diagnostic compared to other disease groups, where biomarkers may represent 
proteins that are indirectly related to pathogenesis and are therefore more likely to be 
subject to variability between patients.  
 
1.7.4. Other considerations in proteomic biomarker discovery 
The problems faced in the above examples are common to many proteomic based 
biomarker discovery studies. The lack of reproducibility between studies is likely to 
be due to several factors including differences in experimental design, patient cohort 
and inherent variability due to machine limitations and the complexity of biological 
samples(206). Serum, cerebrospinal fluid and other biological fluid proteomes are 
complex, with wide protein concentration range and dynamics. In blood, more than 10 
orders of magnitude in concentration separate albumin from the rarest proteins present 
(207). To overcome this complexity, fractionation methods including column 
chromatography and the use of depletion columns specifically designed to remove 
highly abundant proteins can be used. While this allows the study of rarer proteins 
that are more likely to be influenced by infection, the complexity of the process and 
use of different fractionation and depletion methods contributes to the lack of 
reproducibility between studies (208). 
 
With the discovery-based ‘shotgun’ proteomics studies previously described, as many 
proteins as possible were identified in order to discover potential new biomarkers. 
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Another approach is the use of targeted proteomics where a select few proteins of 
interest are analysed in samples with high sensitivity, reproducibility and reliable 
quantification. A commonly used method in target proteomics is selected reaction 
monitoring (SRM). SRM commonly utilises triple quadrupole mass spectrometers, 
with the first stage involving isolation of the precursor ion of interest before further 
fragmentation to yield product ions which form the mass spectra (209). Using isotopic 
labeling as a concentration standard, SRM can be also used to provide highly accurate 
quantification (209). As a more specific approach, targeted proteomics has been 
shown to be more reproducible between studies than shotgun methods. 
 
 
1.8.  TRANSCRIPTOMIC AND METABOLOMIC ANALYSES FOR 
BIOMARKER DISCOVERY 
 
1.8.1. Transcriptomic based study of disease 
Transcriptomics is the study of the transcriptome – the set of all messenger RNA 
present in an organism, single cell or biological sample. Many studies examining the 
human transcriptional response to various bacterial infections have been published. 
The majority of these were designed to investigate the pathogenesis and 
immunological response to specific infections rather than being specific biomarker 
discovery studies; however, with the advent of more sensitive techniques and 
application of algorithms to identify characteristics including machine-learning, many 
researchers are now looking to transcriptomic data to identify transcriptomic patterns 




 1.8.1.1. Transcriptomic based study of Lyme disease 
The first, and currently only, transcriptome analysis of the human host response to 
acute Lyme disease was published in 2015 (210). The study involved longitudinal 
transcriptome analysis of PBMCs from 29 Lyme disease patients and 13 matched 
controls. Transcriptome profiling by RNA sequencing and pathway analysis of 
samples at three time points ranging from time of Lyme disease diagnosis to 6 months 
after completion of antibiotic therapy, revealed distinct differences between study 
groups. As the study involved analysis of the same patients at different stages of 
disease, comparisons could be made between subsets of patients with differing 
clinical outcomes including full recovery at 6 months or development of persistent 
symptoms post-treatment. The underlying pathogenesis and patient predisposition to 
development of persistent symptoms after treatment, also known as post-treatment 
Lyme disease syndrome (PTLDS), is currently poorly understood. Interestingly, the 
study found that the average duration of acute illness i.e. the time of onset of 
symptoms such as EM and initiation of antibiotic treatment was significantly longer 
in patients who went on to develop persistent symptoms; suggesting delayed 
antibiotic treatment may have a role in the development of persistent symptoms and 
highlights the need for Lyme disease diagnostics capable of detecting the earliest 
stages of disease. Analysis of Lyme disease patients at time of diagnosis and normal 
healthy controls revealed a total of 1,235 differentially expressed genes (DEGs). 62% 
of DEGs identified at the first time point were also differentially expressed at the time 
of completion of antibiotic therapy. Notably, no differential gene expression was 
observed between Lyme disease patients with resolved illness after treatment and 
those that developed persistent symptoms at 6 months. The Lyme disease 
transcriptome did not fully return to baseline relative to controls even at the final time 
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point of 6 months showing that the host-response to Lyme disease appears to be 
active even after clinical resolution of symptoms. Pathway analyses revealed the 
activation of genes involved with the inflammatory response. Predicted canonical 
pathways included the elongation initiation factor 2 (eIF2) signaling pathway 
involved in translation initiation in response to stress during infection. Immune cell 
trafficking and hematologic system pathways were also found to be increased in 
Lyme disease positive patients; future studies may therefore benefit from the 
inclusion of related disease control groups to elucidate how specific the identified 
DEGs were to early Lyme disease rather than a generic response to acute bacterial 
infection.  The group did go on to compare the RNA-seq data to 12 previously 
published transcriptome data sets for several other infections other than Lyme disease 
and found that while a proportion of DEGs were common to several groups, the Lyme 
disease transcriptome was still distinguishable; however, many of the transcriptomes 
included used different methodologies or were based on in vitro infection of cells and 
may therefore not be ideal for direct comparison. In a study of the transcriptional 
patterns seen in EM biopsy samples from untreated adult Lyme disease patients, 254 
differentially regulated genes were identified and were characterized by the induction 
of chemokines, cytokines, antimicrobial peptides and other innate and adaptive 
immunity related genes (211).  
 
1.8.1.2. Transcriptomic studies in other diseases  
While very few transcriptomics papers exist for LD, for other infectious diseases that 
have been more widely researched, several problems exist despite some promising 
results. A review of transcriptomic tuberculosis studies by Haas et al found that 
published signatures varied widely in size and showed limited overlap between 
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studies (212). It is likely that differences in study design, as well as patient selection 
form the major contributing factor for the lack of continuity between studies and 
therefore are an important consideration in the design of future transcriptomic studies. 
Gene transcripts do not necessarily correlate to measurable changes in proteins due to 
transcripts being non-protein coding, short protein half-life, degradation of mRNA 
and post-translation modification of proteins(213). A 2012 review found the 
correlation to be as little as 40% in some systems(214).  This is an important 
consideration when transcription data is to be used to identify potential biomarkers for 
follow-up work at the protein level. 
  
1.8.2. Metabolomic based study of disease  
The metabolome represents the total number of metabolites present within an 
organism, cell or biological sample. While transcriptomic and proteomic analysis 
provide information on the set of gene products either being expressed or present in a 
sample, metabolomics involves the study of small molecule metabolites present. As 
with many transcriptomics studies, much of the research into the metabolome in 
infectious disease has the main aim of gaining novel biological insights into 
pathogenesis; however, as the metabolome is known to be highly influenced by acute 
infection, it is an attractive area for diagnostic biomarker discovery.  
 
1.8.2.1. Metabolomic based study of Lyme disease 
A 2014 study by Molins et al. used retrospective serum samples to develop a 
metabolic biosignature for the detection of early active Lyme disease (215). Well-
characterised samples from patients with early Lyme disease were analysed using 
liquid-chromatography-mass spectrometry and the results compared to a large cohort 
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of non-Lyme disease controls including patients with related diseases including 
syphilis, periodontitis, infectious mononucleosis and fibromyalgia. The initial liquid-
chromatography stage allowed the analysis of low molecular mass (<1500 Da) 
biological molecules only and therefore decreased the overall complexity of the 
sample while allowing high-accuracy detection of small molecules. Sera and 
corresponding LC-MS data were randomly separated into discovery/training and test-
samples. A molecular feature extractor algorithm was then used to develop a 
metabolic biosignature for early Lyme disease A biosignature of 95 MFs (molecular 
features) that were consistently increased or decreased was developed for early Lyme 
disease when compared to healthy controls. Predictive chemical formulae were 
developed for the majority of the MFs were found and identified metabolites could be 
classified as lipids or polyunsaturated fatty acids. While the exact origin or function 
of the metabolites identified is difficult to determine, this is not vital information as 
the nature of a test based on metabolomic data would only require that the metabolic 
biosignature would be consistent and reproducible between samples and specific to 
early Lyme disease. A study of metabolites in the urine of Lyme disease patients in 
comparison to infectious mononucleoisis patients and normal healthy controls 
revealed dysregulation of several metabolic processes in early Lyme and showed that 
metabolic biosignatures could be discriminatory between groups (216).  
 
1.8.2.1. Metabolomic based study of other diseases 
Several studies have investigated the potential of metabolic profiling for the diagnosis 
of infectious disease. A notable example is a 2013 study by Tritten et al which 
identified urinary metabolites as candidate diagnostic markers of malaria. The group 
used a nuclear magnetic resonance approach followed by multivariate modelling to 
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identify two urinary metabolites that were found only in Plasmodium infected mice. 
The metabolites have not been described in the mammalian or parasite metabolome to 
date and were present only in Plasmodium infected mice. Antigen-detecting rapid 
diagnostic tests (RDTs) for malaria have been rigorously studied and tested over 
recent years and show many advantages over existing tests; however, clinical 
sensitivity remains relatively poor and high potential of co-infection with parasitic 
worms complicates diagnosis. Potential co-infection and seropositivity due to 
previous infection are issues that also affect Lyme disease diagnosis and need to be 



















1.9.  Aims of the study 
The negative-predictive value of current serological testing protocols for Lyme 
disease including STT have been questioned, particularly in the earliest stages of 
disease. In this study, proteomic (mass-spectrometry based) and transcriptomic 
(RNA-seq based) approaches were taken to attempt to identify host-derived markers  
that may hold diagnostic potential. Particular interest was placed in the discovery of 
markers that were detectable in early disease. In addition, computer analyses of 
proteomic and transcriptomic data were used to further explore the host response to 
Borrelia s.l. infection. The aims of this study are: 
 
1. To investigate the issues surround current testing methodology for Lyme 
disease. 
2. To use label-free quantitative mass-spectrometry and downstream analyses to 
identify protein markers of Lyme disease. 
3. To use mRNA sequencing and differential gene expression analyses to 
identify gene markers of Lyme disease. 
4. To compare early and late stage Lyme disease cases by mRNA sequencing 
and identify gene markers that are indicative of early disease. 
5. To further investigate the host response to Borrelia s.l. infection by computer 




CHAPTER 2: MATERIALS AND METHODS 
 
2.1.  HUMAN CLINICAL SAMPLES 
Human serum, plasma and whole-blood samples were used during this study. The 
samples are divided into 9 groups based on their infectious disease status and 
provider.  
 
2.1.1. Ethics statement 
All samples were anonymised before receipt. Sample groups 1, 2, and 5 were 
provided by the Rare and Imported Pathogen Lab - PHE Porton, and the Bacterial 
Reference Department – PHE Colindale. They consist of residual samples from 
routine diagnostic testing. All patients had given consent for anonymised residual 
samples to be used for research purposes by PHE. Groups 3, 4 and 9 were provided 
by Ales Chrdle, Hospital Ceske Budejovice and had prior ethical approval from 
Czech Republic regulatory bodies for use in research. Group 7 were provided by the 
NHS Blood Transfusion Service (NHS-BT) with ethical approval for their use in 
research in place. Group 8 were also provided by PHE, Porton and consisted of 
healthy/normal control samples. Ethical approval for the use human samples in this 









2.1.2. Sample list 
GROUP 1: UK LYME DISEASE POSITIVE 
Sera submitted for Lyme disease testing that are seropositive and have a clinical 
history / symptoms consistent with early Lyme disease. 
Type: Serum, Retrospective; residual diagnostic samples 





GROUP 2: UK LYME DISEASE SERONEGATIVE 
Sera submitted for Lyme disease testing that are seronegative and have a clinical 
history / symptoms not consistent with early Lyme disease. 
Type: Serum, Retrospective; residual diagnostic samples 





GROUP 3: CZECH LYME DISEASE POSITIVE 
Sera submitted for Lyme disease testing that are seropositive and have a clinical 
history / symptoms consistent with early Lyme disease. 
Type: Serum, Retrospective; residual diagnostic samples 
Source: Hospital Ceske Budejovice                         Table 2.3: Group 3 sample details                                                
 
 
GROUP 4: CZECH LYME DISEASE NEGATIVE 
Sera submitted for Lyme disease testing that are seronegative and have a clinical 
history that is not consistent with early Lyme disease. 
Type: Serum, Retrospective; residual diagnostic samples 
Source: Hospital Ceske Budejovice                     Table 2.4: Group 4 sample details 
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GROUP 5: LEPTOSPIROSIS POSITIVE 
Positive diagnostic samples consistent with acute leptospirosis (seronegative for 
Lyme disease by STT testing) 
Type: Serum 
Source: RIPL & BRD, PHE                              Table 2.5: Group 5 sample details 
 
 
GROUP 6: SYPHILIS POSITIVE 
Positive diagnostic samples consistent with recent/active syphilis 
Type: Serum 
Source: BRD, PHE Colindale 
Sample IDS: SYP1-SYP10 (No clinical information available) 
 
GROUP 7: NORMAL HEALTHY DONORS 1 




Sample IDS: H1-H30 (No clinical information available) 
 
GROUP 8: NORMAL HEALTHY DONORS 2 
Normal healthy donor sera tested seronegative for Lyme disease by routine testing 
protocol 
Type: Serum 
Source: PHE Porton 











GROUP 9: CZECH LYME DISEASE POSITIVE WHOLE-BLOOD 
Whole blood samples from patients with that have a clinical history / symptoms 
consistent with early Lyme disease. Blood was collected in PAXgene tubes to 
stabilise RNA. 
Type: Whole blood 















2.2. SAMPLE PREPARATION FOR MASS SPECTROMETRY 
 
2.2.1. Immunodepletion 
Serum and plasma samples to be included in mass spectrometry analysis (Materials 
and Methods 3.5) were immunodepleted using Pierce Top-12 Spin depletion columns 
(Thermo, Pierce top 12 abundant protein depletion columns, C#85165) according to 
the manufacturer’s standard protocol. Table 2.7 shows the list of proteins removed. 10 
µL of undiluted serum sample was added to the depletion column and incubated at 
room temperature for an hour with continuous end-over-end mixing.  The tubes were 
then centrifuged at 1000g for 2 min. Following centrifugation the total eluate from the 
columns was 450µL per sample (depleted sample in 10 mM PBS, 0.15 M NaCl, 
0.02% azide, pH 7.4).  
 
Table 2.7: Top 12 abundant proteins removed using Pierce immunodepletion columns 
(data according to manufacturer). 
 
Depletion was validated by a bicinconinic acid assay (BCA) to quantify total protein 
before and after depletion, described below. Further validation involved SDS-PAGE 
with SYPRO ruby staining and Western blots using antibodies for human serum 




2.2.2. BCA procedure 
Total protein concentration of serum and plasma samples was determined using BCA, 
using a commercial kit following the manufacturer’s 96 well microplate protocol 
(Thermo Fisher Scientific, Pierce BCA Kit, C#23225). Briefly, kit standards were 
created by serially diluting bovine serum albumin [(BSA) (provided in kit)] in 
distilled water to working concentrations ranging  from 25 to 2000 µg/µL. In 
duplicate, 25 µL of each sample was transferred to a well using a multichannel  
pipette and mixed with  200µL assay development reagent (provided in kit). Plates 
were incubated with shaking for 30 min at 37 °C. Clinical samples were diluted 1:50 
in PBS to ensure the protein concentration fell within the range of the standard curve. 
Microtitre plates were read at an absorbance of 570 nm on a TECAN microplate 
reader. Sample protein concentrations were calculated by reference to the standard 
curve in MS Excel.  
 
 
2.3. SDS-PAGE AND WESTERN BLOTTING 
 
2.3.1. SDS-PAGE 
Gel preparation: A Bio-Rad Mini-Protein system gel electrophoresis tank was used 
for SDS-polyacrylamide gel electrophoresis (SDS-PAGE). Resolving gels of 
appropriate acrylamide concentration and stacking gel (5%) were made as described 
in table 2.8. To cast the gel, immediately after the addition of TEMED to the 
resolving gel mix, the solution was poured between clean glass plates in a casting 
frame. A small volume of water-saturated butanol was added to the top of the gel to 
remove air bubbles and create a level surface for later addition of stacking gel. After 
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15 min when the gel had set, the water-saturated butanol was removed and the 
stacking gel solution was added followed by a plastic well comb. Following stacking 
gel polymerisation (15 min), the comb was removed and the glass plate assembly and 
gel were placed inside an electrophoresis tank. 1x SDS-PAGE running buffer (25 nM 
Tris-HCL [pH 8.3], 250 µM glycine, 0.1% SDS) was added to the tank to submerge 
the gel assembly.  
Sample preparation: Sufficient sample buffer was prepared based on the number of 
unknown samples. 100 µL of beta-mercaptoethanol (B-ME) was added per 900µL of 
4x Laemmli buffer (Biorad C#161-0737) to give 20µL per unknown. Samples were 
diluted 3 parts sample with 1 part 4x Laemmli buffer plus B-ME and then denatured at 
90°C for 10 min before being placed on ice.  
Running gel: 5 µL of pre-stained protein ladder (New England Biolabs: 11-245kDA 
protein ladder, C#: P7712S) was loaded to well 1 as a reference for molecular weight. 
Denatured samples were loaded at a volume of 15 µL or 25 µL depending on the 
number of wells cast (20 and 10 respectively). The gel was run at 100-150 V, current 
200-400 mA for 30 min to 1 hour until optimum separation of proteins (as determined 








Table 2.8: Table showing gel compositions (per 2 gels) for SDS-PAGE with 
recommended resolution (protein size) depending on protein of interest. 
Stacking/loading gels were consistent regardless of target protein size. APS = 
Ammonium persulfate. 
 
2.3.2 Western blotting 
For Western blotting, a semi-dry blotting method was followed using a Bio-rad semi-
dry instrument (Bio-rad, Trans-blot SD Semi-dry transfer cell, C#170-3940). 
Following SDS-PAGE, gels were removed from the gel tank and glass plates using a 
plastic scraper. Polyvinylidine fluoride (PVDF) membranes (Merck-Millipore, 
Immobilon-P PVDF membrane, C#IPVH00010) were briefly submerged in 100% 
methanol before use. Two pieces of filter paper were soaked in Towbin buffer (25 
mM Tris-HCL [pH 8.3], 192 mM glycine, 20% methanol) . The gel, filter paper and 
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membrane were arranged in the following order in the semi-dry blotting apparatus 
(bottom to top): filter paper, PVDF membrane, gel, filter paper. Transfers were carried 
out at 15 V for 1.5 hours. After transfer, the membrane was separated from the other 
materials and blocked in 5% [w/v] fat free skimmed milk buffer made with Tris-
buffered saline [(TBS);50 mM Tris-HCL [pH 8.3], 150 mM NaCl) with 0.5% [w/v] 
Tween-20 (TBST) for 1 hour at room temperature. The blocking buffer was then 
discarded and the membrane was washed 3 times, for 5 min each, in TBST on a 
rocker. Primary antibody was diluted in blocking buffer and 5 mL was added to the 
membrane, sealed in a plastic pouch and incubated at 4 °C overnight on a rocker. 
Unbound primary antibody was removed by 3 washes in TBST as previously 
described. HRP-conjugated secondary antibody was diluted in blocking buffer, added 
to the membrane and incubated for 1 hour at room temperature on a rocker. Unbound 
antibody was again removed with 3 washes in TBST. Bound antibody was visualised 
using enhanced chemiluminescence (ECL). The ECL Western blotting substrate (Bio-
rad, Clarity ECL Western substrates, C#1705061) was prepared according to the 
manufacturer’s instructions and 10 mL added to the blot in a plastic dish. After 30 sec 
of incubation at room temperature, blots were viewed using a Bio-Rad ChemiDoc MP 
Imaging System. Images were acquired using	Image	Lab™	Software	(Bio-rad, Image 








Target Type Antibody 
Rabbit IgG Secondary for WB Goat Anti-Rabbit IgG H&L (HRP) 
(abcam) (ab6721) 
Rabbit IgG Secondary for WB Goat Anti-Rabbit IgG (abcam) (ab6702) 
Lipocalin 2 Primary for WB Anti-Lipocalin-2 / NGAL antibody 
(abcam) (ab63929) 




Antibody pair for 
ELISA 
Carbonic Anhydrase III/CA3 Antibody 
Pair (Novus) (H00000761-AP11) 
Serum amyloid A1 Antibody pair for 
ELISA 
Human Serum Amyloid A1 duoset 
ELISA system (RNDsystems) (DY3019) 
C-reactive protein Primary for WB Anti-CRP antibody (abcam) (ab227507) 
Von Willebrand 
Factor 
Primary for WB Anti-VWF antibody (abcam) (ab6994) 
Tubulin Primary for WB Anti-Tubulin antibody (abcam) (ab6160) 
Beta-Tubulin Primary for WB Anti-beta Tubulin antibody (abcam) 
(ab6046) 








2.3.3. SYPRO ruby staining: Whole protein normalisation 
Whole protein visualisation of SDS-PAGE gels were performed using SYPRO Ruby 
protein gel stain (Invitrogen, SYPRO Ruby gel stain, S1200). Following migration, 
the gel was incubated in fix solution (50% [v/v] methanol / 7% [v/v] acetic acid) for 2 
x 30 min at room temperature with shaking. In dark conditions, the gel was incubated 
with 5 mL of SYPRO gel stain overnight. The stain was then discarded and the gel 
was gently washed in wash solution (10% [v/v] methanol / 7% [v/v] acetic acid) for 
30 min. The gel was rinsed in ddH20 for 2 x 5 min before being imaged using a gel 
imager (Biorad, Chemidoc Touch Imaging System). 
 
2.4. ELISA 
2.4.1. Duoset ELISA kits 
Quantification of Lipocalin 2 and Serum Amyloid A1 proteins in human sera were 
performed using DuoSet ELISA systems (R&D Systems, Human Lipocalin 2 Duoset, 
Human Serum Amyloid A1 Duoset, DLCN20, DY3019-05), according to the 
manufacturer’s protocol. 96-well plates were coated with 100 µL capture antibody 
diluted to working concentration in PBS and incubated overnight at room temperature. 
Wells were aspirated and washed with wash buffer (400 µL) for a total of three times. 
Plates were blocked using 300 µL of kit reagent diluent (BSA based) per well and 
incubated for 1 hour at room temperature. The aspiration/wash step was repeated as 
described. 100 µL of sample or standards diluted in reagent diluent to concentration 
described in the relevant chapter. Plates were covered with an adhesive strip and 
incubated for 2 hours at room temperature. Following an aspiration/wash step, 100 µL 
of detection antibody, diluted in reagent diluent, to each well and incubated for 2 
hours at room temperature. Following an aspiration/wash step, 100 µL of 
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Streptavidin-HRP, diluted to working concentration, was added per well. Following 
an aspiration/wash step, 100 µL of substrate solution was added to each well and 
incubated for 20 min at room temperature. 50 µL of stop solution (acid) was then 
added to each well. Optical density was measured immediately, using a microplate 
reader (Tecan, Infinite 200) set to 450 nm with wavelength correction. Kit standards 
were used to create a standard curve for the calculation of protein concentration in 




2.5. MASS SPECTROMETRY 
2.5.1. Tryptic digestion 
Serum and plasma samples were depleted using Pierce Top 12 immunodepletion 
columns as described in section 3.2.1 Samples were then precipitated by addition of 
ice-chilled trichloroacetic acid (30% [v/v] in acetone) and incubation for three hours 
at 20 °C. Following precipitation of proteins from solution, samples were centrifuged 
at 12,000 g for 10 min at room temperature to pellet proteins. Ice-cold acetone was 
used to wash the protein pellets three times and they were then allowed to air-dry. 
Pellets were re-suspended in suspension buffer (50 mM ammonium bicarbonate with 
0.1% [w/v] RapiGest SF surfactant (Waters, RapiGest, C#87201). Samples were 
heated to 80 °C on a heatblock. After 10 min, 3 mM dithiothreitol (DTT) was added to 
reduce samples which were then cooled and alkylated with 9 mM iodoacetamide for 
30 min at room temperature. Trypsin (Sigma, SOLu-Trypsin Dimethylated, 
proteomics grade, C#EMS0005) was added at a ratio of 50:1, sample protein to 
trypsin by mass, and incubated at 37 °C overnight in the dark. Finally, to remove the 
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surfactant, the samples were precipitated using 1% (v/v) trifluroacetic acid at 37 °C 
for two hours and centrifuged for one hour at 12,000g (4°C).  
 
2.5.2. Mass spectrometry analysis: Nano-LC-ESI MS/MS analysis 
A nanoscale liquid chromatography coupled to tandem mass spectrometry (nano LC-
MS/MS) system was used for protein identification and quantification. Peptides were 
analysed by nanoflow LC using the Thermo EASY-nLC 1000 liquid chromatograph 
coupled with a Q-Exactive mass spectrometer (Thermo, Q Exactive hybrid 
quadrapole-orbitrap, C#IQALAAEGAAPFALGMAZR). 
Pre-prepared samples were loaded on an EASY-SprayTM LC column (Length: 50 cm; 
internal diameter: 75 µm, content: 2 µM C18 particles) and then integrated with a nano-
electrospray emitter (Thermo, Silica nano-electrospray emmiter, C#ES081). The 
column was maintained at a temperature of 35 °C throughout operation.  
Chromatography: Chromatography was performed using C2v2 buffer A (0.1% formic 
acid) and B (80% acetonitrile in 0.1% formic acid). Peptides were separated by a 
linear gradient of 3.8%-50% buffer B over 157 min (flow rate: 300 nl/minute).  
Mass spectrometry: The Q-Exactive was operated in a data-dependent mode with 
survey scans acquired at a resolution of 70,000. The 10 most abundant isotope 
patterns with charge states of +2, +3 and/or +4 from the initial survey scan were 
selected with an isolation window of 2.0Th and fragmented by higher energy 
collisional dissociation with normalized collision energies of 30. The maximum ion 
infection times for the survey scan and the MS/MS scans were 250 and 100 ms, 
respectively. The ion target value of the machine was set to 1E6 (survey scans) and 
1E4 (MS/MS scans). Repetitive sequencing of peptides was minimized through 
dynamic exclusion of the sequenced peptides for 20s. RAW files were automatically 
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transferred for importation into Progenesis software for protein ID and quantification. 
Mass spectrometry analyses were performed at the University of Liverpool by Stuart 
Armstrong.  
 
2.5.3. Progenesis protein identification and quantification  
RAW files from MS/MS (Thermo RAW) were imported into Progenesis LC-MS 
software (Nonlinear Dynamics, Progenesis Software, Version: 4.1). Peaks were 
identified by the software using default settings and filtered (to peaks with charge 
stage between +2 and +7). Spectral data were converted to MGF files with Progenesis 
LC-MS and exported for peptide ID using Mascot search-engine software (Matrix 
Science, Mascot, Version: 2.3.02). Tandem MS data were searched against translated 
Open Reading Frames (ORFs) from the human genome (Uniprot, 2016_08, 20,367 
sequences, 11,398,732 residues) and the Borrelia burgdorferi s.l. genome (NCBI 
Refseq NC_001852, Borrelia burgdorferi). The following search parameters were 
used; Precursor mass tolerance=10, Fragment mass tolerance=0.01Da, Tryptic 
cleavages permitted=2, Carbamidomethylation=fixed modification, 
Oxidation=variable modification, Mascot decoy database function=true. Mascot 
search results were further validated using the embedded semi-supervised machine 
learning algorithm, Percolator to improve the discrimination between correct and 
incorrect spectrum identifications. The false discovery rate was <1% with individual 
Percolator ion scores >13 indicating identity or extensive homology (p<0.05). Search 
results from Mascot were imported into Progenesis LC-MS as XMS files. Relative 
quantification using (non-conflicting) peptides was calculated by Progenesis.  Data 
was exported in an MS Excel document with normalised abundance data for all 




2.5.4. Data analysis of protein data 
Proteins were identified based on detection of at least two unique peptides. The mean 
normalised abundance for a particular protein was calculated per sample group and 
fold difference was calculated along with adjusted p-value. Fold changes with p-value 
<0.05 were considered not significant.  
 
 
2.6. RNA SEQUENCING AND ANALYSIS 
 
2.6.1. RNA extraction and sample preparation 
Whole blood samples were received from the Czech Republic frozen in PAXgene 
Blood RNA tubes (BD, PAXgene Blood RNA Tubes, 762165). Intracellular blood 
was isolated and purified using the relevant PAXgene kit (BD, PAXgene Blood RNA 
kit IVD, 762164) following the manufacturers instructions, as follows: The PAXgene 
tubes were centrifuged for 10 min at 3000-5000 x g using a swing-out rotor. The 
supernatant was removed by pipette and 4mL of RNase-free water was added to the 
pellet. The pellet was dissolved by vortexing and centrifuged again for 10 min at 300-
5000 x g. The supernatant was removed by pipette and 350 µL of Buffer BR1 (kit 
resuspension buffer) was added to the pellet. The sample was pipetted into a new 
1.5mL tube and 300 µL of Buffer BR2 (kit binding buffer) and 40 µL of proteinase K 
were added. The lysate was pipetted into a PAXgene Shredder spin tube and 
centrifuged for 3 min at 15000 x g. The supernatant was transferred to a new 1.5mL 
tube leaving the pellet in the original tube. 350 µL of ethanol was added, vortexed and 
centrifuged briefly (2 sec at 1000 x g) to remove drops in the lid. 700 µL of sample 
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was pipetted into a PAXgene RNA spin column, placed in a 2mL processing tube and 
centrifuged for 1 min at 10000 x g. 10 µL of DNase I (RNase-free) was added to the 
spin column membrane and incubated on the benchtop for 15 min at room 
temperature. 350 µL of Buffer BR3 (kit wash buffer) was added to the spin column 
and centrifuged for 1 min at 10000 x g. 500 µL of Buffer BR4 (kit wash buffer II) was 
added and centrifuged for 1 min at 10000 x g. A further 500 µL of Buffer BR4 was 
added to the spin column and centrifuged for 3 min at 10000 x g. The column was 
placed into a new processing tube and 80 µL of Buffer BR5 (kit elution buffer) was 
added and centrifuged for 1 min at 10000 x g to elute the RNA. The samples were 
aliquoted for quality and quantification testing. Sample not to be used immediately 
was stored at -70oC.  
 
2.6.2. Quantifying RNA content and quality 
The RNA content of samples was measured using the Qubit RNA system (Thermo, 
Qubit RNA HS Assay Kit, Q32855). The Qubit working solution was prepared by 
diluting RNA HS Reagent (kit reagent, 200X concentrate in DMSO) 1:200 in HS 
buffer (kit reagent). Sufficient working solution to allow 200 µL per sample and 
standard was prepared. 190 µL of working solution was added to each of the sample 
tube to be used for standards. 10 µL of each kit standard was added to the relevant 
tube and vortexed for 2-3 sec. 198 µL of working solution was then added to the tubes 
for unknowns. 2 µL of each unknown was then added to a tube containing working 
solution and vortexed for 2-3 sec. All tubes were incubated at room temperature for 2 
min. Samples were read using a Qubit 3.0 Fluorometer using the high sensitivity 




2.6.3. Agarose gel electrophoresis of RNA 
Agrose gel electrophoresis with ethidium bromide staining was used to visualise 
potential RNA degradation. Agarose (AGTC Bioproducts) (1% [w/v]) was melted in 
1X TAE buffer (40mM Tris-acetate, 1mM EDTA, pH 8.0) by heating and ethidium 
bromide was added to molten agarose to give a final concentration of 0.5 µg/mL. The 
molten agarose was added to a gel-casting tray containing a 20 sample comb, and 
allowed to set. The set gel was transferred to a gel tank and submerged with sufficient 
1 x TBE buffer to cover the gel. 0.5 µg of RNA sample in 10µL RNase free water, 
together with 2 µL of loading dye (Thermo, RNA gel loading dye (2X), R0641) was 
loaded into each well. The gel was run at a voltage of 2.5 V/cm and samples were 
migrated until the gel-loading buffer had reached ¾ of the way down the gel. An 
ultraviolet transilluminator was then used to visualise the RNA bands. Any smearing 
of RNA bands would indicate a degraded sample.  
 
2.6.4. Illumina RNA-seq 
Samples were taken on ice to the Centre for Genomic Research at the University of 
Liverpool for sequencing. To include only mRNA data, 3’polyadenylated poly(A) 
selection was used and ribosomal RNA (rRNA) was depleted. Poly(A) selection was 
performed using poly(T) oligomers covalently bound to a magnetic bead substrate. 
RNA was reverse transcribed to cDNA for amplification. Sequencing data was 







2.6.5. RNAseq: Data analysis 
Downstream processing from trimmed reads provided by RNA-seq to Differential 
Gene Analysis (DGE) were performed using the Galaxy online platform (Galaxy, 













Figure 2.1: Diagram of software workflow used for processing trimmed read data 
from RNA-seq.  
 
2.6.5.1. Genome mapping 
TopHat software was used to map RNA-seq reads to a human reference genome 
(Homo sapiens (b38, hg38)). TopHat uses Bowtie to map RNA-seqs to the reference 
genome and then analyses the mapping results to identify splice junctions between 
exons. All default TopHat settings were used. Files were output as accepted hits in 
BAM format. Cufflinks (University of Washington, Cufflinks,Version 2.2.1) software 
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was used to assemble transcripts and estimate their abundance. The BAM files was 
input and Cufflinks then estimated the relative abundance of transcripts based on the 
number of reads mapped to each, taking into account biases potentially introduced in 
library preparation protocols. To summarise this data, featureCounts (Unknown, 
featureCounts, Version: 1.6.4) software was used. The featureCounts software outputs 
data in a tab-separated file for each sample, listing all human genes and the number of 
reads mapping to that gene.  
 
2.6.5.2. Differential gene expression: DESeq2 
The DESeq2 package (Love et al. 2014, DEseq2, Version: 1.25.10) provides methods 
to test for differential expression by use of negative binomial generalised linear 
models. featureCount files were used as input with one file per sequenced sample. 
Samples were split into “exposure” groups to allow DGE comparison. Pre-filtering of 
low count genes was performed before running the DESeq2 functions to reduce the 
amount of memory required and to increase the transformation and testing functions. 
DESeq calculates a Log [2] fold change for each gene input, using one exposure group 
as a reference. The software also calculates a Wald test p value for each gene.  
 
2.6.6. Immquant cell typing 
ImmQuant cell typing was used to estimate the abundance of specific immune cells in 
blood samples using computational deconvolution by the ImmQuant software (omicX, 
ImmQuant, Version: N/A). Patient data was input into the software as relative 
expression profiles from DESeq2 (calculated as the transcription fold-change). The 
software contains a reference dataset consisting of transcriptional signature of 
immune-cell subsets and a list of informative marker genes. The software then 
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decomposes the relative expression profile into cell-type differences between the two 
samples or sample sets.  
 
2.6.7. Quantitative real-time RT-PCR 
Quantitative RT-PCR reactions were performed using the Qiagen OneStep RT-PCR 
platform (Qiagen, OneStep RT-PCR, 210212). A reaction master mix was prepared as 
shown in table 2.10. A negative control (master mix without template RNA) was 
included in every experiment. Master mix was mixed thoroughly and dispensed into 
PCR tubes (total 50 µL per reaction). Template RNA was input at 20 ng per reaction 
(RNA content of samples was measured by Qubit as described above (2.6.2). The 
PCR machine (Bio-rad,  CFX96) was set to the cycling times and temperatures as 
















Component Volume/reaction Final concentration 
Master mix 
RNase-free water Variable - 
5 X QIAGEN Onestep RT-PCR Buffer 
10.0 µL 1X 
dNTP Mix (containing 10 mM of each 
dNTP) 
2.0 µL 400 µM of each dNTP 
Primer A Variable 0.6 µM 
Primer B Variable 0.6 µM 




Template RNA Variable 5-10 units/reaction 
Total volume 
50.0 µL - 




Step Temperature Time 
Reverse transcription 50oC 30 min 
PCR activation 95oC 15 min 
3-step cycling 




Extension 72oC 1 min 
Number of cycles 25-40 cycles 
Final extension 72oC 10 min 












































































2.7. LYME DISEASE DIAGNOSTIC TESTING (STT) 
 
2.7.1. STT Protocol 
Serum samples from NHD, leptospirosis, syphilis and CFS cases were tested to 
determine any seroreactivity that might suggest previous exposure to Borrelia 
burgdorferi spp. pathogens.  The work was undertaken under the guidance of 
laboratory staff at the Porton. PHE Rare and Imported Pathogens Laboratory (RIPL),  
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provides the national Lyme disease testing service for England and Wales and uses 
well validated CE-marked assays that conform to ISO	15189:2012.		
The standard two-tiered (STT) algorithm for Lyme serodiagnosis was followed, using 
a C6 screening ELISA followed by (in C6 positive/indeterminate samples) a Virachip 
IgG and IgM confirmatory immunoblot assay. Routinely, diagnosis of Lyme disease 
must be made based on patient history (including tick-bite), clinical signs and 
symptoms (including erythema migrans) and other laboratory testing data in addition 
to the serological based methods detailed here.  
 
2.7.2. C6 ELISA 
All sera/plasma were first tested using a commercially available C6 screening ELISA 
kit (Immunetics, C6 Lyme ELISA kit, C#DK-E352-096) for the presumptive 
detection of IgG and/or IgM antibodies against B. burgdoerferi s.l. (optimised for 
circulating European species). The antigen used in the assay is a synthetic C6 peptide 
derived from the VlsE protein of B. burgdorferi s.l. 
 
The following procedure was followed using an automated ELISA system (Dynex 
Technologies, DS2 ELISA Processing System, C#62000). 100 µL of diluted positive 
control (10 µL in 90 µL kit diluent) was added to one microwell and 100 µL of  kit 
negative control to the adjacent cell. 100 µL diluted calibrator was added to three 
additional microwells. 100 µL of each diluted patient sample[1:100 ddH20] was then 
added to available microwells and incubated at room temperature for 30 min. Wells 
were aspirated three times using Wash Buffer (supplied). 100 µL of kit conjugate was 
added into each well and incubated for 20 min at room temperature. Wells were again 
aspirated and 4 washes performed as above. 100 µL of tetramethylbenzidine (TMB). 
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ELISA substrate was added into each well and incubated for 4 min at room 
temperature. 100 µL of kit stop solution into each well and the contents gently mixed. 
Plates were read immediately after addition of stop solution. Absorbance was read at 
450nm with a reference filter of 650nm using an ELISA plate reader (Dynex, MRX 
Revelation, C#N/A). The following quality control parameters were followed: 
• Negative control value (A450) <0.18 
• Calibrator values (A450) 0.400-2.00 
• Positive control value (A450) >1.2 
 
Any control value being out of range resulted in the plate being discounted and the 
assay repeated. The assay cutoff value was determined by dividing the mean calibrator 
A450 values by 2.150 (correction coefficient). The Lyme Index value (LI) was 
calculated for each patient sample by dividing the A450 value for the sample by the 
cutoff value. Table 2.13 below shows the interpretation guidance as described in the 
kit manual. Patient samples that tested negative by C6 ELISA were considered 
seronegative for Lyme disease. Samples found to be positive or equivocal went 





Table 2.13: Interpretation of sample Lyme Index values as described in Immunetics 
C6 ELISA kit manual.  
 
2.7.3. ViraChip Borrelia Immunoblot: IgG and IgM 
Confirmatory testing used chip-based immunoblots for the qualitative detection of 
IgG and IgM antibodies against specific Borrelia species antigens. Separate kits were 
used for detection of Borrelia specific IgM (Viramed; Borrelia ViraChip IgM; C# V-
BSCMOK) and IgG (Viramed; Borrelia ViraChip IgG; C#	V-BSCGOK) antibodies. 
Both kits use native antigens from Borrelia afzelli and Borrelia burgdorferi s.s. 
together with recombinant VlsE, applied (in triplicate) at defined positions in each 
well of a 96-well microtitre plate. Using a TECAN automated ELISA instrument, the 
following protocol was followed for both IgG and IgM plates. 300 µL of kit diluent 
was added to each well. 100 µL of diluted kit positive control, 100 µL of kit negative 
control, 100 µL of in-house positive control (PHE) and 100 µL of in-house negative 
control (PHE) was added to the appropriate wells. 100 µL of diluted patient serum 
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was then added to the remaining available wells. Plates were incubated for 30 min at 
room temperature. Wells were then aspirated and washed 3 times in kit wash buffer 
working dilution (300 µL). 100 µL of kit conjugate was added to the wells followed 
by another 30 minute incubation at room temperature. Cells were again aspirated and 
washed as before. 300 µL of deionised water was added to each well and the plate 
incubated for 5 min at room temperature. The liquid was aspirated and 100 µL of 
Chromogen substrate solution added to each well and the plate incubated for 15 min at 
room temperature. The reaction was halted by aspiration of all liquid from wells. A 
final wash was performed 3 times and the plate was left to air dry. Interpretation of the 
assay involved measuring of spot intensities of the microarrays using ViraChip 
software. For a test run to be valid, the serum positive control, conjugate control and 
calibrator controls must all be detectable. Tests in which the negative controls were 
visible were not valid. Automated spot assessments were manually confirmed by eye 
using the ViraChip software. Table 2.14 describes the interpretation of results, as 









Table 2.14: ViraChip result interpretation as detailed in the kit manual. 
 
 
2.8. SEROLOGY LITERATURE REVIEW PARAMETERS 
2.8.1. Literature search For table 1.1-1.4 
Primary research questions of review: Sensitivity and specificity of serological tests 
for the conditions early Lyme (EM), Lyme arthritis, ACA and neuroborreliosis. 
Studies focusing on putative high-risk groups including veterinarians and forestry 
workers were excluded. Serology-based tests associated with STTT were included 
including commercial and in-house. ELISA, IB and two-tier algorithm tests were 
identified. Quality score was based on a version of QUADAS-2. Four domains were 
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considered for quality score including patients cohort selection, index test and risk of 
bias. Table 2.15 shows search terms used across several databases including 
EMBASE, PubMed and Web of Science. Irrelevant studies were excluded including 
those on other diseases, studies in (non-human) animals or where the full study text 




































CHAPTER 3: MASS SPECTROMETRY BASED DISCOVERY OF SERUM 
BIOMARKERS OF SPIROCHAETAL INFECTIONS 
 
3.1. INTRODUCTION 
Current Lyme disease diagnostic methods used in the UK, the STT method, are based 
on the detection of antibodies against the Borrelia pathogen in the patient’s blood. In 
early stages of Lyme disease, levels of Borrelia-specific antibodies are low as the host 
mounts an immune response to infection. During this time, serology based tests have 
lower sensitivity as they rely on the detection of host antibodies to several bacterial 
proteins. Studies vary in their estimation of the length of time before seroconversion, 
when a patient with Lyme disease has sufficient levels of antibody to test positive by 
STT, but it is likely to be at least two weeks or longer (217) 
 
Blood is a commonly used tissue for diagnostic purposes, due to the ease and safety of 
sampling. Blood samples collected by phlebotomy remain the most common type of 
biological sample drawn for analysis, supporting patient diagnosis and monitoring 
(218). Whole blood can be processed into serum or plasma fractions, depending on the 
intended use of the sample. Plasma, which constitutes around 55% of whole blood, 
contains fibrinogen and other secondary clotting factors that contribute to the normal 
clotting of blood. In contrast, serum is prepared by allowing whole blood to form clots 
by the natural conversion of fibrinogen to fibrin. The clot is then removed by 





Measuring the abundance of resident blood proteins, together with proteins from 
tissues that can enter the bloodstream, can allow the detection of putative biomarkers 
associated with a disease state and for better understanding of the host-response to 
disease. Mass spectrometry analyses can be used to quantify proteins in a complex 
biological sample by detection of peptide subunits. Improvements in coverage and 
depth of mass spectrometry methods have allowed better resolution of the blood 
proteome in individual patients, leading to studies with the aim of identifying 
biomarkers for certain diseases, disease states and sequelae, as well as other aspects 
such as host response to treatment including antibiotic therapy. A biomarker can be 
defined as any measurable characteristic that can be quantified as an indicator of 
pathological processes, a host-response to a treatment or exposure, or simply of 
normal biological processes. In this chapter, biomarkers refer to serum proteins 
identified by mass spectrometry analysis that are differentially abundant in different 
diseases and disease states.  
 
This chapter reports the findings of two separate label-free quantitative mass 
spectrometry studies performed on Lyme disease serum samples and  related-disease 
control and normal healthy donor samples with the aim of characterising the serum 
proteome of early Lyme disease patients and identifying serum biomarkers for further 









The serum proteome of patients with Lyme disease, as diagnosed based on clinical 
criteria and positive serology using a standard diagnostic protocol, is distinct from that 
of cases that test negative for Lyme disease and from disease and healthy control 
groups. Mass spectrometry analyses can be used to identify proteins that are found 
consistently at different abundance between groups and these proteins can be taken 





















3.2. MATERIALS AND METHODS 
Full details of the Materials and Methods used in the chapter are provided in Chapter 
2. Table 3.1 below shows the samples including in mass spectrometry runs 1 and 2 
with details of their inclusion criteria and source. Details of individual patient clinical 
history, diagnostic testing results and other information (where available) are included 
in Chapter 2: Materials and Methods (2.1.1). 
 
Table 3.1: Details of serum and plasma samples used during mass spectrometry run 1 






3.3.1. Study sample set 
A total of 50 human serum and plasma samples were compared by quantitative label-
free mass spectrometry. Table 3.1 shows the sample sets within the study, including 
sample type and inclusion criteria. All sample sets comprised serum samples apart 
from those from patients diagnosed with chronic fatigue syndrome (n=5) and normal 
healthy donors (n=5), which were plasma. Serum and plasma are both derived from 
whole blood, but while plasma contains clotting factors including fibrinogen serum 
samples are centrifuged to remove these leaving only the fluid fraction. The 
importance of this distinction in mass spectrometry analysis is discussed later in this 
chapter. 
 
3.3.2. Sample preparation for mass spectrometry 
The dynamic range of protein abundance within blood spans several orders of 
magnitude. Albumin, the most abundant blood protein, constitutes around 55% of the 
entire blood proteome, over 10 orders of magnitude in concentration greater than the 
rarest proteins measured clinically. Globulins and fibrinogen constitute up to 38% and 
7% of whole-blood proteins respectively. Together, high-abundance proteins represent 
more than 99% of the total bulk mass of protein content. Removal of abundant 
proteins by immuno-affinity baits can significantly reduce the complexity and 
dynamic range of serum and plasma samples, allowing better resolution of low-
abundance proteins that may be of clinical interest. Samples were received in either 
serum or plasma form and underwent protein depletion using Pierce Top 12 Abundant 
Protein Depletion Spin Columns. The proteins depleted by this method are listed in 
Materials and Methods 2.2.1. To quantify the amount of protein removed by the 
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depletion columns, total protein was measured before and following immuno-
depletion using a bicinchoninic acid assay (BCA). Table 3.2 shows this data. The 
average decrease in total protein following immuno-depletion was 77.43% (75.38-
77.47%). This is in line with the depletion efficiency stated by the manufacturer, 
>99% of albumin and >90% of globulins. To visualise the removal of highly-abundant 
proteins, SYPRO ruby was used to stain total protein in samples before and after 
depletion. Figure 3.1 shows a Western blot of serum samples (Lyme disease 
seropositive and leptospirosis positive) before and after immuno-depletion, stained by 
SYPRO ruby. The oversaturated band at around 66.5kDa, assumed to be albumin, can 
be seen to be reduced following depletion. Better resolution of distinct bands can be 








Figure 3.1: Western blot showing serum samples before and after depletion by 
immuno-affinity columns. Total protein is stained using SYPRO ruby. The 
oversaturate band at the molecular weight of albumin can be seen to be reduced 
following depletion.  Lanes 1-2: Lyme disease positive sample (LP 3), Lanes 3-4: 







Table 3.2: Total protein depletion by Pierce Top 12 spin columns, as measured by 
BCA. ID represents individual sample ID. Protein concentration is shown before and 
following depletion, along with percentage reduction. The mean concentration pre- 










3.3.3. Label-free mass spectrometry run 1 
3.3.3.1. Overview 
To identify differences in serum proteome between groups a label-free quantitative 
mass spectrometry study was undertaken. Mass spectrometry run 1 compared the 
following sample groups: UK Lyme disease seropositive (n=15), UK Lyme disease 
seronegative (n=15), Syphilis positive (n=5), Leptospirosis positive (n=5), 
Normal/health donors 1 (Plasma) (n=15), and Chronic Fatigue Syndrome diagnosed 
(Plasma) (n=15). 
 
A total of 296 proteins were successfully identified and their abundance quantified in 
all study groups included in mass spectrometry run 1. Mass spectrometry data was 
normalised between sample groups using Progenesis software as described in 
Materials and Methods 2.5.3. All samples were plotted using principal component 
analysis (PCA), an orthogonal transformation that allows complex mass spectrometry 
data to be shown on a 2D graph The PCA allows a visualisation of similarity between 
sample groups at the proteome level. Figure 3.2 shows clear separation of 
leptospirosis positive samples from the other sample groups, reflecting a distinctive 
proteome in this sample set. Syphilis positive samples can be seen to group close 
together, reflecting a relatively consistent proteome across samples. Overlap between 
syphilis and the Lyme disease groups (seropositive and seronegative) can be seen. 
Lyme disease seropositive and Seronegative groups show near complete overlap, with 
Lyme disease seropositive samples sowing closer grouping together. This indicates 
Lyme disease seropositive and seronegative sera share a broadly similar proteome that 




Figure 3.2: Principal Component Analysis (PCA) plot showing normalised data from 
mass spectrometry run 1. Each point represents a single sample, with colour overlay 
showing sample groups. 
 
3.3.3.2. Mass spectrometry run 1: Lyme disease seropositive vs. seronegative 
Of the proteins identified between Lyme disease seropositive and seronegative groups, 
12 proteins were found consistently at significantly different abundances between 
groups (p<0.05). Of these, 9 were found to be increased in abundance in seropositive 
and 3 decreased in abundance in seropositive. Figure 3.3 shows a volcano plot 
comparing the abundance of individual proteins in the Lyme disease seropositive 
group compared to the seronegative group. A cut-off value for Log[2] Fold Change of 
either >1 or <-1 was applied with significantly changed proteins shown in red. The 
protein Lipocalin-2 (LCN2) shows the highest significant increase in abundance in the 
Lyme disease seropositive group (p=0.33, Log[2] Fold Change =2.323). Lipocalin-2 
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was taken forward for further analysis in chapter 5. Table 3.3 shows the other 
significantly altered proteins between these 2 groups. The proteins identified were 














Figure 3.3: Volcano plot using mass spectrometry run 1 data comparing Lyme 
disease seropositive group to Seronegative. Proteins on the right of the graph are 
increased in abundance in Lyme disease seropositive, with proteins decreased shown 
on the left. A p-value of 0.05 (Log[10]p=1.4) was used as a significance cut-off along 
with a value of 1 for fold change (Log[2]). Proteins with values above these cut-offs 














































































































3.3.3.3. Mass spectrometry run 1: Lyme disease seropositive vs. other sera 
To identify proteins that are differentially abundant between the Lyme disease 
seropositive group and all other sera groups, normalised abundance data was 
compared between the subsets. Including data from related-disease controls allowed 
identification of proteins that were differentially abundant in Lyme disease patients 
but not in other disease. 22 proteins were found to be significantly changed. Of these, 
19 were found to be increased in abundance in Lyme disease seropositive samples and 
3 were decreased in abundance.  While a greater number of proteins were significantly 
changed than when the Lyme disease seropositive and seronegative groups were 
compared, the average fold change differences are smaller, with only 2 proteins 
showing a significant increase or decrease with a fold change of >1 or <-1. 
Coagulation factor XIII alpha chain (Factor XIII) was found to be increased in Lyme 
disease seropositive (p=0.02, Log[2]Fold Change =1.241). Tubulin alpha-4A chain 
was found to be decreased in Lyme disease seropositive (p=0.06, Log[2]Fold Change 
= -1.208). Table 3.4 shows all proteins found to be at significantly different 
abundances between groups. Several of the proteins increased in Lyme disease 

























Figure 3.4: Volcano plot using mass spectrometry run 1 data – Lyme disease 
seropositive vs. all other sera. Proteins on the right of the graph are increased in 
abundance in Lyme disease seropositive, with proteins decreased shown on the left. A 
p-value of 0.05 (Log[10]p=1.4) was used as a significance cut-off along with a value 

















































































































































































3.3.3.4. Mass spectrometry run 1: Syphilis positive vs. other sera 
As fewer differentially abundant proteins were identified between the Lyme disease 
seropositive and seronegative groups than expected, further analyses of the infectious 
control groups was conducted to examine whether greater changes could be identified 
in the serum proteome of patients with other infections. Sera from syphilis positive 
patients (n=5) were compared to all other sera, a total of 20 proteins were found be at 
significantly different abundances between groups. Of these, 9 were increased in 
abundance in syphilis positive while 11 were decreased in abundance. Figure 3.5 
shows a volcano plot of syphilis positive sera compared to all other sera groups. Table 
3.5 lists all proteins significantly increased or decreased in syphilis positive sera. Of 
those increased in syphilis, 6 proteins identified had a Log[2]Fold Change of >1, with 
the greatest increase seen for apolipoprotein L1(APO-A1) (p=2.6E-07, Log[2]Fold 
Change =1.588). In contrast to the comparison between Lyme disease groups, several 
proteins were found to be highly differentially abundant between groups (Fold Change 
>4), with high significance. In general, proteins identified as significantly increased in 
abundance in syphilis positive were associated with cellular metabolic processes. 2 
proteins associated with activation of Mitogen-Activated Protein Kinase (MAPK) 
were found to be increased, suggesting a host response to stimuli during syphilis 
infection. Of those proteins found to be decreased in abundance in syphilis positive 









Figure 3.5: Volcano plot using mass spectrometry run 1 data – Syphilis positive vs. 
all other sera. Proteins on the right of the graph are increased in abundance in syphilis 
positive, with proteins decreased shown on the left. A p-value of 0.05 (Log[10]p=1.4) 
was used as a significance cut-off along with a value of 1 for fold change (Log[2]). 








































































































3.3.7. Mass spectrometry run 1: Leptospirosis positive vs. other sera 
Of the groups included in mass spectrometry run 1, those from the leptospirosis 
positive group showed the greatest difference in serum proteome. A total of 146 
proteins were found to be in significantly different abundance in the leptospirosis 
positive group, over 50% of all proteins identified between groups. 121 proteins were 
found to be significantly increased in abundance in leptospirosis positive but only 25 
were significantly decreased. Of those increased, 96 had a Log[2]Fold Change >1, 
while of those decreased, 12 had a Log[2]Fold change <-1. The mass spectrometry 
analysis of leptospirosis sera therefore shows a marked change in proteome, likely 
reflecting various host-responses to leptospiral infection and the systemic, multi-organ 
nature of the disease. Figure 3.6 shows a volcano plot of leptospirosis positive sera 
against all other sera groups. Differentially abundant proteins in leptospirosis positive 
sera were associated with a wide range of biological functions. Tables 3.6 and 3.7 
show the top 20 proteins significantly increased and decreased in leptospirosis over all 
other sera respectively. Of those significantly increased were carbonic anhydrase III, a 
muscle-specific protein that is usually own found at very low concentration in serum. 
Several acute phase proteins including serum amyloid A2, c-reactive protein and 
lithostathine-1-alpha were found to be increased in abundance in leptospirosis positive 
sera. Proteins decreased in leptospirosis sera were found to have a wide range of 
biological functions. To better understand these changes, together with potential 
patterns in protein change, the mass spectrometry data from leptospirosis positive sera 
was compared to Seronegative as a negative control using Ingenuity Pathway 
Analysis. IPA requires a minimum number of protein/gene inputs that were not met 
for other proteomic comparisons. For each biological function or pathway, a statistical 
quantity is computed called the activation z-score. Table 3.8 shows the top upstream 
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regulators identified by increased abundance in target molecules in the mass 
spectrometry dataset. IL6 (Activation z-score = 2.935) and the presence of 
lipopolysaccharide (Activation z-score =  2.604) were identified as important 
upstream regulators of pathways induced in leptospirosis positive sera. To illustrate 
the wide range of protein abundance between leptospirosis positive and other sera, as 
measured by mass spectrometry, figure 3.6 shows normalised abundance data for top 










Figure 3.6: Volcano plot using mass spectrometry run 1 data – Leptospirosis positive 
vs. all other sera. Proteins on the right of the graph are increased in abundance in 
leptospirosis positive, with proteins decreased shown on the left. A p-value of 0.05 
(Log[10]p=1.4) was used as a significance cut-off along with a value of 1 for fold 
































































































































































































































































































































































































































































































































































































































3.3.4. Label free mass spectrometry run 2 
3.3.4.1. Overview 
As very few proteins were identified as present at different abundances between Lyme 
disease seropositive and seronegative groups, a second mass spectrometry run was 
undertaken to further confirm these findings. Due to the source of Lyme disease 
samples in the initial run (residual sample from diagnostic testing), their storage 
history and freeze-thaw count were unknown and therefore there was possibility of 
protein degradation in these samples. In this second mass spectrometry run, samples 
acquired from the Czech Republic, a country with endemic Lyme disease, were used. 
The following sample sets were compared: Czech Lyme disease seropositive (n=8), 
Czech Seronegative (n=8) and normal/healthy donors (serum) (n=8). Figure 3.8 
shows a PCA plot of the three sample groups included in mass spectrometry run 2. 
While normal healthy donor cells group and can be seen to be distinct, the Lyme 
disease seropositive and seronegative groups were found to overlap to a high degree. 
This indicates that at the resolution available by this method, the serum proteome of 
Lyme disease seropositive and seronegative are highly similar. No proteins were 
identified between Lyme disease seropositive and seronegative groups that were 




Figure 3.8: Principal Component Analysis (PCA) plot showing normalised data from 
mass spectrometry run 2. Each point represents a single sample, with colour overlay 















3.3.4.2. Mass spectrometry run 2: Lyme disease groups vs. healthy sera 
In contrast to the high similarity of serum proteome seen between Lyme disease 
seropositive and seronegative, the NHD control group was seen to be consistently 
distinct at the proteome level from these groups. A total of 72 proteins were found to 
be at significantly different abundance in the Lyme disease seropositive group when 
compared directly to the NHD controls. Of these, 41 were increased in abundance in 
Lyme disease seropositive, with 31 decreased. Table 3.9 lists the top proteins 
significantly increased or decreased in Lyme disease seropositive. Of the top 20 
proteins increased in Lyme disease seropositive, at least 18 (90%) had a known 
function related to immunity. Comparisons of Seronegative to NHD controls showed 














































































































































































































































The aim of this study was to use label-free quantitative mass spectrometry as an 
exploratory method of identifying novel biomarkers of Lyme disease in human sera. 
Two mass spectrometry runs were undertaken using serum and plasma samples from 
patients with Lyme together with related-disease controls and normal healthy donor 
samples. During the initial discovery run it was found that plasma samples, including 
the normal healthy donor sample set, were unable to be normalised for comparison to 
the Lyme and other control groups due to inherent differences introduced during 
sample preparation. This left the first mass spectrometry effectively with no negative 
control. Comparisons were made against Seronegative samples as a proxy negative 
control; however, the nature of these samples meant that the donor had been subjected 
to routine Lyme disease serological testing and, whilst testing negative, they 
presumably had another illness with broad symptoms that led to referral for Lyme 
testing.   
 
When compared directly following mass spectrometry run 1, the Lyme disease 
seropositive and seronegative groups were found to have highly similar proteomes. A 
total of 12 proteins were found in significantly different abundances between these 
groups, with 9 increased in seropositive and 3 decreased. The majority of these 
changes were relatively small (Log[2]Fold Change between -1 and 1). Lipocalin 2 
(LCN2), also known as neutrophil gelatinase-associated lipocalin  (NGAL), was 
found to have the largest difference between these groups (Log[2]Fold Change=2.323, 
p=0.033), and was taken forward for further analysis in Chapter 4. LCN2 is an innate 
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immune protein released in particular by neutrophils, epithelial cells and 
macrophages, and has previously been identified as a biomarker of various processes 
including inflammation, infection and acute kidney damage(219-221). LCN2 is a 25-
kDa secretory glycoprotein, a member of the lipocalin family: a group of proteins that 
transport small hydrophobic molecules. LCN2 is best described role is it’s ability to 
capture bacterial siderophores, often produced by extracellular bacterial species, 
ultimately depriving the bacterial cells from obtaining iron. LCN2-deficient mice have 
been shown to be more prone to infection and sepsis (222). Interestingly, the Lyme 
pathogen Borrelia burgdorferi does not require host iron to survive and has been 
shown to not alter gene expression in the presence of iron chelators. Therefore the 
impact of an increase in serum lipocalin 2 in host defence from Borrelia is difficult to 
explain without further study. One possibility is that LCN2 is produced in the host as 
a response to detection of bacterial presence but, due to a lack of bacterial 
siderophores to bind, the protein builds up in abundance. LCN2 has also previously 
been identified as increased in skin lesions caused by psoriasis, an autoimmune 
disease of the skin. Neutralisation of LCN2 led to decrease in inflammation, 
neutrophilic infiltration and improved epidermal hyperplasia in a murine model (223). 
LCN2 has also been previously associated with acute kidney injury, caused by 
leptospirosis infection (224). In a study of host responses in a mouse model to 
infection by B. burgdorferi, LCN2  was identified as being significantly increased 
(225). In this study, LCN2 was also found to be elevated in leptospirosis positive 
samples. Given the pathogenesis of Lyme and the associated erythema migrans skin 
rash, it is possible that LCN2 plays a role in the inflammatory processes involved in 
Lyme disease. Further study is required to better understand the involvement of LCN2 
in Lyme and why it may be increased in Lyme disease patient sera. Regardless of role 
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or function in Lyme disease, LCN2 was identified as the protein most changed in 
abundance when comparing Lyme disease seropositive and seronegative and was 
therefore taken forward as a protein of interest in Chapter 4. 
 
The cross-linked envelope protein, Small proline-rich protein 2D (SPRR-2D), was 
found to have the second largest abundance difference between Lyme disease 
seropositive and seronegative by mass spectrometry (Log[2]Fold Change=1.363, 
p=0.027). At the time of writing, SPRR-2D has not been implicated in Lyme disease 
Small-proline rich proteins are a group of structural proteins that constitute cornified 
cell envelope precursors(226). They are therefore involved in the development of 
epithelial layers, and have been shown to be increased during injury and wound 
healing. An increased presence of SPRR-2D in Lyme disease seropositive sera may 
therefore reflect the host skin damage caused by borrelial colonisation at the site of 
tick-bite. Further structural proteins involved in cell cytoskeletal development, tubulin 
alpha-4A chain and actin alpha cardiac muscle 1, were found to be lower in 
abundance in Lyme disease seropositive over seronegative. It is also important to be 
wary of the presence of skin-associated proteins in mass spectrometry data sets. The 
presence of the protein keratin, the predominant cytoskeletal protein in epithelia of 
vertebrates, is often an indication of contamination introduced during sample 
processing, either during collection or during preparation for mass spectrometry (227). 
The protein is also highly resistant to digestion by trypsin and pepsin, meaning they 
are likely to remain at high abundance in the sample. SPRRs and tubulin-subunits are 
found at much lower abundance and their presence is less likely to be due to simple 
contamination; however, further work is required understand their presence at 




Fewer differences in protein abundance were detected between Lyme disease 
seropositive and seronegative samples than expected. Their proteomes were found to 
be largely similar, with relatively small differences in abundance found. Of the 296 
proteins identified across all groups, only 12 (4.1%) were found to be in significantly 
different abundances between the Lyme disease groups. There were also few 
significant differences found when comparing the Lyme disease seropositive group to 
all other sera. As the healthy control group data could not be successfully normalised 
to allow comparison, analyses lacked a true negative control and were therefore likely 
to mask general host immune responses to bacteria that may be increased in all groups 
in mass spectrometry run 1. It was therefore difficult to conclude why so few changes 
were seen between Lyme disease groups. Firstly, due to the residual diagnostic nature 
of the samples used, their freeze-thaw cycle count and cold storage history were no 
known exactly, and the samples could be of poor quality having undergone protein 
degradation. Lyme disease group samples had been taken in primary care or local 
phlebotomy departments and are then sent for centralised testing, a process that can 
take several days and storage conditions are not always fully controlled. This could 
explain the relatively low protein identification (296) across groups and the presence 
of proteins that are resistant to proteolytic degradation, notably lipocalin 2 and SPRR-
2D. A second possibility for a lack of differences between the 2 Lyme disease groups 
is a fundamental error in experimental protocol; however, the degree and wide range 
of changes seen at the proteome level in leptospirosis positive sera indicate that the 
methodology was capable of detecting proteome changes.  Finally, it is possible that 
the serum proteome level, as measured by label-free quantitative mass spectrometry, 
of a patient that tests positive for Lyme by Standard Two-Tier testing is largely 
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similar to those that test seronegative. How these compare to normal, healthy 
individuals could not be determined in MSI. 
 
3.4.2.  Mass spectrometry run 1: Leptospirosis and syphilis positive control 
groups 
In contrast to the Lyme disease seropositive and seronegative groups, the related-
disease controls groups (leptospirosis & syphilis positive) showed greater differences 
in serum proteome.  While the main aim of the study was to find distinguishing 
features between the Lyme disease groups, the control groups showed consistent 
differences in protein abundances. Some proteins identified in the leptospirosis 
positive group were taken forward for further analysis in the subsequent chapter. This 
served as a proof-of-concept to show the ability of mass spectrometry based studies to 
identify protein biomarkers, but also gave an insight into the host response to 
leptospiral infection.  
Syphilis positive sera were found to have 21 proteins (7.1%) at significantly different 
levels when compared to all other groups. The protein apolipoprotein A1 (APO-A1) 
was found to be the most increased in abundance when comparing syphilis and other 
sera groups (Log[2]Fold Change=1.588, p=2.6E-07). The protein acts as the main 
lytic component in the trypanosome lytic factor (TLF), a component of innate 
immunity in primates that is characterised by an ability to kill extracellular protozoon 
pathogens(228). It should be noted that apolipoprotein A1 and apolipoprotein A2 are 
removed by the affinity columns used during sample preparation. Whilst structurally 
distinct and not targeted by affinity depletion, APO-A1 forms part of the 
apolipoprotein group of proteins that share similar lipid binding properties. The 
presence of APO-A1 in significantly differing amounts may be an artefact as a result 
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of differences in procedure when processing whole blood to serum. This may also 
account partially for differences in abundances of several blood coagulation factors, 
including fibulin-1 (C1QC) and coagulation factor IX (FA9) in the mass spectrometry 
data. Whilst normalisation of samples can better represent the serum proteome, it will 
not be able to remove proteins present as a result of differing sample preparation 
techniques. To better understand results in the context of sample preparation in future 
mass spectrometry studies, all sample groups could be processed from frozen, 
stabilised whole blood by exactly the same method to ensure abundance differences 
identified were due to differences in serum proteome.  
 
Of all sample groups compared during mass spectrometry run 1, the leptospirosis 
positive set showed the greatest differences in abundance of proteins when compared 
to all other sera. A total of 146 proteins (75%) were found at significantly different 
abundance from all other sera. Of these, 121 were increased in leptospirosis positive 
sera with 25 decreased. The proteins represented a wide-range of functions, with 
many associated with innate and adaptive host immune response. The scale of the 
change in proteome seen is likely to be a reflection of the systemic, multi-organ nature 
of leptospiral infection and the associated robust host immune and inflammatory 
response that contribute to several disease manifestations. The protein serpin B4 was 
found to be the most increased in abundance when comparing leptospirosis positive 
against all other sera, and the greatest difference in abundance across the entire 
sample set (Log[2]Fold Change=7.456, p=2.4E-04). Serpins are a superfamily of 
proteins with similar structures. Serpin B4 is a potent inhibitor of serine protease, 
enzymes that cleave peptide bonds in proteins (229). The fact that a protease inhibitor 
that is itself resistant to degradation is found at high abundance in leptospirosis 
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positive sera is highly likely to be as a result of overall sample degradation, rather 
than a difference that would be observable in the host. Carbonic anhydrase III (CAH3) 
protein was found to be have the second largest fold change between leptospirosis 
positive and other sera (Log[2]Fold Change=7.327, p=0.006). CAH3 is an enzyme 
that catalyses the reversible hydration of carbon dioxide. Importantly, the expression 
of CAH3 is highly tissue-specific, with high levels seen in skeletal and cardiac 
muscle(230). It is usually found in low abundance in human blood. Due to the large 
difference in abundance across sample sets, CAH3 was taken forward for further 
validation in the subsequent chapter. A possible hypothesis for increased abundance in 
leptospirosis positive sera is that muscle damage, a common symptom of 
leptospirosis, causes the release of CAH3 into the bloodstream. 
 
Other proteins identified as differentially abundance in leptospirosis positive sera 
included apolipoprotein A-1 (APO-A1), transthyretin (TTR) and transferrin (TF) 
during this study were also previously found to be increased in abundance in a study 
by Tan et. al (231)  that compared mild to severe leptospirosis sera. APO-A1 
(Log[2]Fold Change=-1.963, p=0.003) and APO2 (Log[2]Fold Change=-1.555, 
p=0.004) represent the largest decrease in abundance in protein when comparing 
leptospirosis positive to all other sera. Transthyretin was also found to be highly 
decreased in abundance in leptospirosis (Log[2]Fold Change=-0.951, p=0.012) as was 
the transferrin precursor (TRFE) (Log[2]Fold Change=-1.367, p=0.033). In total, the 
Tan study found 5 proteins that were found at significantly different abundance 
between healthy and mild leptospirosis (231). The presence of all of these proteins in 
the mass spectrometry run 1 data set, with significant differences in abundances in the 
	
	 132	
same direction, showed that mass spectrometry methods are capable of reproducibility 
across studies.  
 
Ingenuity pathway analysis, based on the data from mass spectrometry 1, identified 
several key upstream regulators in the leptospirosis positive group. The analysis is 
based on the presence of specific proteins in the dataset at differing abundance across 
groups. Interleukin 6 (IL-6) was identified by IPA an important upstream regulator in 
leptospirosis (Activation z-score = 2.935, p=1E-30).  IL-6 has been shown to be an 
important mediator of fever and of the acute phase response in a number of infections 
(232). IL-6 has been shown to differentiate severe cases of leptospirosis from mild 
disease, along with IL-10(233), suggesting it plays an important role in the 
development of the cytokine storm that leads to severe disease (234). 
 
3.4.3.		Mass	spectrometry	run	2:	Overview	
During mass spectrometry run 1, plasma samples were excluded from the analysis due 
to the inability of normalisation methods to reliably compare them to serum-based 
groups. As so few changes were seen between the Lyme disease seropositive and 
seronegative groups, and 2 of the differentially expressed proteins were highly 
resistant to proteases, the quality of the residual-diagnostic samples used in the first 
run was questionable. To address these issues, mass spectrometry run 2 was 
undertaken.  
Sera taken and stored at time of diagnostic testing for Lyme was used in this run, 
rather than older residual diagnostic samples. It was hypothesised that the samples 
would be of better quality than those used in mass spectrometry run 1 and that more 
proteins would be identifiable.  A negative control group was also included, 
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comprising serum samples from healthy normal donors, recruited locally at PHE 
Porton. Despite the assumed higher sample quality, fewer proteins (n=285) were 
successfully quantified across the three sample groups included in mass spectrometry 
run 2 than in the first run. Of these, 205 were detected in both mass spectrometry run 
1 and 2. 91 proteins were only identified in mass spectrometry run 1 only. 80 proteins 
were identified in mass spectrometry run 2 only. Data from mass spectrometry run 2 
showed that sample quality was unlikely to be a limiting factor during the first run, 
and that a lack of changes in protein abundance observed between Lyme disease 
seropositive and seronegative is more likely to be due to high similarity in serum 
proteome between these groups. 
 
3.4.4.	 Mass	spectrometry	run	2:	Lyme	disease	positive	vs.	NHD	
In a comparison of Lyme disease positive against normal/healthy donor samples 
following mass spectrometry run 2, 72 proteins were found at significantly different 
abundances between groups. Of 41 proteins found to be significantly increased, the 
majority were directly associated with immune processes. Of the top 20 increased 
proteins, 13 comprised immunoglobulin subunits, chains or precursor proteins. Other 
increased proteins in the Lyme disease seropositive group included complement 
system subunits and activators. The protein found to be at the lowest abundance in 
relation to the NHD controls was fibrinogen alpha chain. As fibrinogen should largely 
be removed by affinity columns in the sample preparation process, the presence of this 
fibrinogen chain again points towards potential influence of sample preparation on 
results. Several proteins associated with actin cytoskeleton organisation were 
identified including profilin-1 and filamin-A. This concurs with the results from MSI 
where several mediators of actin rearrangement were also identified as being 
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disrupted. The data suggests that host actin rearrangement may be influenced by 
borrelial infection; however, based on these datasets any consistent changes or mode-
of-action are difficult to interpret without further study of the host response. 
 
In general, comparison of Lyme disease seropositive to NHD controls shows a serum 
proteome that may reflect general host response to bacterial infection. An increase in 
several immune mediators is seen, as well as increased abundance of immunoglobulin 
subunits. Without infectious-disease controls present in this run, it was not possible to 
identify markers that may be more specific to early Lyme disease. As STT testing in 
the Czech Republic is part of a referral system, it is likely that those tested for Lyme 
disease have some sort of illness, even if they test seronegative for Lyme disease 
 
3.4.5.  Conclusions                                                                              
The sensitivity of STT in early Lyme has been discussed extensively before (181, 235, 
236). Most studies concluded that in early disease, when the human host is still 
developing an immune response against the pathogen, the level of Borrelia-specific 
antibodies in serum are too low to be readily detectable. The data from the two mass 
spectrometry runs undertaken in this chapter show that the serum proteome in early 
Lyme disease may also not be significantly altered. This may reflect the pathogenesis 
of the disease. In early infection, the pathogen is localised to the skin and circulating 
levels of bacteria are negligible. It is therefore probable that changes to the serum 





CHAPTER 4: ANALYSIS OF BIOMARKERS FOR SPIROCHAETAL 
INFECTION IN HUMAN SERA 
 
4.1. INTRODUCTION 
In chapter 3, two separate label-free mass spectrometry experiments were undertaken 
on Lyme disease patient serum samples, together with infectious disease controls and 
normal healthy donors. A comparison of Lyme disease seropositive (as diagnosed by 
Standard Two-Tier testing) sera to Seronegative revealed a small number of 
differentially abundant proteins between groups. Considerations of initial mass-
spectrometry experimental design and extensive follow-up analyses are required 
before assuming the value of any potential biomarker identified. Biomarkers identified 
as differentially abundant by mass spectrometry do also not necessarily directly 
translate to reliable measurement by more routine methods including by Western blot 
and Enzyme-Linked Immunosorbent Assay (ELISA). Both of these methods utilise 
antibodies against ligands (in this case proteins) of interest in order to indirectly 
measure abundance. Discrepancies in mass spectrometry and methods such as ELISA 
can exist for several reasons including bias introduced during sample preparation for 
mass spectrometry (237), presence of host-antibodies in biological samples interfering 
with ELISA binding and any issues surrounding specificity of the primary and 
secondary antibodies used in such tests. Therefore optimisation and validation of 
ELISA and WB protocols for use in sera is essential. 
 
In this study, proteins previously identified in chapter 3 as differentially abundant in 
Lyme disease seropositive sera over Seronegative by mass spectrometry were further 
analysed in patient sera by WB and ELISA. The aim of this study to was to further 
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investigate earlier mass spectrometry by common laboratory methods and to assess 
the ability of WB and ELISA techniques to accurately quantify the abundance of 
proteins of interest in human serum. To further understand the association between 
mass spectrometry data and subsequent serological analysis, proteins of interest 
identified in the leptospirosis positive controls were also included for study. 
 
4.1.1. Hypothesis 
The main hypothesis of this chapter was that disease-specific protein abundance 
changes identified in serum by label-free quantitative mass spectrometry could be 


















4.2. MATERIALS AND METHODS 
Full materials and method details are provided in Chapter 2. Table 4.1 gives a 
summary of all sample groups included in this study for analysis by WB and ELISA 
methods. All available clinical information and diagnostic testing results are described 
for each sample in Chapter 2 (2.1.1). 





4.3.1. Lyme disease 
During mass spectrometry, 7 proteins were identified as differentially abundant with a 
log[2]fold change greater than 1 in Lyme disease seropositive sera as compared to 
Seronegative sera. Very low abundance and/or blood-coagulation related proteins 
were discounted and the proteins lipocalin 2 (LCN2), tubulin alpha (TUBA4A) and 
small proline rich protein 2D (SPRR2D) were taken forward for further analysis by 
WB and/or ELISA. 
 
4.3.1.1. Lipocalin-2 Western blot 
Mass spectrometry identified the protein lipocalin 2 (LCN2) as significantly increased 
in abundance in Lyme disease seropositive sera when compared to Seronegative (Log2 
Fold Change =2.323, p=0.33). Figure 4.1 shows the normalised abundance data for 




Figure 4.1: Chart showing normalised protein abundance data for lipocalin 2 in 
human sera by label-free quantitative mass spectrometry. Error bars represent standard 
error of the mean (SEM). Sample groups; Leptospirosis positive n=5, syphilis positive 












In order to corroborate these findings, a Western blot method for LCN2 was 
performed on additional serum samples not used in the mass spectrometry discovery 
run. Serum samples were diluted to 1:50 concentration in BSA 10% buffer, ran using 
polyacrylamide gel electrophoresis (PAGE) and blotted using a semi-dry Western blot 
method (Materials and Methods: 3.2.3), using a primary antibody against LCN2 
(abcam ab63929). All blots were also stained by SYPRO ruby to allow normalisation 
by total protein, as described by Eaton et al (238) and summarised in Materials and 
Methods: 3.2.3.  Figure 4.2(A) shows an example WB image for all sample groups. 
The expected band size for LCN2 is 22kDA. As predicted, leptospirosis positive and 
syphilis positive sera showed the highest abundance of LCN2, showing oversaturated 
bands at the predicted molecular weight. A secondary, unidentified band was observed 
in several samples.  In order to measure differences in LCN2 abundance for Lyme 
disease seropositive and seronegative groups, 12 samples from each of these groups 
(n=24) were blotted for LCN2.  Each blot contained a negative control (diluent only) 
and a gel reference sample (LEP-8) to allow comparison between blots. Density of the 
LCN2 band was measured for each sample using Bio-Rad Image Lab software and 
results normalised using total protein staining by SYPRO ruby (Materials and 
Methods: 3.2.4). Results are given as adjusted-relative band density (as compared to a 
gel reference value = 1).  Table 4.2 shows the results for each sample. The mean 
relative band density for Lyme disease seropositive sera was 1.059(±0.0363) and for 
seronegative was 0.927(±0.033).  An unpaired t-test on the data gave a p-value of 
0.0409, indicating that a small but significant increase in LCN2 abundance can be 








Figure 4.2: Western blots for the protein LCN2 in human sera. A: Blot showing 
predicted LCN2 bands for leptospirosis positive, syphilis positive, Lyme disease 
seropositive (by STT), Seronegative (by STT) and normal healthy donor (NHD) sera. 
B: Blot showing predicted LCN2 band in 5 Lyme disease seropositive serum samples. 
C: Blot showing predicted LCN2 band in 5 Seronegative serum samples. Primary 
antibody: Abcam Anti-Lipocalin 2 (ab63929). NC = Negative control (loading buffer 
only), GR = Gel reference, a highly diluted leptospirosis positive serum sample used 








Table 4.2: Relative band density for LCN2 in Lyme disease seropositive and 
seronegative sera (by STT).  Lyme disease positive samples are shown on the left 
hand side of the table and seronegative on the right. All density values are relative to 
the gel reference band (LEP-8) that was given the value of 1.0. Mean density for each 
group is shown with 95% confidence interval.  
 
 
4.3.1.2. Lipocalin 2 ELISA 
In order to further confirm these findings by a more sensitive and quantitative method, 
and to allow the processing of a higher number of samples, an ELISA kit for LCN2 
(R&D Human-Lipocalin DuoSet ELISA kit: DY1757) was used.  In general, kit 
protocol was followed as described; however, to optimise the ELISA for use with 
serum samples, a diluent containing PBS and 10% bovine serum albumin was used 
(Materials and Methods: 3.3.2). Figure 4.3 shows a graph of LCN2 serum 
concentration for all groups, as measured by ELISA. Figure 4.3(A) shows all sample 
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groups separately, with each point representing one serum sample. The mean 
concentration for each group were as follows: UK Lyme disease positive = 
102.9(±30.5) ng/mL (n=26), UK Lyme disease seronegative = 57.37(±21.88) ng/mL 
(n=17), Czech Lyme disease positive = 92.88(±28.32)ng/mL (n=25), Czech Lyme 
disease seronegative = 64.5(±17.51)ng/mL (n=24), leptospirosis positive = 
418.7(±167.8)ng/mL (n=18), syphilis positive (159.3±51.3) n=10, NHD = 
39.64(±11.21)ng/mL (n=30). These data corroborate the previous results of the mass 
spectrometry analysis, with leptospirosis positive sera showing the highest abundance. 
Figure 4.3(B) shows the combined results for the Lyme disease seropositive groups 
(UK and Czech Lyme disease seropositive) and for the Seronegative groups (UK and 
Czech Seronegative).  The mean concentration in Lyme disease seropositive was 
99.93(±10.04)ng/mL (n=50) and in Seronegative was 63.08(±6.463)ng/mL. Therefore 
a difference of means of 36.85(±12.64)ng/mL was found between groups with a p-
value of 0.0035, demonstrating a significant difference in abundance of LCN2 











Figure 4.3: Graphs showing Lipocalin 2 abundance as measured by ELISA (R&D 
Human-Lipocalin DuoSet ELISA kit: DY1757). 5.3(A) shows abundance data for all 
groups. 5.3(B) shows abundance data for combined Lyme disease positive groups 
(UK and Czech Lyme disease seropositive) and combined Lyme disease seronegative 
groups (UK and Czech Seronegative) along with the NHD group. Combined Lyme 
disease positive n=52, combined Lyme disease seronegative n=50, NH donor n=30. 
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4.3.1.3. Tubulin-alpha 4A Western blot 
Previously, mass spectrometry identified the protein tubulin-alpha 4A (TUBA4A as 
significantly decreased in abundance in Lyme disease seropositive sera when 
compared to Seronegative (Log2 Fold Change =-1.926, p=0.3). Figure 4.4 shows a 














Figure 4.4: Chart showing normalised protein abundance data for tubulin-alpha 4A in 
human sera by label-free quantitative mass spectrometry. Error bars represent standard 
error of the mean (SEM). Sample groups; Leptospirosis positive n=5, syphilis positive 







To assess if differences in serum abundance of TUBA4A could be measured and 
corroborated by WB, serum samples were ran using primary antibodies for tubulin-
alpha 4A protein (abcam ab15246). The Western blot procedure as described for 
LCN2 in section 5.3.1.2 was followed. Figure 4.5 shows a Western blot for TUBA4A 
with a range of sample types. By eye, the abundance of the presumed tubulin alpha 
band (tubulin alpha = 50kda) is similar across sample types. In order to measure 
protein abundance difference previously identified by mass spectrometry between 
Lyme disease seropositive and seronegative groups, 12 Lyme disease seropositive and 
12 seronegative serum samples not previously used for mass spectrometry were run 
on gels with a leptospirosis positive gel reference. Samples were normalised using 
total protein staining by SYPRO ruby and band density was measured against the gel 
reference (Materials and Methods: 3.2.4). Table 4.3 shows relative band density for 
each sample as compared to the gel reference. Only very small differences in band 
density were observed between sample, and no significant difference in band density 
was found between groups (p=0.152). For all sample groups, extensive smearing of 
bands and the presence of unexpected bands were observed. Problems were still 
experienced when using an alternative primary antibody. Presence of bands of lower 











Figure 4.5: Blot showing predicted tubulin-alpha 4A bands for leptospirosis positive, 
syphilis positive, Lyme disease seropositive (by STT), Seronegative (by STT) and 













Table 4.3: Relative band density for TUB4A in Lyme disease seropositive and 
seronegative sera (by STT).  Lyme disease positive samples are shown on the left 
hand side of the table and seronegative on the right. All density values are relative to 
the gel reference band (LEP-8) that was given the value of 1.0. Mean density for each 













4.3.1.4. SPRR-2D, F13A and other low abundance proteins 
Several proteins found to be in significantly different abundances between Lyme 
disease seropositive and Seronegative by mass spectrometry were identified at 
relatively low abundance. To investigate if these changes were detectable by Western 
blot, additional serum samples (not used in mass spectrometry) were run using 
primary antibodies against these proteins. Ultimately, in order for bands of interest to 
be visible, high concentrations of serum were required to be run on the gel and protein 
load over-saturation and cross-reactivity were seen across the blot. Due to the 
unreliability of over-saturated gel to correctly resolve proteins by molecular weight, 
these proteins were not taken forward for further analysis by Western blot.  In general, 
proteins with a mean normalised abundance of <100,000 in mass spectrometry were 




During mass spectrometry analysis of serum proteome, leptospirosis positive sera 
were seen to be highly distinct from other sera groups. A total of 108 proteins were 
found to be in significantly different abundance when comparing leptospirosis 
positive sera to all other sera groups. In order to further demonstrate the ability of 
label-free quantitative mass spectrometry to identify novel biomarkers for infectious 
disease, two proteins of interest, serum amyloid A1 (SAA1) and carbonic anhydrase 






4.3.2.1. Serum amyloid A1 ELISA 
Quantitative mass spectrometry identified the protein serum amyloid A1 (SAA1) as 
increased in abundance in leptospirosis positive sera compared to all other groups 
(Log2 Fold Change =5.942, p=0.033). Figure 4.6 shows the normalised abundance 
data for SAA1 as measured by mass spectrometry. 
 
 
Figure 4.6: Chart showing normalised protein abundance data for serum amyloid A1 
(SAA1) in human sera by label-free quantitative mass spectrometry. Error bars 
represent standard error of the mean (SEM). Sample groups; Leptospirosis positive 
n=5, syphilis positive n=5, Lyme disease seropositive (by STT) n=15, Seronegative 






SAA1 is a commonly measured protein in serum and several pre-optimised ELISA 
kits are commercially available for quantification in human sera. As with LCN2, a 
Duoset ELISA kit (R&D Human-SAA1 DuoSet ELISA kit DY3019-05) was chosen 
to allow processing of a large number of samples across multiple plates. In general, kit 
protocol was followed as described; however, to optimise the ELISA for use with 
serum samples, a diluent containing PBS and 10% bovine serum albumin was used 
(Materials and Methods: 3.3.2). Figure 4.7 shows a graph of SAA1 serum 
concentration, as measured by ELISA. Figure 4.7(A) shows all sample groups 
separately, with each point representing one serum sample. The mean concentration 
for each group were as follows: UK Lyme disease positive = 7592(±1635) ng/mL 
(n=26), UK Lyme disease seronegative = 7070(±2347) ng/mL (n=17), Czech Lyme 
disease positive = 7864(±2109) ng/mL (n=25), Czech Lyme disease seronegative = 
7071(±17.51)ng/mL (n=24), leptospirosis positive = 17922(±2311)ng/mL (n=18), 
syphilis positive =12386(±974)ng/mL n=10, NHD = 6039(±1136)ng/mL (n=30).  
Figure 4.7(B) shows a graph of the ELISA data split into leptospirosis, NHD and a 
final group with all other sera. The mean concentration of leptospirosis positive sera 
was 15990(±880.4)ng/mL, while in the related-control group the mean was 
8044(±466.5)ng/mL. This equates to a log[2]fold change increase of 0.991 in 
leptospirosis positive. The data demonstrate the ability of mass spectrometry to 
identify potential biomarkers in human sera even in this small sample set 



























Figure 4.7: Graphs showing serum amyloid A1 abundance as measured by ELISA 
(R&D Human-SAA1 DuoSet ELISA kit DY3019-05). A: Abundance data for all 
groups. B: Abundance data for combined Lyme disease positive groups (UK and 
Czech Lyme disease seropositive) and combined Lyme disease seronegative groups 
(UK and Czech Seronegative) along with the NHD group. Combined Lyme disease 
positive n=52, combined Lyme disease seronegative n=50, N.H donor n=30 
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4.3.2.3 Carbonic anhydrase III ELISA 
Quantitative mass spectrometry identified the protein carbonic anhydrase III (CAH3) 
as highly increased in abundance in leptospirosis positive sera compared to all other 
groups (Log2 Fold Change =7.327, p=0.006).. Figure 4.8 shows the normalised 














Figure 4.8: Chart showing normalised protein abundance data for carbonic anhydrase 
III (CAH3) in human sera by label-free quantitative mass spectrometry. Error bars 
represent standard error of the mean (SEM). Sample groups; Leptospirosis positive 
n=5, syphilis positive n=5, Lyme disease seropositive (by STT) n=15, Seronegative 




In the absence of commercial ELISA kits for large-scale analysis of sample (>39 
samples), an ELISA platform for CAH3 was developed using a primary and 
secondary antibody pair for the protein (Novus CAH3 antibody pair H00000761-
AP11)(Materials and Methods: 2.3.2).. In order to optimise the concentration of 
primary and secondary antibody for ELISA, a checkerboard antibody titration assay 
was undertaken. Figure 4.9(A) shows the layout of the 96-well plate for titration 
assay. Figure 4.9(B) shows the results of this assay, given as signal to noise ratios for 
each possible capture and detection antibody detection. A higher signal to noise ratio 
is desirable. An antibody at a concentration of 2µg/mL and detection antibody at a 
concentration of 0.5µg/mL (signal/noise=20.072) were chosen as suitable 



















Figure 4.9: Optimisation of primary and secondary antibodies for a CAH3 ELISA. A: 
Table showing the 96-well plate layout of checkerboard optimisation assay. Standards 
of CAH3 at the following dilutions were used to assess range: 10ng/mL, 20ng/mL and 
40ng/mL. ∆ = wells with only sample diluent (no standard). B: Signal-to-noise ratio 
calculated by dividing OD read for each sample by the corresponding OD read for 
negative control (∆ = diluent only). This was performed for each standard and a mean 







In order to quantify CAH3 abundance in serum samples, a standard curve was 
developed using a commercial recombinant purified CAH3 protein (abcam ab82823). 
Following the suggested total range of detection for the antibody pair used (1-
100ng/mL), standards at 1,5,10,20,40,50,80 and 100ng/mL CAH3 concentration were 














Figure 4.10: A standard curve for carbonic anhydrase III protein using recombinant 
protein. Standards were run in triplicate, with error bars representing standard error of 
the mean (SEM). The red shows and example of the standard curve (R-squared 







A total of 103 serum samples were tested for CAH3 abundance using the optimised 
ELISA protocol. Figure 4.12(A) shows all sample groups separately, with each point 
representing one serum sample. The mean concentration for each group were as 
follows: UK Lyme disease positive = 117.8(±65.6)ng/mL (n=26), UK Lyme disease 
seronegative = 138(±68.1)ng/mL (n=17), Czech Lyme disease positive = 139.8(±57) 
ng/mL (n=25), Czech Lyme disease seronegative = 92.08(±35.52)ng/mL (n=24), 
leptospirosis positive = 290.5(±98.8) ng/mL (n=18), syphilis positive 
=145.8(±28.2)ng/mL n=10, NHD = 104.8(±38)ng/mL (n=30).  Figure 4.7(B) shows a 
graph of the ELISA data split into leptospirosis, NHD and a final group with all other 
sera. The mean concentration of the combined other sera group was 
127.8(±12.13)ng/mL. This equates to a log[2]fold change increase of 1.185 in 
leptospirosis positive. This data corroborates the mass spectrometry findings with a 
large increase in abundance of CAH3 in leptospirosis positive sera, with other sera 


































Figure 4.11:Graphs showing CAH3 abundance as measured by ELISA. A: 
Abundance data for all groups. B: Abundance data for combined Lyme disease 
positive groups (UK and Czech Lyme disease seropositive) and combined Lyme 
disease seronegative groups (UK and Czech Seronegative) along with the NHD group. 
Combined Lyme disease positive n=52, combined Lyme disease seronegative n=50, 




In chapter 4, label-free quantitative mass spectrometry revealed that the serum 
proteome of Lyme disease seropositive patients was largely similar to that of those 
that had been tested for Lyme by STT testing but were found to be seronegative. 
Despite this, several proteins were found to be differentially abundant between these 
groups including lipocalin-2, which was increased in Lyme disease seropositive sera, 
and tubulin-alpha 4A, which was seen to be decreased in Lyme disease seropositive 
sera. WB and ELISA methods were able to corroborate lipocalin-2 findings, with the 
protein found to be in significantly higher abundance in Lyme disease seropositive 
(99.93(±10.04)ng/mL than Seronegative 63.08(±6.463)ng/mL. WB analysis did not 
identify any significant differences for tubulin alpha abundance between these groups. 
To further assess the ability of mass spectrometry to identify potential biomarkers the 
proteins serum amyloid A1 (SAA1) and carbonic anhydrase III (CAH3), previously 
identified to be highly increased in abundance in leptospirosis positive sera. ELISA 
data for SAA1 and CAH3 corresponded to mass spectrometry findings, with 
leptospirosis sera having the highest abundance of these proteins 
(17922(±2311)ng/mL and 290.5(±98.8)ng/mL respectively).  
 
A recurring problem during Western blotting for proteins of interest was the presence 
of smeared bands and/or the presence of unspecific bands. For several proteins, these 
problems reoccurred despite using alternative primary antibodies. There are several 
possible reasons for the difficulty in developing clear blots with a single clear band at 
the expected molecular weight. The presence of smeared bands is often an indication 
of protein degradation, with smaller fragments of protein that contain the target 
antigen spread below the band of interest. As disruption of cell membranes during 
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blood collection and subsequent processing to serum releases proteases, kinases and 
phosphatases, degradation of sample begins early (239).  While enzyme activity is 
halted when samples are frozen, once thawing begins samples are again susceptible to 
degradation.  Another possible explanation for the presence of multiple bands is poor 
specificity in the primary or secondary antibody. In a highly complex biological 
sample such as total serum, the possibility of non-specific bands developing is greater. 
The use of monoclonal antibodies against a single antigen theoretically reduces the 
possibility of non-specific bands forming when compared to polyclonal antibodies 
produced by multiple B-cell lineages. Despite this, non-specific binding was still 
observed when using monoclonal primary antibodies for several proteins. Poor WB 
band formation may be due to the complex nature of serum, several orders of 
magnitude exist between abundance of several of the proteins-of-interest identified by 
mass spectrometry and the most abundant proteins in serum. When attempting to blot 
for lower abundance proteins, larger total protein loads per well are required to allow 
detection. This may have resulted in separation of proteins as the gel is overwhelmed 
by protein load. Budgetary constraints meant that samples not used in mass 
spectrometry did not undergo depletion by Pierce top-12 columns. In future work, 
sample fractionation by other means such as simple pore filters or more advanced 96-
well plates that fractionate proteins based on isoelectric point could be used. In the 
context of this study, the use of non-fractionated serum better represents the biological 
specimen that would likely be used in any potential biomarker-based diagnostic assay.  
 
Mass spectrometry data indicated that tubulin alpha 4A and several actin isoforms 
were differentially abundant across sample groups. This finding was unusual as these 
proteins are generally considered to be found at consistent levels regardless of 
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physiological state, and both tubulin alpha and actin alpha are recommended as 
“housekeeping” loading controls for Western blot. In this study, alpha tubulin was 
found to be consistent across Lyme disease seropositive and Seronegative by WB at 
the resolution possible. In previous studies, however, these proteins have been shown 
to have inconsistent abundance across sample types(240-242). For this reason, a 
protocol using total protein staining by SYPRO ruby was used instead of a traditional 
housekeeping gene during WB analyses for all proteins.  
 
The serum acute phase-response protein, serum amyloid A1 (SAA1), was previously 
found to be increased in abundance in leptospirosis positive sera by mass 
spectrometry (Chapter 3) (Log[2]Fold Change=5.942, p=5.0E-05) and was again 
found to be increased in leptospirosis positive sera by ELISA (leptospirosis positive: 
17922(±2311)ng/mL, other sera 8106(±1045)). Acute-phase serum amyloid A 
proteins (A-SAAs) are secreted during inflammation acute phase and have a variety of 
functions including immune cell recruitment to inflammatory sites.  Differences in 
abundance of SAA1 have previously been identified in a 2017 study by Tan et al 
when comparing mild and severe leptospirosis cases using 2DE analysis LC-MS/MS. 
In that study both serum amyloid A-1 and A-2 were significantly increased between 
healthy to mild and again between mild to severe leptospirosis cases (243). A-SAAs 
have been shown to be deposited in the kidney and liver during infection and probably 
contribute to kidney and liver failure commonly reported in severe leptospirosis (244).  
 
For LCN2 and SAA1, commercial ELISA kits were able to corroborate the findings 
found by mass spectrometry. The LCN2 ELISA showed excellent performance 
(correlation) for the development of standard curves (LCN2 R squared value = 
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0.9901. For SAA1, correlation was found to be poor at highest levels of standards 
with very little increase in OD seen between the top two standards (50ng/mL and 
100ng/mL). Despite this, correlation was very good at lower standard concentrations, 
and the majority of serum samples tested were well within this range. In future, a 
better standard range and/or further optimisation of primary and secondary antibodies 
could improve the precision of SAA1 levels as measured by this ELISA. Following 
development and optimisation, the CAH3 ELISA was able to quantify CAH3 protein 
across serum samples. In order to determine if protein detection was affected by 
standard curve diluent and biological sample (serum), a spike-and-recovery and 
linearity-of-dilution assessment for ELISA could be undertaken.   
 
4.4.1. Conclusions 
Several proteins found to be differentially abundant in different disease states by mass 
spectrometry in chapter 4 were successfully quantified by WB and/or ELISA 
methods. In general, results for WB and ELISA corroborated mass spectrometry 
findings. Lipocalin 2 protein was shown to be significantly increased in abundance in 
Lyme disease seropositive over seronegative by WB and ELISA. The results of this 
study demonstrated the ability of quantitative mass spectrometry to identify proteins 
that are differentially abundant in the serum of Lyme disease and other infectious-






CHAPTER 5: RNA-SEQ ANALYSIS OF WHOLE BLOOD FROM PATIENTS 
WITH LYME DISEASE 
 
5.1. INTRODUCTION 
The impact of Lyme disease on the host can result in changes in protein abundance 
and potentially post-translational regulation. However, often at the root of these 
signalling events are changes in the host transcriptome.  Blood represents an excellent 
sentinel to examine the impact of a pathogen on the host as this sample contains 
multiple cell types whose abundance and transcriptomic profile reflects pathogen/host 
interactions. To date, relatively few transcriptomic-based studies have been published 
on Lyme disease. Of these, two have focused on studying gene expression in the 
Borrelia pathogen itself (245, 246) both in vitro and in vivo. A 2016 study by Bouquet 
et al examined the molecular basis of acute Lyme and ensuing post-treament 
symptoms by undertaking a longitudinal study of patients followed up to 6 months 
post treatment. They found a large change in gene expression during acute infection 
showing fewer than 50% differentially expressed genes in common with other 
infectious diseases. No differential gene expression signature was observed between 
Lyme disease patients with resolved illness to those with persistent symptoms 
(247)(Bouquet 2016). In this study, 14 whole-blood samples from 8 Lyme disease 
patients underwent RNA extraction and subsequent sequencing by Illumina RNA-seq. 
Sequencing data from previous studies were used to form control groups and allow 
relative gene expression to be calculated. Machine learning algorithms based on DGE 
were used to identify a panel of genes that could distinguish early Lyme disease 
patient samples from those of the control group. Analysis of gene expression also 
allowed study of the host response to Lyme disease and the identification of 
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associated biological pathways. Finally, RT-PCR was used to corroborate findings in 
a different platform and showed significant changes in presence of gene transcripts in 
genes associated with eIF2a signalling, as identified by RNA-seq and downstream 
analyses. 
 
RNA sequencing (RNA-seq) is a technique that utilises Next Generation Sequencing 
(NGS) to sequence fragments of RNA in a biological sample that can be mapped to 
expressed RNA in the host genome (248). The technology allows quantification of 
gene expression at the time of sampling, and can therefore give a representation of 
host biological processes occurring during a particular biological state including acute 
infection, progression of a disease and response to therapy. RNA-seq protocols 
involve the conversion of RNA to cDNA fragments which are subjected to NGS, 
producing short sequences that correspond to a specific host gene. Single-read 
sequencing methods involve reading of the cDNA from one end only. Paired-end 
methods, including that used in this study, involves the sequencing of cDNA from 
both ends of the fragment (249). While more time consuming and costly, paired-end 
reading allows more accurate mapping of fragments relative to the genome and allows 
detection of insertion-deletion variants. RNA-seq produces raw sequence data, often 
provided in text-based FASTQ files. The data provides only nucleotide sequences 
together with a corresponding quality score for each base, a measure of the probability 
of correct base calling based on properties including signal-to-noise ratios. The data 
are commonly filtered based on quality score, and then sequences can be mapped to 
their corresponding position on the host genome using mapping software. The number 
of reads mapped to certain genes allows a quantification of the expression of that gene 
in that sample. Comparison of two or more cohorts allow Differential Gene 
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Expression (DGE) to be identified between groups. This is particularly important in 
biomarker discovery studies, where identifying quantifiable changes in gene 
expression in a certain group may be of more value than understanding underlying 
biological processes.  
 
Several other tools exist for the use of RNA sequencing data, either from the raw read 
data itself or from DGE output such as DESeq2. These include pathway analysis tools 
such as Ingenuity Pathway Analysis (IPA), software that estimates differential 
expression of biological pathway based on the increased or decreased expression of 
specific combinations of genes in the cohorts compared (250). Similar programmes 
are available that predict the make-up and quantity of immune cells present in a 
biological sample or group of samples based on gene expression data (251).  
 
The sheer abundance of data generated by RNA sequencing makes it an attractive 
target for the discovery of biological biomarkers with diagnostic or prognostic 
properties. The availability of expression data for tens of thousands of genes allows 
for identification of genes and gene panels that are diagnostic of a certain condition, 
often with a high degree of accuracy; however, whole RNA sequencing of biological 
samples is expensive and time consuming, and it is unlikely that routine diagnostic 
tests could be based on sequencing of patient sample in the near future. Diagnostic 
tests could theoretically be based on performing multiplex RT-PCR assays for the 
detection of a panel of host genes, and this has been proposed before, including for 
distinguishing between viral and bacterial respiratory infections (252). RT-PCR 
methods for host-genes have also been used for over a decade in quantification of 
minimal residual disease, the presence of tumor mass remaining following treatment 
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in leukemia patients (253). RT-PCR methods for the detection of infectious pathogen 
genome or genes present in the host are far more commonly used as diagnostics, with 
the presence of high levels of pathogen nucleic acid often being a clear indication of 
ongoing infection. In the case of Lyme disease, previous studies attempting to use 
PCR for the detection of Borrelia have been largely unsuccessful, or have required the 
use of biological samples such as erythema migrans skin biopsies that are not 
appropriate for routine diagnosis (254, 255). In samples commonly used for 
diagnostics, including blood and urine, Borrelia are often present in too low 
abundance to be quantified using PCR, even during acute disease. In these cases, the 
value of RNA-seq often lies in the identification of genes that are highly differentially 
expressed between groups, or in the use of machine-learning algorithms to identify 
panels of genes that can distinguish a sample from a control group. RNA-seq together 
with downstream bioinformatics can also give a picture of the on-going host 
biological processes that underlie or influence disease progression. It can also identify 
certain biological pathways associated with a disease that have previously gone 
unrecognised.  
5.2. MATERIALS AND METHODS 
Table 5.1 shows summary data of samples used during RNA analyses. Group 1: Lyme 
disease patients, were provided as whole-blood samples in PAXgene tubes. They were 
sequenced and mapped as described in the main Materials and Methods chapter 
(3.7.4). Group 2: Controls – Ebola virus (EBOV) positive and convalescent, were 
provided as trimmed Illumina sequencing data. These data were processed using the 
same pipeline as the Group 1. Group 3: Controls – NHD, were obtained as trimmed 
Illumina sequencing data (online database). Again, these data were processed as with 









Table 5.1: Summary data for Lyme disease samples used in this study together with 
details of control groups. All Lyme disease samples were sequenced for use in this 
study, while control groups were based on sequence data from previous studies (not 





5.3.1. RNA sequencing (RNA-seq) 
Samples were collected in PAXgene blood RNA tubes allowing for immediate 
stabilisation of intracellular RNA during blood sample collection. A PAXgene 
purification kit was then used for the purification of intracellular RNA from whole 
blood. To further purify samples, a Qiagen spin-column based kit was used and 
samples were run on a denaturing agarose gel to assess their quality by presence of 
distinct 28S and 18S rRNA bands (Materials and Methods 2.7.1).  Samples were then 
run using Illumina RNA-seq by the Centre for Genomic Research (CGR), University 
of Liverpool (Materials and Methods 2.7.4).  Sequencing statistics for each sample are 
provided in table 5.2. A mean of 78.42 (±52.5) million reads were sequenced per 
sample. This is considered very good for blood samples and provided ample depth for 
downstream DGE analyses. Following sequencing, trimmed reads provided by CGR 
were mapped and quantified following the method described in Materials and 
Methods 2.7.4. Briefly, trimmed read data for forward and reverse sequencing were 
concatenated, aligned to the human genome using TopHat and were then converted to 
read count files using featureCounts. This pathway was also used for raw read data 
used in the Ebola positive and NHD (normal healthy donor) control groups. Figure 5.1 
shows a Venn diagram of all human genes detected per sample group. A total of 























































































Figure 5.1: Venn diagram showing the number of unique human genes successfully 
detected and quantified following RNA sequencing and genome mapping for each of 
the three groups.  
 
5.3.2. Differential gene expression: Lyme disease 
To understand differences in gene expression in patients with Lyme disease, a 
differential gene expression study was undertaken, comparing 6 early/mid Lyme 
disease patient sample data (Samples: L 8/1, L 10/1, L 11/1, L 12/1, L 11/14) against 
Ebola and NHD controls. All Lyme disease samples were positive or borderline for 
Lyme by CLIA IgG, CLIA IgM and IgM WB at the time of sample collection. 
Differential gene expression analysis was performed using a DESeq2 pathway, as 
described in Materials and Methods 2.7.4. Briefly, featureCount data was normalised 
by internal normalisation by DESeq2 and differential gene expression was calculated 
by use of negative binomial generalised linear models. DESEq2 results files provided 
a list of differentially expressed genes and a calculated log [2] fold change estimate 
between groups for each gene. Only genes found to be differentially expressed with a 
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statistical significance of p<0.05 are included in these data. In this study, 5 early/mid 
Lyme disease samples were compared to a control group of 13 control samples 
(composed of Ebola convalescent and NHD). Figure 5.2 shows a MA plot of the 
DGE data. A total of 9435 genes were found to be significantly increased and 3817 
decreased in the Lyme disease group. 
 
Figure 5.2: A MA-plot of DGE data from a comparison of early Lyme disease patient 
blood RNA to a combined infectious and normal/healthy control group. The data is 
transformed onto the M (log ratio) and A (mean average) scales and plotted. This 
allows visualisation of differences in the dataset. All points represent one gene, with 





In order to identify a panel of genes that were able to distinguish between the Lyme 
disease group and controls, the MLSeq package in R was used to generate a 
Probabilistic Linear Discriminant Analysis (PLDA) machine learning protocol. 
Normalised abundance data generated during DESeq2 were used as an input. Sample 
data were then split into training and test sets. This allowed development of the 
machine learning protocol and subsequent testing of the model to verify its accuracy. 
Developing a protocol using only a training set is likely to output genes that are 
indicative of the input sample data, rather than changes that are conserved across 
samples of that group. A PLDA (probabilistic linear discriminant analysis) based 
machine learning algorithm was used.  From the training set, 9 genes were identified 
as discriminatory between Lyme and control groups. Of these, 6 had a higher mean 
read count value in the Lyme disease group (S100A9, EEF1A1, CSF3R, MYO1F, 
LITAF and CORO1A), while 3 (IFITM2, SELL and ACTB) and had a lower value in 
the Lyme disease group. Figure 5.3 shows the normalised read counts (Log [2]) of all 
samples within these groups. Using the machine learning testing set, values for  the 
accuracy of the gene-panel (based on cut-off values) to discriminate between Lyme 
disease samples and controls were generated. Accuracy, sensitivity and specificity 
values nearing 100% were predicted based on the model. It should be noted, however, 
that these values were based on a very small number of samples being tested by the 
model, and without robust downstream analysis using additional samples; no 
meaningful conclusions about the model accuracy can be made at this time. The study 







Figure 5.3: Graphs showing read count data for the 9 genes identified by PLDA-
based machine learning as discriminatory between Lyme disease blood RNA and 
controls. Read counts for each gene (Log [2]) are plotted for each sample. Mean read 




5.3.3. Differential gene expression: Early vs. Late Lyme disease 
The Lyme disease samples used in this study were collected from patients with a 
range of days post-presentation, as described in the Materials and Methods section of 
this chapter. This allowed for a DGE study based on groupings of “early” and 
‘late/convalescent” Lyme disease samples with the aim of identifying markers that 
may be elevated in early disease and fall over time. A DESeq2 method was used 
comparing the early group (Sample: L 8/1, L 10/1, L 11/1, L 12/1) to late samples (L 
1/84, L 2/92, L 7/88). A total of 727 genes were identified as differentially expressed 
between these groups. Of these, 501 were significantly decreased in late/convalescent 
samples, while 226 were significantly increased in this group. Figure 5.4 shows a MA 
plot of this data following normalisation.  
 
Following DESeq, a PLDA-based machine-learning algorithm was again applied to 
the data. This provided a list of 11 genes that were differentially expressed between 
the early and late group. To visualise these changes, the Lyme sample group was then 
split into three subgroups based on days post presentation; an “early” group (samples 
8/1, 10/1, 11/1 and 12/1) a “mid” group (samples 7/17, 7/30, 8/20, 9/18, 9/33, 11/14 
and 12/18) and a “late” group (samples 1/84, 2/92 and 7/88). Normalised read count 
data were then plotted for each gene across sample groups (figure 5.5). The DEseq2 
protocol combined with PLDA-based machine-learning was able to identify a set of 
genes that fell during the course of Lyme disease. Proper matching of samples across 
time points was not possible due to lack of samples, the major limiting factor of this 
study. Generally, Lyme disease patients showed movement of blood transcriptome 





Figure 5.4: MA-plot of DGE data from early Lyme disease vs. mid/late Lyme disease 
as based on days post presentation. Each point represents a human gene, with points in 










Figure 5.5: Graphs showing read counts (Log [2]) over time of 11 genes identified by 
PLDA-based machine learning as discriminatory between early and late Lyme disease 
Read count (Log [2]) data are shown for the 6 genes found to be decreased in the late 
group (top) and for the 5 genes found to be increased in the late group (bottom). Each 
point shows the mean value for that gene per group, with SEM error bars. 
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5.3.4 Ingenuity pathway analysis: Lyme disease 
To gain a better understanding of the host response to Lyme disease, a further DGE 
experiment was conducted using early Lyme disease samples (Samples: L 8/1, L 10/1, 
L 11/1, L 12/1, L 11/14) and comparing to the healthy control group (Samples: H1-
H6) using DESeq2. This generated a list of 6301 differentially expressed genes 
between these groups. This data was then input into the Ingenuity Pathway Analysis 
(IPA) software. IPA uses DGE data for pathway analyses based on differential 
expression of specific genes between groups. IPA generates a z-score and p-value for 
each pathway identified - based on the number of specific pathway genes identified 
and the differential expression of these between groups. A positive z-score indicates 
up regulation of that pathway, while a negative z-score indicates down regulation. For 
pathways in which no activity pattern is available, either through contradiction in 
expression of certain genes, or lack of reference material for the pathway, no z-score 
is given; in these instances a high p-value for the pathway indicates that the pathway 
is being influenced between group in some way, without a clear direction. Figure 5.6 
shows the top 15 pathways identified by IPA when comparing Lyme disease patients 
to healthy controls. Disruption of oxidative phosphorylation was identified as the top 
influenced pathway (based on p-value), showing an increase in expression of this 
pathway in Lyme disease patients. Further to this, IPA identified “mitochondrial 
dysfunction” as the top biological process in Lyme disease patients, when compared 
to healthy controls. The eIF2a signalling pathway was predicted to be highly increased 
in Lyme disease patients, along with regulation of the related initiation factor protein 
eIF4. The eIF2a pathway had previously been identified in previous transcriptomic-
based studies of Lyme disease, where it was also found to be one of the top pathways 
influenced by Lyme disease (258). Figure 5.7 shows a diagram generated by IPA for 
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the eIF2a signalling pathway.  Interestingly, iron homeostasis signalling was found to 
be consistently disrupted in Lyme disease patients. The iron homeostasis associated 
protein lipocalin-2 has been described as a potential biomarker of Lyme in chapters 3 
and 4. Pathways associated with cytoskeletal rearrangement, including regulation of 
actin-based motility by Rho were also identified by IPA. The potential association 
between host cell rearrangement disruption and Lyme disease has also been discussed 
in earlier chapters. The association between several of these biological processes and 
Lyme disease are unclear, but have consistently been identified as disrupted 
throughout this study.  
 
Figure 5.6: Top 15 biological pathways identified as being significantly altered 
between early Lyme disease patients and normal/healthy controls, as predicted by 
Ingenuity Pathway Analysis of DGE data. Calculated p-value (-log) is plotted along 
the x-axis for each pathway as calculated by IPA. Pathways with a positive z-score 
(decrease in activity in Lyme disease patients) are shown in blue, with negative z-
score (increase in activity in Lyme disease patients) shown in orange. Where no 





























Figure 5.7: Ingenuity pathway analysis (IPA) network diagram of eIF2 illustrating 
annotated interactions between genes differentially expressed in Lyme disease patients 
against healthy controls. Molecules/genes identified as up regulated are shown in red, 




5.3.5. Ingenuity pathway analysis: Early vs. late Lyme disease 
In order to identify pathways that may be increased in early Lyme disease, but 
decrease over the course of disease to convalescence, the DGE data generated in 
section 5.3.3 for “early” vs. “late” Lyme disease were input into IPA.  No healthy 
controls were included in this analysis, and pathway changes represent only those 
between early and late disease, in this sample set. Figure 5.8 shows 10 pathways 
identified by IPA between these groups. Of particular note is the significant increase 
seen in eIF2a signalling, suggesting that over the course of disease, this pathway 
reverts back to that  seen in healthy patients. Again, oxidative phosphorylation as seen 
to be influenced between groups; in this case no particular activity pattern was 
identified. This result further suggests some mechanism occurring during early Lyme 
disease that disrupts or influences mitochondrial function in the human host. IL-10 
and TLR signalling were identified as being decreased in activity in late Lyme 
disease, suggesting the down regulation of innate immunity and inflammatory 
processes back to normal levels. A small decrease in activity of actin-based motility 








Figure 5.8: Top biological pathways detected by IPA software when comparing early 
Lyme disease to late Lyme disease, based on DGE data. Pathways with blue bars have 
a positive z-score (decrease in activity from early to late Lyme), while orange bars 
represent a negative z-score (increase in activity from early to late Lyme).  
 
 
5.3.6. Cell typing analysis: ImmQuant 
A final analysis based on the sequencing data for Lyme disease patients was 
conducted using omicX ImmQuant software (Materials and Methods 2.7.5). 
ImmQuant again uses DGE data to identify a list of specific genes that are associated 
with the presence of certain types of host immune cell. The software produces an 
estimation of the presence of cells of the presence together with a significance value 
for each. Figure 5.9 shows the immune cells identified by ImmQuant as being 
significantly increased or decreased in early Lyme disease when compared to 
normal/healthy controls. Only cells with a significance of p<0.05 are shown. 
Erythroid CD34- CD71+ cells were found to have to have a large increase in presence 
in blood from Lyme disease patients compared to very low levels in normal/healthy 
controls. Myeloid dendritic cells (mDCs, also known as conventional dendritic cells) 
were found to be increased in abundance in the Lyme disease group. Dendritic cells 
Positive z-score 
Negative z-score 
No activity pattern available 
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are antigen-presenting cells that have major importance in the mammalian immune 
system, allowing progress from innate to adaptive immune systems. Conversely, 
plasmacytoid dendritic cells (pDCs) were estimated to be decreased in abundance in 
the Lyme disease group. pDCs resemble plasma cells but share some features of 
mDCs including secretion of interferon-alpha and presentation of TLRs. Altered 
balance between pDCs and mDCs has been examined previously in other diseases, but 
an underlying biological reason for their contrasting abundance in early Lyme disease 
is difficult to explain without further study. Early and proto B-cells were found to be 
in lower abundance in Lyme disease patients, while mature B-cells were increased as 
compared to the control group. This finding suggests a decrease in proto-B cells as 











Figure 5.9: ImmQuant cell-typing data based on DGE analyses between early Lyme 
disease blood RNA to that of a normal/healthy control group. Bars in green represent 
the Lyme disease positive patient data, showing mean and SEM bars, with control 
data in blue. The Y-axis shows cell-type quantities as estimated by ImmQuant 







 *  P<0.05 




5.3.7. RT-PCR analyses: eIF2A signalling in Lyme disease 
To further examine expression of genes related to the eIF2A pathway, identified by 
IPA as significantly down regulated in early Lyme disease patients compared to 
normal/healthy controls, a RT-PCR based study was utilised. Primers were designed 
based on the mRNA sequence of several genes of interest. Sequence and design 
protocol for these primers is given in Materials and Methods 2.7.6. A total of 8 genes 
from the eIF2a signalling pathway were tested for in RNA extracts from early Lyme 
disease patients and compared to a set of 5 blood RNA extracts from normal/healthy 
controls.  A quantitative PCR method was used (Materials and Methods 2.7.6). Full 
details and PCR cycling temperatures are provided in Materials and Methods. Cycle 
threshold (CT) was recorded per sample, and delta-delta-CT was calculated using the 
normal/healthy control group samples by means of a set of housekeeping genes. Of 
the 8 genes, 5 were successfully detected using RT-PCR in both Lyme disease 
patients and normal/healthy controls (figure 5.10). The genes AKT, eIF2a, eIF4g, 
XIAP and eIF5 were all shown to be increased or decreased in expression as 




Figure 5.10: Graph showing RT-PCR data for 5 genes associated with eIF2a 
signalling in Lyme disease patients, compared with normal/healthy controls. Error 




In this study, RNA was extracted from 14 whole blood samples from patients with 
Lyme disease, sequenced and compared to previously published reports of control 
groups comprising Ebola patients and normal/healthy controls. DGE analyses 
revealed large and consistent differences in blood transcriptome between early Lyme 
disease patients and healthy controls. These data were processed by a machine-
learning algorithm to identify a panel of 9 genes that were together discriminatory of 
Lyme disease positive patients from controls in this dataset.  Ingenuity Pathway 
Analysis (IPA) of the Lyme disease vs. normal/healthy controls DGE data identified a 
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number of pathways as being differentially expressed between groups. eIF2a 
signalling was found to be significantly decreased in Lyme disease patients by IPA. 
This supports previous findings of decreased activity of eIF2a signalling in Lyme 
disease (258). In eukaryotic cells, eIF2 (Eukaryotic Initiation Factor 2) is involved in 
translation initiation. eIF2 signalling has been shown to be induced following 
infection in response to endoplasmic reticulum stress, heavy metal toxicity and 
pathogen detection (260). Conversely, eIF2(a) signalling was found to be significantly 
decreased in Lyme disease patients by IPA in this study. The bacterial virulence factor 
YopJ has previously been shown to limit eIF2 signalling in mammalian cells, and was 
found to be of particular importance to several intracellular bacterial pathogens 
including Listeria monocytogenes and Chlamydia trachomatis (261). In contrast, the 
Lyme disease pathogen Borrelia burgdorferi s.l. does not express any known 
homologue of YopJ virulence factor; however, it can be hypothesised that the 
pathogen gains an evolutionary advantage from down regulation of eIF2 signalling 
due to decreased expression of proteins including those of the innate and adaptive 
response, and that some mechanism of bacterial influence over host signalling may 
exist. IPA also identified oxidative phosphorylation and several other pathways 
related to mitochondrial dysfunction as being influenced or disrupted in Lyme disease 
patients. Disruption of host phosphorylation has previously been described as a 
mechanism of pathogenesis, again by the intracellular pathogen L. monocytogenes 
(262). The immune effects of oxidative phosphorylation pathway are not clear, 
although previous studies have shown influence of neutrophils and T cells, reducing 
reactive oxygen species (ROS) production (263). This result again provides an 
example of the presumed extracellular pathogen behaving in a way associated with 
intracellular bacteria. No sound scientific evidence to date has shown Borrelia to act 
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as a intracellular pathogen during its life cycle, although this has been proposed (264, 
265). eIF2(a) signalling was seen to increase back towards normal/healthy levels of 
expression in late Lyme disease patient samples. Actin rearrangement pathways were 
also identified as being altered in Lyme disease patients. Actin, tubulin and several 
other cell structural related proteins were also identified as being differentially 
abundant in sera of Lyme disease patients compared to controls by mass spectrometry 
(Chapters 3 and 4). As host defence mechanisms involve maintenance of numerous 
barriers to pathogens, including at the skin level and in connective tissues (266), 
disruption of cell structural rearrangement may confer a biological advantage to the 
infectious agent. Several examples also exist of intracellular bacterial pathogens 
effectively hijacking host cellular rearrangement mechanisms to physically transport 
themselves (267) or to promote internalisation into cells (268). As Borrelia has a well-
described flagellar-based system for movement, the advantage to the pathogen of 
influencing host cytoskeletal rearrangement is unclear.  
 
All analyses in this chapter were based on a set of 14 blood samples taken from 8 
patients at different times after develop symptoms of Lyme disease. Due to time 
constraints, samples available during the early stages of the collaborative study with 
the colleagues in the Czech Republic were used. The main limitation of this study was 
a lack of consistent number of samples across time points, with some patients having 
undergone sampling at multiple time points, whilst others were sampled at only one 
time point with no RNA data available at time of presentation. No information about 
the age of the normal/healthy donors was available and these were matched based 
only on number of male/female samples included. Ebola acute and convalescent 
samples were included as an infectious disease control. The suitability of these as 
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controls may be questionable in this study due to the viral and severe nature of this 
infection, however they did provide some control against general immune response in 
the host. For future studies, a larger sample set could be utilised. Gene panels 
identified for early Lyme could be tested using well-defined Lyme disease samples, 
including from those that tested seronegative for Lyme using conventional diagnostic 
testing. A larger control group of samples, including appropriate infectious disease 
controls such as blood from syphilis patients would also be advantageous. Despite 
these limitations, the study was able to find significant and consistent changes at the 
transcriptome level in Lyme disease patients, and showed that these changes generally 
begin to revert back to normal/healthy levels late in the course of infection. 
 
4.5.1.  Conclusions 
DGE analyses revealed large and consistent differences in blood transcriptome 
between early Lyme disease patients and healthy controls. A machine-learning 
algorithm to identify a panel of 9 genes that were together discriminatory of Lyme 
disease positive patients from controls.  Ingenuity Pathway Analysis (IPA) of the 
Lyme disease vs. normal/healthy controls DGE data identified a number of 
differentially expressed pathways. Of note, eIF2a signalling was found to be 
significantly decreased in Lyme disease patients by IPA. Several findings of this study 
corroborate an earlier DGE study of Lyme disease, demonstrating the reproducibility 
of findings. Future host-gene expression analyses using well-characterised Lyme 
disease patient cohorts will help further our understanding of the complicated, 




CHAPTER 6: CONCLUSIONS 
 
The majority of Lyme disease diagnosis currently relies on the detection of host 





positive	serology	does	not	necessarily	indicate	on-going	infection. The aims of 
this thesis were to use quantitative proteomics and RNA sequencing to analyse the 
blood of Lyme disease patients, to make comparisons to normal healthy donors and 
related-disease control groups including those with syphilis and leptospirosis, and to 
identify potential biomarkers of early Lyme disease.  
 
6.1. Proteomics-based investigation of Lyme disease and other spirochaetal 
infections 
A proteomic approach using label-free mass spectrometry revealed very few 
differences in serum proteome between Lyme disease seropositive and seronegative 
groups. Differences observed between Lyme disease seropositive sera and normal 
healthy control sera showed that a range of innate and adaptive immune responses 
were occurring in the Lyme disease patients but, when compared to Seronegative, few 
of these changes were specific to the seropositive group. Possible reasons for this 
finding include that, because B. burgdorferi s.l. infection is marked by low 
bacteraemia that is initially localised to the site of tick bite with a relatively brief 
dissemination period, beyond triggering common host responses to bacterial infection, 
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the influence of Lyme disease on the serum proteome is modest in early disease. The 
findings are clouded by the fact that there is no real gold standard diagnostic test to 
confirm or rule out Lyme disease, particularly in the earliest stages, and that a patient 
that tests seronegative for Lyme disease may later seroconvert and test positive. 
Patients with documented retesting and seroconversion at a later date were not 
included in analyses, but in the majority of cases it was not possible to confirm 
whether the patient was subsequently diagnosed and treated for Lyme disease or a 
different ailment.  A future study that attempted to identify protein signatures in the 
serum of early Lyme disease patients would ideally be a longitudinal study that 
involved retesting of all subjects at several time points.  
 
To confirm that the quality of the residual diagnostic serum samples used in mass 
spectrometry run 1 was not responsible for the lack of difference observed, a second 
mass spectrometry run using samples taken at the time of presentation and 
immediately frozen was undertaken. The results of mass spectrometry run 2 again 
showed very few differences in protein abundance between Lyme disease seropositive 
and seronegative groups, and it was concluded that, at the resolution of mass 
spectrometry used in this study, the proteomes of individuals that test seropositive or 
seronegative for Lyme disease are highly similar. Of the few proteins found to be at 
significantly different abundance between Lyme disease seropositive and seronegative 
groups during mass spectrometry run 1, the protein Lipocalin 2 was of particular 
interest. The increased abundance of LCN2 in Lyme disease seropositive sera over 
seronegative was demonstrated by ELISA in additional samples (chapter 4). LCN2 is 
involved in a range of biological processes and is a well-described iron scavenger that 
is capable of removing iron from the site of bacterial infection so that the pathogens 
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are unable to meet their basic iron requirements for growth. Somewhat contradictory 
to this finding is the fact that Borrelia remain the only known organisms that can exist 
without iron (269). It is possible that LCN2 is induced as part of the innate response to 
borrelial infection despite the fact that it has little or no effect on the growth of 
Borrelia. The increased abundance of LCN2 in Lyme disease seropositive sera over 
seronegative was demonstrated by ELISA in additional samples; however, it should 
be noted that, as a protein often expressed during the immune response to infection, 
LCN2 was also elevated in leptospirosis and syphilis sera and was not specific to 
Lyme disease.  As a proof-of-concept for the proteomic approach, a range of proteins 
were identified during mass spectrometry as differentially abundant in the sera of 
leptospirosis patients. The proteins serum amyloid A1 and carbonic anhydrase III 
were shown to be increased in leptospirosis positive sera by mass spectrometry and 
were both shown to be elevated above all other groups by ELISA in additional 
leptospirosis samples. The presence of elevated levels of the muscle-specific CAH3 in 
leptospirosis positive sera was hypothesised to be due to muscle damage during 
systemic infection and release of proteins into the bloodstream. Elevated CAH3 serum 
level has not previously been reported in leptospirosis.  
 
6.2. Transcriptomic-based investigation of Lyme disease 
A RNA-seq based study of the blood transcriptome of Lyme disease patients gave an 
insight into the host response to Borrelia infection. Studying a set of 14 early Lyme 
disease blood samples from Czech patients with an EM rash, clinically diagnosed 
Lyme disease and supporting laboratory serology, it was found that the eIF2 signalling 
was downregulated in Lyme disease patients. This is consistent with a finding that has 
previously been described in a transcriptomics study of Lyme disease in US cases, 
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suggesting this may be a shared response across infection with different borrelia 
genospecies (258). To investigate which responses may be limited to early disease, a 
comparison of early to late Lyme disease samples found that eIF2 signalling generally 
increased back towards levels found in normal healthy controls and therefore may be a 
potential indicator of successful treatment. RT-PCR analysis of 5 genes associated 
with eIF2 signalling were shown to be decreased in Lyme disease positive blood 
samples when compared to normal healthy controls. Ingenuity pathway analysis of the 
transcriptome data revealed a range of biological processes occurring in Lyme disease 
patients, from those associated with host immune responses to bacterial infection, to 
more unusual findings such as alterations in oxidative stress pathways and cell 
cytoskeletal rearrangement. The wealth of information provided by RNA-seq allows 
gene panels to be created that are highly specific to the exposure group and therefore 
the disease in question; however this process is sensitive to bias and could potentially 
reveal a gene panel that is diagnostic only of the input data. Any conclusions on the 
diagnostic potential of a gene panel would require extensive confirmatory testing in 
additional samples. A longitudinal study with regular sampling from well-defined 
Lyme disease patients could further identify genes and pathways that differentially 
expressed in early Lyme disease and revert back to normal levels following successful 
antibiotic treatment. 
 
6.3. Comparison of proteomic and transcriptomic findings 
Generally, proteomic findings were quite consistent with later transcriptomic data, 
with several of the proteins identified as being differentially abundant in Lyme also 
found to be differentially expressed; however, for some proteins, the link between 
expression and protein abundance was not as clear. RNA-seq involved sequencing of 
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mRNA from PBMCs and while proteins produced in these cells may be released into 
the serum, the serum also contains proteins produced in other areas of the body. It is 
also an overly simplistic view that all gene expression, as quantified by presence of 
specific mRNA, will result in a matching increase or decrease in protein abundance. A 
number of technical and biological factors are likely to contribute to the modest 
correlation seen between the transcriptome and proteome. At the transcript level, the 
effects of translational efficiency, RNA degradation, complex assembly, cell transport 
and alternative splicing all contribute to the tenuousness seen between the abundance 
of a particular mRNA transcript and translation into a protein. Further study into the 
correlation between the proteomic and transcriptomic findings presented here would 
be of interest and may help to elucidate discrepancies seen between data sets.  
 
6.4. Translation of proteomic and transcriptomic findings  
In chapters 3 and 4, the protein LCN2 was shown to be elevated in patients that were 
seropositive for Lyme disease over those that tested negative, both by mass 
spectrometry and subsequent WBs and ELISAs. As LCN2 was seen to be elevated in 
other infectious disease, it is likely that any diagnostic potential of LCN2 would be as 
part of a multifaceted test. Several other practical considerations also need to be made 
when assessing the suitability of a protein biomarker. Diagnostic samples taken at the 
point of primary care often need to be transported to other sites for centralised 
diagnosis, as is the case with Lyme disease. Any biomarker proteins would need to be 
quantifiable during diagnostic tests and therefore, labile proteins that are likely to 




In chapter 5, differential gene expression data and a PLDA machine learning method 
identified a panel of 11 genes was identified as being discriminatory of early Lyme 
disease patient blood. Whilst the marker panel showed very high levels of sensitivity 
and specificity when tested in additional samples, the study was limited by a lack of 
available samples to serve as appropriate infectious controls. Theoretically, RT-PCR 
could be used to measure the expression of a specific gene panel but any 
transcriptomic based diagnostic of this type would also require whole blood to be 
collected and RNA stabilised, a process that isn’t compatible with conventional 
diagnostic pathways and workflows; however, the transcriptomic data may be useful 
in identifying gene markers that could be verified at the protein level.  
 
Throughout these studies emphasis was placed on early Lyme disease samples to try 
and identify signatures of the host response to active Borrelia infection. Subsequent 
studies to assess the potential of these markers would require testing in a large set of 
well characterised longitudinal patient samples to confirm whether they decline with 
treatment or in cases of spontaneous recovery and whether they are again elevated in 
cases of reinfection. This would be of particular interest in groups that are at high risk 
of Lyme including those with occupational exposures to ticks. Finally, the level of 
biomarkers associated with active Borrelia infection could be studied in patients with 
symptoms of post-treatment Lyme disease syndrome or apparent chronic Lyme 







6.5. Final conclusions 
In the world of human bacterial infections, Lyme disease is quite unusual. Borrelia b. 
s.l. begins preparing for invasion as soon as mammalian blood begins to flow into the 
midgut of an infected Ixodes tick whilst taking a blood-meal. Gene expression is 
altered as the spirochaete migrates through the tick vector, corkscrewing by use of 
intricate bundles of internal flagella, to the tick salivary glands. From here, it propels 
itself to the dermal skin layer of the human host, and colonisation can begin. The 
bacteria multiplies at the site of tick-bite and a characteristic erythema migrans rash 
may form; an unusual bullseye rash caused by the complex interplay between the 
multiplying invader and the inflammatory reaction of the host. From here, the timeline 
splits. A GP that recognises an EM rash on a patient presenting with a flu-like illness, 
who had been hiking in the Trossachs a week before, may immediately prescribe three 
weeks of doxycycline. If they are unsure, they can send a serum sample for diagnostic 
testing for Lyme disease. Serology results are taken into consideration, together with 
the clinical details of the case and, if deemed Lyme disease positive, antibiotics can be 
prescribed. Evidence shows that if diagnosed and treated at this early stage, bacterial-
clearance and patient recovery rates are very high. In some cases, however, those 
infected with Borrelia b. s.l. may initially be asymptomatic, or show symptoms 
atypical of Lyme disease. Unrecognised and untreated, the infection can spread from 
the skin to the bloodstream, travel to various sites within the host,  potentially causing 
late stage manifestations including Lyme arthritis, carditis and neuroborreliosis.   
 
While the value of a diagnostic test capable of detecting Lyme disease at its earliest 
stages is clear, the nature of serological testing means that results are dependent on the 
humoral response of each individual being tested. Two-tiered testing algorithms 
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remain the most valuable tool for routine Lyme disease diagnostics and perform well 
in the majority of referrals. The protocols are being continually assessed and 
improved. However, issues remain around the efficacy of the test in the earliest stages 
of Lyme disease. Future proteomic, transcriptomic and metabolomic research may 
reveal further markers that will improve early diagnostic testing.   
 
Late stage Lyme disease is often a complicated,  multi-organ disease that is known to 
cause a wide range of symptoms, many of which are common to other diseases. As 
arguments continue over attributing Lyme disease (or Chronic Lyme disease) to a 
diverse range of cases, it should be remembered that there remains a group of 
individuals that feel that they have been let down; suffering from long-term maladies 
and unable to find a definitive diagnosis. Future understanding of these complicated 
cases lies in expanding our knowledge of both Lyme disease and other diseases, 













































































































































































































































































































































































































































































































































































































































































































































































































































































































































Appendix B: Presentation of Data 
 

























American Society for Microbiology Conference, Atlanta 2018 – oral presentation 
abstract 
Lyme disease (LD) is a multisystem infection caused by tick-borne spirochaetes of the 
Borrelia burgdorferi sensu lato group. UK laboratory diagnosis of Lyme disease 
involves the two-tier serological approach. The negative predictive value of the test 
has been challenged, particularly in early stage Lyme disease There is considerable 
interest, therefore, in the development of improved diagnostic tests. The main aim of 
the project is to identify new markers that could form the basis for improved tests. The 
project is part of collaboration between the University of Liverpool and Public Health 
England that aims to improve diagnostic testing for several infectious diseases. 
A mass spectrometry biomarker discovery study was undertaken on Lyme disease 
positive and negative residual diagnostic samples from UK Lyme disease testing by 
Public Health England. A control group of healthy subjects serum samples (from NHS 
blood transfusion service) were also included. To ensure differences were specific to 
Lyme disease rather than genetic to infection, a “related-disease control group” 
including serum samples from syphilis, leptospirosis and chronic fatigue syndrome 
were included. A total of 50 human samples were compared by label-free quantitative 
mass spectrometry. 
Surprisingly, Lyme disease seropositive and seronegative groups were found to have 
very few proteins that were significantly different when directly compared. One 
protein, Lipocalin-2 was found at a significantly higher abundance in the LD-positive 
patients compared with those that were LD-negative. This is of interest due to 
involvement in innate immunity. Lipocalin-2 has been found in mice exposed to B. 
burgdorferi. Leptospirosis samples showed increased levels of several proteins 
involved in host-immune response including neutrophil defensin-1. Several key 
differences were also found in CFS and syphilis patients. 
The results of the mass spectrometry run have generated several proteins of interest 
that will be further investigated by Western blot analyses on larger sample groups to 
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Background: Lyme disease (LD) is a multisystem infection caused by tick-borne spirochaetes of the 
Borrelia burgdorferi sensu lato group. Human cases have increased steadily in the UK in recent 
years with over 1100 confirmed cases in 2013. In the same year, over 27,000 cases were reported in 
the US. UK laboratory diagnosis of LD involves the internationally accepted two-tier serological 
approach: a C6 ELISA followed by confirmatory IgG and IgM line blots. The negative predictive 
value of the test has been challenged, particularly in early stage LD and in some chronic infections. 





•  Review of current UK testing protocols 
•  Discovery of host-derived markers of early LD and potential risk markers for 
development of long term symptoms or failed response to treatment. 
Hypotheses: 
•  That novel host biomarkers are characteristic of LD  and have diagnostic potential 
•  That host biomarkers present early the course of infection are of prognostic value 
in determining the clinical manifestation or outcome of LD 
 
 
(i)   Serum depletion:  
Top-12 spin columns were 
used to remove  several  
proteins present in blood at 
high concentrations 
including serum albumin 
and IgG  
(ii) Quantitative mass spectrometry: 
Discovery of proteins which  show significant changes in 
abundance  consistently between the two groups 
(iii) Biomarker validation 
•  Can protein biomarkers differentiate between patients 
with (seropositive) and without (seronegative, healthy) 
LD 
•  Western blot analysis – using antibodies for proteins 
discovered in discovery mass spectrometry run.  
Residual serum 
samples from UK LD 
diagnostic testing at 
RIPL, PHE Porton 
Positive n=15 
Negative n=15 
Control patient samples 
 
Control samples from 
patients with related-
diseases (similar 
morphology of causative 







Biomarker discovery protocol Diagnostic test review 
The SYPRO ruby stained 
electrophoresis gel (right) shows 
protein bands before and after 
depletion with equal quantities of 
protein loaded (2.5µg). Lanes 
1,3,5 show serum before depletion 





Analysis of current literature on sensitivity and specificity of serological tests for LD showed 
lower sensitivity/specificity at early stages of disease (EM). The development of antibodies in 
response to infection, particularly of IgG, may take over 4-6 weeks to reach detectable 
levels. Results from studies investigating the efficacy of Lyme serology were highly variable 
giving broad confidence intervals. The data also suggested that two-tiered tests did not 
outperform single tests at all stages of disease. However, results were highly variable with 
many studies showing high risk of bias 
Mass spectrometry results 
Lyme disease 
       EM NB LA ACA 
%
 
Sensitivity and specificity of LD serology (TTTA) at 
different stages of disease 
Lipocalin-2 (LCN2): Protein involved in innate immunity 
expressed in neutrophils. Despite presence in many infections, 
presence of lipocalin-2 was shown to to be significantly 




5 Future work 
Sensitivity 
Specificity 
•  Further quantification of potential biomarkers of Lyme 
and leptospirosis using WB and ELISA using serum 
bank 
•  Mass Spec II: In order to investigate the lack of 
differences between LD seropositive and seronegative, 
a second mass spectrometry run will use well-
characterised, freshly collected sera  
•  Transcriptomic analysis: Whole-blood samples are 
currently being collected for use in a transcriptomic-
based study of the host-response to early Lyme 
disease. Samples are being collected on presentation, 
after antibiotic treatment and then at 3 monthly intervals 
up to 1 year. Data will be analysed on MinION and 
Illumina RNAseq platforms and compared to normal/
healthy volunteer blood. Differential gene analysis will 
be used with the aim of identifiying a minimal marker 
set that is able to distinguish early Lyme samples 
Host-derived biomarkers: Their discovery and diagnostic 
potential in Lyme disease and other spirochaetel infections 
Introduction 
Leptospirosis: In contrast to the Lyme disease sera, leptospirosis positive sera  
was found to be highly distinct to other sera and grouped closely based on the 
proteome of individual samples. Proteins known to be elevated in leptospirosis 
infection, including the current biomarker Creatine Kinase M, were identified as 
significantly increased in abundance in the sample set. Further proteins of interest 
were identified for follow-up analysis by WB and ELISA. 
Carbonic anhydrase III (CA3): catalyzes the reversible 
hydration of carbon dioxide. CA3 is highly tissue specific 
and present in high levels in skeletal muscles and at 
lower levels in cardiac and smooth muscle.  It’s inreased 
presence in leptospirosis patient sera may be due to 
rhabdomyolysis (muscle breakdown during infection) 
Myosin (heavy chain 7): Actin motor protein with role in 
muscle contraction. Potential marker of myocardial cell 
damage but is also found in skeletal muscles and high 
serum levels may indicate muscle trauma due to infection  
Fewer differences between Lyme seropositive and 
seronegative were found than expected, with both groups 
closely grouping together in PCA.   
Volcano plot showing proteins significantly increased (right) or decreased (left) in Lyme 
disease positive sera when compared to Lyme negative sera 
Abundance of Lipocalin 2 in Lyme positive and 
negative sera as measured by ELISA. Lyme 
positive n=42. Lyme negative n=64 
PCA (principal component analysis) of mass spectrometry data. Red circle shows grouping of Lyme positive and Lyme negative sera  
There are several possible reasons for the lack of  
•  Sample quality: Samples used in initial MS run were residual diagnostic samples with 
unknown storage history. Repeated freeze-thaw and poor storage may have led to 
degradation of samples. 
•  True result: Borrelia is only transiently present in the blood, the differences in patients 
with LD may be too subtle to detect using current proteomic techniques 
These results will be further investigated using further MS and transcriptomic analysis 
WB for CA3: Left: sera from Lepto positive 
patients (not included in MS). Right: other 
sera from related diseases and normal/
healthy patients 
Volcano plot showing proteins significantly increased (right) or decreased (left) in Lepto positive sera 
when compared to related disease and normal/healthy sera 
Right: Sensitivity and specificity of LD serology at different stages of disease 
Total patients: Acute stage (Erythema migrans rash) n=3758, neuroborreliosis n=1120, Lyme arthritis n=458, Acrodermatitis 
chronica atrophicans n=462 
EM = Erythema migrans (acute stage), NB = neuroborreliosis, LA = Lyme arthritis, ACA = Acrodermatitis chronica atrophicans  
Volcano Plot: Lyme seropostive vs. Lyme seronegative (UK) 
Volcano Plot: Leptospirosis positive vs. “other” sera 
